US10385028B2 - Compounds for the treatment of neuromuscular disorders - Google Patents
Compounds for the treatment of neuromuscular disorders Download PDFInfo
- Publication number
- US10385028B2 US10385028B2 US15/842,823 US201715842823A US10385028B2 US 10385028 B2 US10385028 B2 US 10385028B2 US 201715842823 A US201715842823 A US 201715842823A US 10385028 B2 US10385028 B2 US 10385028B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- group
- alkenyl
- alkynyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC.[1*]C([2*])([Y]C1=CC=CC=C1)C(=O)O Chemical compound CC.[1*]C([2*])([Y]C1=CC=CC=C1)C(=O)O 0.000 description 149
- MGENXEGIYKIOSP-YFKPBYRVSA-N C[C@H](OC1=NC=C(Br)C=C1)C(=O)O Chemical compound C[C@H](OC1=NC=C(Br)C=C1)C(=O)O MGENXEGIYKIOSP-YFKPBYRVSA-N 0.000 description 5
- MONMTZLCRRBKIN-UHFFFAOYSA-N CC(C(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 Chemical compound CC(C(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 MONMTZLCRRBKIN-UHFFFAOYSA-N 0.000 description 4
- GJWRAZLDTHVTBF-UHFFFAOYSA-N CC.CC(C)[C@H]([Y]C1=CC=CC=C1)C(=O)O Chemical compound CC.CC(C)[C@H]([Y]C1=CC=CC=C1)C(=O)O GJWRAZLDTHVTBF-UHFFFAOYSA-N 0.000 description 4
- SFQXCTBXCLEXQM-ZETCQYMHSA-N CC1=C(O[C@@H](C)C(=O)O)C=CC(Br)=C1 Chemical compound CC1=C(O[C@@H](C)C(=O)O)C=CC(Br)=C1 SFQXCTBXCLEXQM-ZETCQYMHSA-N 0.000 description 4
- HMIVVAPMRQMNAK-VIFPVBQESA-N C[C@H](OC1=CC2=C(C=CC=C2)C=C1)C(=O)O Chemical compound C[C@H](OC1=CC2=C(C=CC=C2)C=C1)C(=O)O HMIVVAPMRQMNAK-VIFPVBQESA-N 0.000 description 4
- JTWFPECYXPTIKC-ZQOTUPPBSA-N *.CC1=NN(C)C=C1C1=C(O[C@@H](C)C(=O)O)C=CC(Cl)=C1.C[C@H](OC1=C(C2=CC=NN2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=NC=CN2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(C2CCOC2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=CC=NO1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=CN=CN1)C(=O)O.O=C(O)[C@H](CF)OC1=CC=C(Br)C=C1C1=CC=NO1.S.S.S.S.S.S Chemical compound *.CC1=NN(C)C=C1C1=C(O[C@@H](C)C(=O)O)C=CC(Cl)=C1.C[C@H](OC1=C(C2=CC=NN2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=NC=CN2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(C2CCOC2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=CC=NO1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=CN=CN1)C(=O)O.O=C(O)[C@H](CF)OC1=CC=C(Br)C=C1C1=CC=NO1.S.S.S.S.S.S JTWFPECYXPTIKC-ZQOTUPPBSA-N 0.000 description 3
- LLHLQYXETJGNKV-UDPOCFCUSA-N *.CC1=NOC(C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)=C1.CC1=NO[C@@H](C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)C1.CC1=NO[C@H](C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)C1.C[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=NC2=C(C=CC=C2)S1)C(=O)O.C[C@H](OC1=CC=C(Cl)C=C1C1=NC=CS1)C(=O)O.S.S.S.S.S.S.S Chemical compound *.CC1=NOC(C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)=C1.CC1=NO[C@@H](C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)C1.CC1=NO[C@H](C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)C1.C[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=NC2=C(C=CC=C2)S1)C(=O)O.C[C@H](OC1=CC=C(Cl)C=C1C1=NC=CS1)C(=O)O.S.S.S.S.S.S.S LLHLQYXETJGNKV-UDPOCFCUSA-N 0.000 description 3
- MCYSJOFSCNWIBX-FXPIJHRYSA-N CC(C)C1=NOC(C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)=C1.CC(C)[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.CC1=CON=C1C1=C(O[C@@H](C)C(=O)O)C=CC(Br)=C1.CC[C@H](OC1=C(C2=CC=NO2)C=C(Br)C=C1)C(=O)O.CC[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1Cl)C(=O)O.S.S.S.S.S Chemical compound CC(C)C1=NOC(C2=CC(Br)=CC=C2O[C@@H](C)C(=O)O)=C1.CC(C)[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.CC1=CON=C1C1=C(O[C@@H](C)C(=O)O)C=CC(Br)=C1.CC[C@H](OC1=C(C2=CC=NO2)C=C(Br)C=C1)C(=O)O.CC[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1Cl)C(=O)O.S.S.S.S.S MCYSJOFSCNWIBX-FXPIJHRYSA-N 0.000 description 3
- QSZAYARATHCZAS-JIVKCJJNSA-N CC1=CC(C2=C(O[C@@H](C)C(=O)O)C=CC(Br)=C2)=NO1.CC1=NOC(C2=C(O[C@@H](C)C(=O)O)C=CC(Cl)=C2)=N1.C[C@H](OC1=C(C2=NC=CC=C2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=NOC(C2CC2)=C1)C(=O)O.S.S.S.S.S.[H]C12CCCC1([H])C(C1=C(O[C@@H](C)C(=O)O)C=CC(Br)=C1)=NO2 Chemical compound CC1=CC(C2=C(O[C@@H](C)C(=O)O)C=CC(Br)=C2)=NO1.CC1=NOC(C2=C(O[C@@H](C)C(=O)O)C=CC(Cl)=C2)=N1.C[C@H](OC1=C(C2=NC=CC=C2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=NOC(C2CC2)=C1)C(=O)O.S.S.S.S.S.[H]C12CCCC1([H])C(C1=C(O[C@@H](C)C(=O)O)C=CC(Br)=C1)=NO2 QSZAYARATHCZAS-JIVKCJJNSA-N 0.000 description 3
- DGIARBNURSBXAA-XTCSUJCASA-N C[C@H](OC1=C(C2=CC=CS2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=CC=NO2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=CN(C)N=C2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=NC3=C(C=CC=C3)S2)C=CC=C1)C(=O)O.C[C@H](OC1=C(C2=NN=CO2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(N2C=CC=N2)C=C(Cl)C=C1)C(=O)O.S.S.S.S.S.S Chemical compound C[C@H](OC1=C(C2=CC=CS2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=CC=NO2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=CN(C)N=C2)C=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C(C2=NC3=C(C=CC=C3)S2)C=CC=C1)C(=O)O.C[C@H](OC1=C(C2=NN=CO2)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(N2C=CC=N2)C=C(Cl)C=C1)C(=O)O.S.S.S.S.S.S DGIARBNURSBXAA-XTCSUJCASA-N 0.000 description 3
- HCUOEKZNOAAJPO-YFKPBYRVSA-N C[C@H](OC1=CC=C(Cl)N=C1)C(=O)O Chemical compound C[C@H](OC1=CC=C(Cl)N=C1)C(=O)O HCUOEKZNOAAJPO-YFKPBYRVSA-N 0.000 description 3
- QNSSZNXIJNBXPI-UHFFFAOYSA-N CC(=O)NCC(OC1=CC=C(Br)C=C1)C(=O)O.CCOC1CC(C(OC2=CC=C(Br)C=C2)C(=O)O)C1.COCC(C)C(OC1=CC=C(Br)C=C1)C(=O)O.COCC(C)C(OC1=CC=C(Br)C=C1)C(=O)O.CS(=O)(=O)NCC(OC1=CC=C(Br)C=C1)C(=O)O.O=C(O)C(CC(F)F)OC1=CC=C(Br)C=C1 Chemical compound CC(=O)NCC(OC1=CC=C(Br)C=C1)C(=O)O.CCOC1CC(C(OC2=CC=C(Br)C=C2)C(=O)O)C1.COCC(C)C(OC1=CC=C(Br)C=C1)C(=O)O.COCC(C)C(OC1=CC=C(Br)C=C1)C(=O)O.CS(=O)(=O)NCC(OC1=CC=C(Br)C=C1)C(=O)O.O=C(O)C(CC(F)F)OC1=CC=C(Br)C=C1 QNSSZNXIJNBXPI-UHFFFAOYSA-N 0.000 description 2
- CBPPHEASPVUHRO-UHFFFAOYSA-N CC(C)(OC1=CC=CC=C1)C(=O)O.CC(OC1=CC=C(Cl)C=C1)C(=O)O.CC(OC1=CC=C(Cl)C=C1Cl)C(=O)O.CC1=CC(C)=CC(OCC(=O)O)=C1.COC(=O)C(C)OC1=CC(C)=CC=C1.O=C(O)COC1=C2C=CC=CC2=C(Cl)C=C1 Chemical compound CC(C)(OC1=CC=CC=C1)C(=O)O.CC(OC1=CC=C(Cl)C=C1)C(=O)O.CC(OC1=CC=C(Cl)C=C1Cl)C(=O)O.CC1=CC(C)=CC(OCC(=O)O)=C1.COC(=O)C(C)OC1=CC(C)=CC=C1.O=C(O)COC1=C2C=CC=CC2=C(Cl)C=C1 CBPPHEASPVUHRO-UHFFFAOYSA-N 0.000 description 2
- UEIAOELNTXDNJH-JVVCLSQVSA-N CC(C)C(OC1=CC=C(Cl)C=C1)C(=O)O.CC(OC1=CC=C(Br)C=C1)C(=O)O.CC(OC1=CC=C(F)C=C1)C(=O)O.CCC(OC1=CC=C(Cl)C=C1)C(=O)O.CCCC(OC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC=C(Cl)C=C1)C(=O)O Chemical compound CC(C)C(OC1=CC=C(Cl)C=C1)C(=O)O.CC(OC1=CC=C(Br)C=C1)C(=O)O.CC(OC1=CC=C(F)C=C1)C(=O)O.CCC(OC1=CC=C(Cl)C=C1)C(=O)O.CCCC(OC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC=C(Cl)C=C1)C(=O)O UEIAOELNTXDNJH-JVVCLSQVSA-N 0.000 description 2
- GXDZAETYCIAWEK-HVIAZGFUSA-N CC(C)[C@H](OC1=CC=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(C(=O)O)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(I)C=C1)C(=O)O.NCC(OC1=CC=C(F)C=C1)C(=O)O.O=C(O)C(OC1=CC=C(Br)C=C1)C1CC1 Chemical compound CC(C)[C@H](OC1=CC=C(Br)C=C1)C(=O)O.C[C@H](OC1=C(C(=O)O)C=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1)C(=O)O.C[C@H](OC1=CC=C(I)C=C1)C(=O)O.NCC(OC1=CC=C(F)C=C1)C(=O)O.O=C(O)C(OC1=CC=C(Br)C=C1)C1CC1 GXDZAETYCIAWEK-HVIAZGFUSA-N 0.000 description 2
- IIZIKWPKGJSVKD-MHIKSZRASA-N CC(CC1=CC=C(Br)C=C1)C(=O)O.CC(OC1=CC=C(Br)C=C1C=O)C(=O)O.C[C@H](OCC1=CC=C(Cl)C=C1)C(=O)O.O=C(O)C1(OC2=CC=C(Cl)C=C2)CC1 Chemical compound CC(CC1=CC=C(Br)C=C1)C(=O)O.CC(OC1=CC=C(Br)C=C1C=O)C(=O)O.C[C@H](OCC1=CC=C(Cl)C=C1)C(=O)O.O=C(O)C1(OC2=CC=C(Cl)C=C2)CC1 IIZIKWPKGJSVKD-MHIKSZRASA-N 0.000 description 2
- GFRQUFUZYOTBGM-ZVBYXLBTSA-N CC(OC1=CC(Cl)=CC(Cl)=C1)C(=O)O.CC(OC1=CN=CC=C1)C(=O)O.C[C@H](OC1=C2C=CC=CC2=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC2=C/C=C/C=C\2N=C1)C(=O)O.C[C@H](OC1=CC=C(F)N=C1)C(=O)O.O=C(O)COC1=CC(Cl)=NC=C1 Chemical compound CC(OC1=CC(Cl)=CC(Cl)=C1)C(=O)O.CC(OC1=CN=CC=C1)C(=O)O.C[C@H](OC1=C2C=CC=CC2=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC2=C/C=C/C=C\2N=C1)C(=O)O.C[C@H](OC1=CC=C(F)N=C1)C(=O)O.O=C(O)COC1=CC(Cl)=NC=C1 GFRQUFUZYOTBGM-ZVBYXLBTSA-N 0.000 description 2
- PRBSYTHVZHLWMA-UHFFFAOYSA-N CC(OC1=CC=C(F)C=C1)C(=O)OC1=CC=C(Cl)C=C1 Chemical compound CC(OC1=CC=C(F)C=C1)C(=O)OC1=CC=C(Cl)C=C1 PRBSYTHVZHLWMA-UHFFFAOYSA-N 0.000 description 2
- WBQQHBKEGSCGHD-GVQAZJOZSA-N CC(OCC1=CC=CC=C1)C(=O)O.CC(SC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](NC1=C2C=CC=CC2=NC=C1)C(=O)O.C[C@H](NC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C2C=CC=CC2=C(C#N)C=C1)C(=O)O.C[C@H](OC1=C2C=CC=CC2=C(Cl)N=C1)C(=O)O.O=C(O)COCCC1=CC=CC=C1 Chemical compound CC(OCC1=CC=CC=C1)C(=O)O.CC(SC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](NC1=C2C=CC=CC2=NC=C1)C(=O)O.C[C@H](NC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](OC1=C2C=CC=CC2=C(C#N)C=C1)C(=O)O.C[C@H](OC1=C2C=CC=CC2=C(Cl)N=C1)C(=O)O.O=C(O)COCCC1=CC=CC=C1 WBQQHBKEGSCGHD-GVQAZJOZSA-N 0.000 description 2
- OPDINIUQMMBMSW-UHFFFAOYSA-N *.C.C.C.CC(C)C(N)C(=O)O.CC(C)C(O)C(=O)O.CC(C)C(OC1=CC=C(Br)C=C1)C(=O)O.CC(C)C(OC1=CC=C(N(=O)=O)C=C1)C(=O)O.COC(=O)C(OC1=CC=C(Br)C=C1)C(C)C.COC(=O)C(OC1=CC=C(N(=O)=O)C=C1)C(C)C.COC(=O)C(OC1=CC=C(N)C=C1)C(C)C.N.O=[N+]([O-])C1=CC=C(F)C=C1.[KH] Chemical compound *.C.C.C.CC(C)C(N)C(=O)O.CC(C)C(O)C(=O)O.CC(C)C(OC1=CC=C(Br)C=C1)C(=O)O.CC(C)C(OC1=CC=C(N(=O)=O)C=C1)C(=O)O.COC(=O)C(OC1=CC=C(Br)C=C1)C(C)C.COC(=O)C(OC1=CC=C(N(=O)=O)C=C1)C(C)C.COC(=O)C(OC1=CC=C(N)C=C1)C(C)C.N.O=[N+]([O-])C1=CC=C(F)C=C1.[KH] OPDINIUQMMBMSW-UHFFFAOYSA-N 0.000 description 1
- JALAIDSUIYUTDB-SGNQUONSSA-N *.C.CCC(O)C(=O)OC.NCC(OC1=CC=C(F)C=C1)C(=O)O.[2HH] Chemical compound *.C.CCC(O)C(=O)OC.NCC(OC1=CC=C(F)C=C1)C(=O)O.[2HH] JALAIDSUIYUTDB-SGNQUONSSA-N 0.000 description 1
- QNIHVEKWOITPCC-FTESIAPGSA-N *.C.COC(=O)[C@H](C)OC1=C2C=CC=CC2=C(Cl)C=C1.C[C@H](OC1=C2C=CC=CC2=C(Cl)C=C1)C(=O)O.OC1=C2C=CC=CC2=C(Cl)C=C1 Chemical compound *.C.COC(=O)[C@H](C)OC1=C2C=CC=CC2=C(Cl)C=C1.C[C@H](OC1=C2C=CC=CC2=C(Cl)C=C1)C(=O)O.OC1=C2C=CC=CC2=C(Cl)C=C1 QNIHVEKWOITPCC-FTESIAPGSA-N 0.000 description 1
- GWOCYFOQOUNHLA-UHFFFAOYSA-N B.CC(C(=O)O)S(=O)(=O)C1=CC=C(F)C=C1.CC(SC1=CC=C(F)C=C1)C(=O)O Chemical compound B.CC(C(=O)O)S(=O)(=O)C1=CC=C(F)C=C1.CC(SC1=CC=C(F)C=C1)C(=O)O GWOCYFOQOUNHLA-UHFFFAOYSA-N 0.000 description 1
- XFBREVNVQHEUGT-QVKUWJPQSA-N C#CC1CC1.CCN(CC)CC.C[C@@H](O)C(=O)OC(C)(C)C.C[C@H](OC1=CC=C(Br)C=C1C1=NOC(C2CC2)=C1)C(=O)O.OC1=CC=C(Br)C=C1C1=NOC(C2CC2)=C1.[H]/C(=N\O)C1=CC(Br)=CC=C1O.[H]C(=O)C1=CC(Br)=CC=C1O Chemical compound C#CC1CC1.CCN(CC)CC.C[C@@H](O)C(=O)OC(C)(C)C.C[C@H](OC1=CC=C(Br)C=C1C1=NOC(C2CC2)=C1)C(=O)O.OC1=CC=C(Br)C=C1C1=NOC(C2CC2)=C1.[H]/C(=N\O)C1=CC(Br)=CC=C1O.[H]C(=O)C1=CC(Br)=CC=C1O XFBREVNVQHEUGT-QVKUWJPQSA-N 0.000 description 1
- ORBCRVWWFIGPRS-CGLBOOABSA-M C#C[Si](C)(C)C.C[C@@H](O)C(=O)OC(C)(C)C.C[C@H](OC1=CC=C(Br)C=C1C1=NOC=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=NOC=C1)C(=O)O[Na].OC1=CC=C(Br)C=C1C1=NOC=C1.[H]/C(=N\O)C1=CC(Br)=CC=C1O Chemical compound C#C[Si](C)(C)C.C[C@@H](O)C(=O)OC(C)(C)C.C[C@H](OC1=CC=C(Br)C=C1C1=NOC=C1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=NOC=C1)C(=O)O[Na].OC1=CC=C(Br)C=C1C1=NOC=C1.[H]/C(=N\O)C1=CC(Br)=CC=C1O ORBCRVWWFIGPRS-CGLBOOABSA-M 0.000 description 1
- SKWBBETWQFRDSI-IBFIFTMCSA-N C.COC(=O)[C@@H](C)O.COC(=O)[C@@H](C)OS(=O)(=O)C(F)(F)F.COC(=O)[C@H](C)NC1=CC=C(Cl)C=C1.C[C@H](NC1=CC=C(Cl)C=C1)C(=O)O.S.[3HH] Chemical compound C.COC(=O)[C@@H](C)O.COC(=O)[C@@H](C)OS(=O)(=O)C(F)(F)F.COC(=O)[C@H](C)NC1=CC=C(Cl)C=C1.C[C@H](NC1=CC=C(Cl)C=C1)C(=O)O.S.[3HH] SKWBBETWQFRDSI-IBFIFTMCSA-N 0.000 description 1
- ILXDXSOCPBBGDL-QRAPKSRASA-N C.C[C@H](OC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC=C(Cl)C=C1)C(=O)OC1=CC=C([N+](=O)[O-])C=C1 Chemical compound C.C[C@H](OC1=CC=C(Cl)C=C1)C(=O)O.C[C@H](OC1=CC=C(Cl)C=C1)C(=O)OC1=CC=C([N+](=O)[O-])C=C1 ILXDXSOCPBBGDL-QRAPKSRASA-N 0.000 description 1
- DDCLDKOPVREQKL-QOAIKHJGSA-N C.[H]C(=NCCO)[C@H](C)OC1=CC=C(Cl)C=C1.[H]C(=O)[C@H](C)OC1=CC=C(Cl)C=C1 Chemical compound C.[H]C(=NCCO)[C@H](C)OC1=CC=C(Cl)C=C1.[H]C(=O)[C@H](C)OC1=CC=C(Cl)C=C1 DDCLDKOPVREQKL-QOAIKHJGSA-N 0.000 description 1
- JTNJOTDWDXGYFA-UBKPKTQASA-N COC(=O)[C@H](C)OC1=CC=C(Cl)C=C1.F.[H]C(=O)[C@H](C)OC1=CC=C(Cl)C=C1 Chemical compound COC(=O)[C@H](C)OC1=CC=C(Cl)C=C1.F.[H]C(=O)[C@H](C)OC1=CC=C(Cl)C=C1 JTNJOTDWDXGYFA-UBKPKTQASA-N 0.000 description 1
- KBONZGSOLLMNCR-ZEPDPTIVSA-M C[C@@H](O)C(=O)OC(C)(C)C.C[C@H](OC1=CC=C(Br)C=C1C1=CC=NO1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=CC=NO1)C(=O)O[Na].OC1=CC=C(Br)C=C1C1=CC=NO1 Chemical compound C[C@@H](O)C(=O)OC(C)(C)C.C[C@H](OC1=CC=C(Br)C=C1C1=CC=NO1)C(=O)O.C[C@H](OC1=CC=C(Br)C=C1C1=CC=NO1)C(=O)O[Na].OC1=CC=C(Br)C=C1C1=CC=NO1 KBONZGSOLLMNCR-ZEPDPTIVSA-M 0.000 description 1
- HCUOEKZNOAAJPO-RXMQYKEDSA-N C[C@@H](OC1=CC=C(Cl)N=C1)C(=O)O Chemical compound C[C@@H](OC1=CC=C(Cl)N=C1)C(=O)O HCUOEKZNOAAJPO-RXMQYKEDSA-N 0.000 description 1
- GZCSLUDSLJHPLF-FJXQXJEOSA-N C[C@H](OC1=C(C2=CC=NO2)C=C(Br)C=C1)C(=O)O.S Chemical compound C[C@H](OC1=C(C2=CC=NO2)C=C(Br)C=C1)C(=O)O.S GZCSLUDSLJHPLF-FJXQXJEOSA-N 0.000 description 1
- DYJXGVCEXFIIIQ-FJXQXJEOSA-N C[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.S Chemical compound C[C@H](OC1=C(C2=NOC=C2)C=C(Br)C=C1)C(=O)O.S DYJXGVCEXFIIIQ-FJXQXJEOSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
Definitions
- the present invention relates to compounds for use in treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade.
- the compounds as defined herein preferably inhibit the CIC-1 ion channel.
- the invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.
- NMJ neuromuscular junction
- Neuromuscular transmission refers to the sequence of cellular events at the NMJ whereby an action potential in the lower motor neuron is transmitted to a corresponding action potential in a muscle fiber.
- a neuronal action potential arrives at the pre-synaptic terminal it triggers influx of Ca 2+ through voltage gated P/Q-type Ca 2+ channels in the nerve terminal membrane. This influx causes a rise in cytosolic Ca 2+ in the nerve terminal that triggers exocytosis of acetylcholine (ACh). Released ACh next diffuses across the synaptic cleft to activate nicotinic ACh receptors in the post-synaptic, muscle fiber membrane.
- ACh receptors Upon activation, ACh receptors convey an excitatory current flow of Na + into the muscle fiber, which results in a local depolarization of the muscle fiber at the NMJ that is known as the endplate potential (EPP). If the EPP is sufficiently large, voltage gated Na + channels in the muscle fiber will activate and an action potential in the muscle fiber will ensue. This action potential then propagates from NMJ throughout the muscle fiber and triggers the Ca 2+ release from the sarcoplasmic reticulum. The released Ca 2+ activates the contractile proteins within the muscle fibers thus resulting in contraction of the fiber.
- EPP endplate potential
- myasthenia gravis the most common finding is an autoimmune attack on the post-synaptic membrane either against the nicotinic ACh receptors or the musk-receptor in the muscle fiber membrane. Congenital forms of myasthenia are also known.
- Common to disorders with neuromuscular transmission failure (Lambert Eaton syndrome, amyotrophic lateral sclerosis, spinal muscular atrophy and myasthenia gravis) is that the current flow generated by ACh receptor activation is markedly reduced, and EPPs therefore become insufficient to trigger muscle fiber action potentials.
- Neuromuscular blocking agents also reduce EPP by antagonizing ACh receptors.
- the EPP may be of normal amplitude but they are still insufficient to trigger muscle fiber action potentials because the membrane potential threshold for action potential excitation has become more depolarized because of loss-of-function of voltage gated Na + channels in the muscle fibers.
- ACh release (Lambert Eaton, amyotrophic lateral sclerosis, spinal muscular atrophy), ACh receptor function (myasthenia gravis, neuromuscular blockade) and function of voltage gated Na + channels (CIM) are essential components in the synaptic transmission at NMJ
- the magnitude of the EPP is also affected by inhibitory currents flowing in the NMJ region of muscle fibers. These currents tend to outbalance excitatory current through ACh receptors and, expectedly, they thereby tend to reduce EPP amplitude.
- the most important ion channel for carrying such inhibitory membrane currents in muscle fibers is the muscle-specific CIC-1 Cl ⁇ ion channel.
- ACh esterase (AChE) inhibitors are traditionally used in the treatment of myasthenia gravis. This treatment leads to improvement in most patients but it is associated with side effects, some of which are serious. Because ACh is an import neurotransmitter in the autonomic nervous system, delaying it's breakdown can lead to gastric discomfort, diarrhea, salivation and muscle cramping. Overdosing is a serious concern as it can lead to muscle paralysis and respiratory failure, a situation commonly referred to as cholinergic crisis. Despite the serious side effects of AChE inhibitors, these drugs are today the treatment of choice for a number of disorders involving neuromuscular impairment.
- pyridostigmine a parasympathomimetic and a reversible ACHE inhibitor
- corticosteroid treatment prednisone
- immunosuppressive treatment azathioprine
- the CIC-1 ion channel is emerging as a target for potential drugs, although its potential has been largely unrealized.
- the present inventors have identified a group of compounds that alleviate neuromuscular junction disorders through inhibition of CIC-1 channels.
- the present invention thus concerns the use of CIC-1 ion channel inhibitors in the treatment of a range of conditions, such as reversal of block, ALS and myasthenic conditions, in which muscle activation by the nervous system is compromised and symptoms of weakness and fatigue are prominent.
- the invention concerns a composition
- a composition comprising a compound of Formula (II):
- the invention concerns a method of treating, preventing and/or ameliorating a neuromuscular disorder, said method comprising administering a therapeutically effective amount of the composition as defined herein to a person in need thereof.
- the invention concerns use of a composition as defined herein, for the manufacture of a medicament for the treatment, prevention and/or amelioration of a neuromuscular disorder, and/or for reversing and/or amelioration of a neuromuscular blockade after surgery.
- the invention concerns a method of reversing and/or ameliorating a neuromuscular blockade after surgery, said method comprising administering a therapeutically effective amount of the composition as defined herein to a person in need thereof.
- the invention concerns a method for recovery of neuromuscular transmission, said method comprising administering a therapeutically effective amount of the composition as defined herein to a person in need thereof.
- the invention concerns a composition as defined herein for use in recovery of neuromuscular transmission.
- the invention concerns use of a composition as defined herein for the manufacture of a medicament for the recovery of neuromuscular transmission.
- the invention concerns a compound of Formula (I.3.4):
- the invention concerns a compound of Formula (I.3.4):
- the invention concerns a composition comprising a compound as defined herein.
- FIGS. 1A-1C Experimental methods for compromising neuromuscular transmission and the approaches employed to selectively activate contractions either via stimulation of the motor nerve or by directly exciting the rat muscle fibers.
- Soleus muscles were stimulated to contract using three different methods: In FIG. 1A , the muscle was stimulated to contract either directly using field stimulation with pulses of 0.2 ms duration or indirectly through stimulation of the nerve using a suction electrode.
- FIG. 1B and FIG. 1C muscles were stimulated directly as described above or indirectly via the nerve using field stimulation with short pulses of 0.02 ms.
- Two different methods of compromising neuromuscular transmission were applied: In FIG. 1A and FIG.
- FIG. 1B a sub-maximal concentration of tubocurarine (0.2 ⁇ M) was used to inhibit ACh receptors in the post-synaptic muscle fiber membrane.
- FIG. 1C neuromuscular transmission was reduced by elevating extracellular Mg 2+ to 3.5 mM.
- nerve-stimulation was conducted using a suction electrode, the electrical activity of the muscle could be recorded as M-waves (Inserts in FIG. 1A ). The entire M-wave train is shown with the first and the last M-waves in the trains enlarged above.
- FIGS. 2A-2B Effect of CIC-1 channel inhibition with 9-AC on nerve-stimulated force in rat soleus muscles exposed to tubocurarine or elevated extracellular Mg 2+ .
- Muscles were stimulated to contract by activation of the motor nerve using a suction electrode. During experiments, the muscles contracted every 10 min for 2 s in response to 60 Hz stimulation.
- FIG. 2A shows representative recordings of tetani from a soleus muscle from a 4-week-old animal that first contracted in control conditions, then during the pre-incubation with tubocurarine and, finally, in the presence of both tubocurarine and 9-AC. At the end of the experiment, tubocurarine was washed out to ensure full recovery of contractile force.
- FIG. 2B shows representative recordings of tetani from a soleus muscle from a 4-week-old animal that first contracted in control conditions, then during the pre-incubation with 3.5 mM Mg 2+ and, finally, at 3.5 mM Mg 2+ in the presence of 9-AC. When returned to normal extracellular Mg 2+ of 1.2 mM, full contractile force ensued.
- M-wave recordings from the muscle have been included for the force responses indicated by i, ii and iii as described in A.
- FIGS. 3A-3B Example of recovery of nerve-stimulated force with a clofibric acid derivative, C8, in muscles exposed to 150 nM tubocurarine.
- the motor nerve was stimulated every 10 min for 2 s with 30 Hz with field stimulation using short duration pulses.
- FIG. 3A shows force recordings from two muscles with the traces being overlaid to illustrate the effect of C8 clearly. Traces are shown before addition tubocurarine, after 40 min with tubocurarine, and after 110 min tubocurarine. After 40 min with tubocurarine, 50 ⁇ M C8 was added to the muscle that is presented by black traces.
- FIG. 3B shows average observations from 5 muscles treated with C8 and 5 control muscles exposed to only tubocurarine. Dotted lines indicate the recovery of nerve-stimulated force in the muscles treated with C8 compared to their force production after 40 min with tubocurarine. This recovery of force was used in Table 1.
- FIGS. 4A-4C A three-electrode technique was used to determine the effect of clofibric acid derivatives on the resting membrane conductance, G m .
- Three electrodes were inserted into the same muscle fiber enabling recordings of the membrane potential response to the injection of square current pulses at three inter-electrode distances (dist1 ⁇ dist2 ⁇ dist3).
- FIG. 4A shows the voltage responses at three inter-electrode distances in a control muscle fiber, and in a fiber exposed to 10 ⁇ M C8.
- FIG. 4B to determine G m the steady state deflection of the membrane potential was measured at each of the three inter-electrode distances.
- FIG. 4C shows G m at a range of C8 concentrations.
- FIGS. 5A-5E Effect of C8 and neostigmine on the tubocurarine concentration required to reduce nerve-stimulated force in soleus muscles. Muscles from 4-week-old rats were stimulated to contract by activating the motor nerve with short duration pulses in field stimulation. Muscles contracted every 10 min for 2 s in response to 30 Hz stimulation. Four different experimental conditions were used. Thus, muscles were initially incubated for 30 min in either i) control conditions, ii) with 50 ⁇ M C8, iii) in the presence of 10 nM neostigmine, or iv) with the combination of neostigmine and C8.
- FIG. 5A shows representative recordings of force at different concentrations of tubocurarine in a control muscle.
- FIG. 5B similar to FIG. 5A but this muscle had been pre-incubated with C8.
- FIG. 5C similar to FIG. 5A but this muscle had been pre-incubated with neostigmine.
- FIG. 5D similar to FIG. 5A but this muscle had been pre-incubated with the combination of C8 and neostigmine.
- the force integral (AUC) was determined at each tubocurarine concentration. Such AUC determinations were plotted against tubocurarine concentration for each muscle.
- FIG. 5E shows such plots of AUC for muscles in
- FIG. 5A - FIG. 5D The lines connecting the symbols are fits of the data to a sigmoidal function from which the tubocurarine concentration that was required to reduce AUC to 50% could be obtained (Tub 50 ).
- the averages of Tub 50 in the four groups of muscles are given in Table 3.
- FIGS. 6A-6E Effect of a C8 and 3,4-AP on the extracellular Mg 2+ concentration required to reduce nerve-stimulated force in soleus muscles.
- Muscles from 4-week-old rats were stimulated to contract by activating the motor nerve with short duration pulses in field stimulation. Muscles contracted every 10 min for 2 s in response to 30 Hz stimulation.
- Four different experimental conditions were used. Thus, muscles were initially incubated for 30 min in either i) control conditions, ii) with 50 ⁇ M C8, iii) in the presence of 10 ⁇ M 3,4-AP, or iv) with the combination of 3,4-AP and C8. After this pre-incubation, the extracellular Mg 2+ was progressively increased in the bath solutions every 60 min resulting in six contractions between each increase in extracellular Mg 2+ .
- FIG. 6A shows representative recordings of force at different concentrations of Mg 2+ in a control muscle.
- FIG. 6B similar to FIG. 6A but this muscle had been pre-incubated with C8.
- FIG. 6C similar to FIG. 6A but this muscle had been pre-incubated with 3,4-AP.
- FIG. 6B similar to FIG. 6A but this muscle had been pre-incubated with the combination of C8 and 3,4-AP.
- the force integral (AUC) was determined at each extracellular Mg 2+ concentration. AUC was plotted against Mg 2+ concentration and the data was fitted to a sigmoidal function. This provided the extracellular Mg 2+ concentration that was required to reduce the nerve-stimulated force to 50% (Mg 50 ) under the four different conditions (see Table 4).
- FIGS. 7A-7B Effects of C8 on EPP amplitude in rat soleus muscle. Intracellular electrodes were inserted near visible nerve branches in the muscle. The solution contained 1 ⁇ M ⁇ -conotoxin GiiiB to block NaV1.4. Under these conditions nerve-stimulation only resulted in EPP formation in the fibers and it did not trigger muscle fiber action potentials.
- FIG. 7A shows representative EPPs under control conditions and with two concentrations of C8.
- FIG. 7B shows average EPP amplitudes in the fibers. *Indicates significantly different from control as evaluated using a student t-test.
- FIGS. 8A-8B Effects of C8 on contractile force in human muscles depressed by elevated extracellular K + and low dose of TTX.
- FIG. 8A shows effect of adding 150 ⁇ M C8 on force in a muscle at elevated K + and with TTX.
- FIG. 8B shows the average force at elevated K + in the presence or absence of C8. *Indicates significant different as evaluated using a one-tailed student t-test.
- FIGS. 9A-9D Effects of I.P. C8 injection (20 mg/kg) on running performance of rats after I.P. injection of tubocurarine (0.13 mg/kg).
- FIG. 9A illustrates the design of the experiments. Prior to Day One the animals had been familiarized to the rotarod in three training sessions distributed over two days.
- FIG. 9B shows the distance covered by the rats on the two days 21-26 mins after injection of tubocurarine.
- FIG. 9C shows the increase in performance on Day Two when compared to performance on Day One.
- FIG. 9D shows the number of animals that on Day Two had an increased performance of more than 100% compared to performance on Day One.
- FIG. 10 Effects of C8 on running performance after inducing passive myasthenia gravis in rats using MAB35 monoclonal antibody.
- MAB35 monoclonal antibody.
- the animals Prior to I.P. injection of MAB35 the animals had been familiarized to the rotarod over three training sessions distributed over two days. After I.P. injection of MAB35 the running performance of the animals was monitored regularly and if a stable reduction in performance developed, the animals were given either sham, 20 mg/kg C8 or 30 mg/kg C8. After this treatment performance was monitored every second hour. *Indicates significant different as evaluated using student t-test.
- FIGS. 11A-11C show a schematic representation of the positioning of the three microelectrodes (V 1 , V 2 and V 3 ) when inserted in a single skeletal muscle fibre for G m determination. Please note that the drawing illustrates only the impaled fibre although it is part of an intact muscle that contains many such fibres. All electrodes recorded the membrane potential of the fibre and the two peripheral electrodes were used to inject current ( ⁇ 30 nA, 50 ms). The electrodes were inserted with known inter-electrode distances (X 1 , X 2 and X 3 ). After insertion, current was passed first via the V 1 electrode and then via the V 3 electrode. The resulting deflections in the membrane voltage were measured by the other electrodes.
- FIGS. 12A-12B show representative force traces before and after exposure to compound A-22. Force traces from a representative muscle stimulated to contract in 1) control condition before addition of neuromuscular blocking agent, 2) the force response to stimulation after 90 minutes incubation with Tubocurarine. Here the muscle displays severe neuromuscular transmission impediment, and 3) The muscle force response after addition of 50 ⁇ M compound A-22.
- FIG. 12B shows average force (AUC) from 3 muscles relative to their initial force. The traces presented in FIG. 12A (1, 2, 3), correspond to the dotted lines in FIG. 12B , respectively. Thus, force is lost due to 90 min incubation in tubocurarine and is subsequently recovered when compound A-19 is added.
- halogen means fluoro, chloro, bromo or iodo.
- Halo means halogen.
- C 1-3 alkyl and “C 1-5 -alkyl” refers to a branched or unbranched alkyl group having from one to three or one to five carbon atoms respectively, including but not limited to methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl and pent-3-yl.
- C 1-5 -alkenyl refers to a branched or unbranched alkenyl group having from one to five carbon atoms, two of which are connected by a double bond, including but not limited to ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl and isopentenyl.
- C 1-5 -alkynyl to a branched or unbranched alkynyl group having from one to five carbon atoms, two of which are connected by a triple bond, including but not limited to ethynyl, propynyl, butynyl and pentynyl.
- —C( ⁇ O)— refers to a carbonyl group and is used herein followed by a specification of the group connected thereto, such as for example the term “—C( ⁇ O)—C 1-5 alkyl” which refers to a carbonyl group connected to a branched or unbranched alkyl group having from one to five carbon atoms, including but not limited to a carbonyl group connected to methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl or pent-3-yl.
- C 3-5 -cycloalkyl refers to a group having three to five carbon atoms including a monocyclic or bicyclic carbocycle, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethyl, cyclopropylethyl and cyclobutylmethyl.
- C 5 -cycloalkenyl refers to a group having five carbon atoms including a monocyclic or bicyclic carbocycle wherein two carbon atoms in the ring are connected by a double bond, including but not limited to cyclobutenylmethyl.
- 5-6 membered heterocycle refers to a group having five to six carbon atoms wherein between 1 and 3 carbon atoms in the ring have been replaced with a heteroatom selected from the group comprising nitrogen, sulphur and oxygen. Binding to the heterocycle may be at the position of the heteroatom or via a carbon atom of the heterocycle.
- 5-membered heterocycles include but are not limited to furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole, isoxazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,5-thiadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, dihydrofuran, dihydrothiophene, 3-pyrroline, 2-pyrroline, 2-imidazoline, 2-pyrazolidine, dihydro-oxazole, dihydro-thiazole, dihydro-isoxazole, dihydro-isothiazole, dihydro-1,2,3-triazole, dihydro-1,2,4-triazole, dihydro-1,
- 6-membered heterocycles include but are not limited to pyridine, pyrazine, pyrimidine, pyridazine, tetrahydropyran, thiane, piperidine, 1, 4-dioxane, morpholine, 1,4-oxathiane, 1,4-diathiane and piperazine.
- 8-10 membered bicyclic heterocycle refers to a group having eight to ten heavy atoms in which two ring systems have been fused together, wherein between 1 and 3 carbon atoms in the ring have been replaced with a heteroatom selected from the group comprising nitrogen, sulphur and oxygen. Binding to the heterocycle may be at the position of the heteroatom or via a carbon atom of the heterocycle.
- 8-membered bicyclic heterocycles include but are not limited to tetrahydro-4H-cyclopent[d]isoxazole, hexahydro-1H-pyrrolizine, 1,4-dihydropyrrolo[3,2-b]pyrrole, 1,6-dihydropyrrolo[2,3-b]pyrrole, 6H-furo[2,3-b]pyrrole, 4H-furo[3,2-b]pyrrole, 6H-thieno[2,3-b]pyrrole and 4H-thieno[3,2-b]pyrrole.
- 9-membered bicyclic heterocycles include but are not limited to benzofuran, benzothiophene, indole, benzimidazole, indazole, benzothiazole, benzoxazole, 1,2-benzisoxazole, 1,2-benzisothiazole, benzotriazole, pyrrolopyridine, pyrazolopyridine and imidazopyridine.
- 10-membered bicyclic heterocycles include but are not limited to quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine and naphthyridine.
- C 1-8 -alk(en/yn)yl means C 1-8 -alkyl, C 2-8 -alkenyl or C 2-6 -alkynyl; wherein:
- C 3-6 -cycloalk(en)yl means C 3-6 -cycloalkyl or C 3-6 -cycloalkenyl, wherein:
- half-life is the time it takes for the compound to lose one-half of its pharmacologic activity.
- plasma half-life is the time that it takes the compound to lose one-half of its pharmacologic activity in the blood plasma.
- treatment refers to the combating of a disease or disorder.
- Treatment includes any desirable effect on the symptoms or pathology of a disease or condition as described herein, and may include even minimal changes or improvements in one or more measurable markers of the disease or condition being treated. “Treatment” or “treating” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof.
- amelioration refers to moderation in the severity of the symptoms of a disease or condition. Improvement in a patient's condition, or the activity of making an effort to correct, or at least make more acceptable, conditions that are difficult to endure related to patient's conditions is considered “ameliorative” treatment.
- prevent refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action.
- reversal refers to the ability of a compound to restore nerve-stimulated force in skeletal muscle exposed either ex vivo or in vivo to a non-depolarizing neuromuscular blocking agent or another pharmaceutical that is able to depress neuromuscular transmission
- ester hydrolysing reagent refers to a chemical reagent which is capable of converting an ester functional group to a carboxylic acid with elimination of the alcohol moiety of the original ester, including but not limited to acid, base, a fluoride source, PBr 3 , PCl 3 and lipase enzymes.
- non-depolarizing blockers refers to pharmaceutical agents that antagonize the activation of acetylcholine receptors at the post-synaptic muscle fibre membrane by blocking the acetylcholine binding site on the receptor. These agents are used to block neuromuscular transmission and induce muscle paralysis in connection with surgery.
- recovery of force in muscle with neuromuscular dysfunction refers to the ability of a compound to recover contractile force in nerve-stimulated healthy rat muscle after exposure to submaximal concentration of (115 nM) tubocurarine for 90 mins. Recovery of force is quantified as the percentage of the force prior to tubocurarine that is recovered by the compound.
- total membrane conductance is the electrophysiological measure of the ability of ions to cross the muscle fibre surface membrane. It reflects the function of ion channels that are active in resting muscle fibres of which CIC-1 is known to contribute around 80% in most animal species.
- compositions of the present invention comprise compounds capable of inhibiting the CIC-1 channel thereby improving or restoring neuromuscular function.
- the invention relates to a composition
- a composition comprising a compound of Formula (I):
- A is a monocyclic or bicyclic aromatic or heteroaromatic ring.
- A may for example be a monocyclic ring comprising 5 to 6 carbon atoms or a bicyclic ring comprising 8 to 10 C-atoms.
- A is five-membered or six-membered aromatic ring.
- A can also be a five-membered or six-membered heteroaromatic ring.
- A is phenyl or naphthyl.
- the heteroaromatic ring may for example comprise S, O or N atoms.
- A is a five or six-membered aromatic ring comprising at least one N.
- A is a five-membered heteroaromatic ring comprising an S and four C atoms.
- A is a five-membered heteroaromatic ring comprising an O and four C atoms.
- the invention concerns a composition comprising a compound of Formula (I.3.4):
- the invention relates to a composition
- a composition comprising a compound of Formula (I.3.4), wherein:
- the invention concerns a compound of Formula (I.3.4):
- the invention concerns a compound of Formula (I.3.4):
- the invention relates to a composition
- a composition comprising a compound of Formula (II):
- R 4 is selected from the group consisting of H, C 1-6 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl. In an embodiment thereof R 4 is selected from the group consisting of H, C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl, from the group consisting of H, C 1-4 -alk(en)yl and C 3-6 -cycloalk(en)yl or from the group consisting of H, C 1-4 -alkyl and C 3-6 -cycloalk(en)yl. In one embodiment R 4 is selected from the group consisting of H and C 1-4 -alkyl.
- R 4 is selected from the group consisting of NR 9 —CO—R 10 , —NR 10 —SO 2 —R 12 , —CO—NR 9 R 10 , —SO 2 —NR 9 R 10 , —R 13 —O—R 11 , NR 9 R 10 or O—R 11 , wherein R 9 , R 10 and R 11 are independently selected from H, C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl whereas R 12 is selected from C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl.
- R 9 , R 10 and R 11 may for example be independently selected from H and C 1-4 -alkyl or from the group consisting of H and C 1-3 -alkyl. In one embodiment R 9 , R 10 and R 11 are independently selected from H and —CH 3 .
- R 4 is selected from the group consisting of cyano, fluorinated C 1-3 , nitro and halo. In one embodiment R 4 is selected from the group consisting of Cl, Br, I or F. In one embodiment R 4 is selected from the group consisting of Cl and Br.
- R 4 can be located in either ortho- meta or para-position with respect to Y.
- m can be 0, 1, 2, 3, 4 or 5.
- m is 0, 1, 2, 3 or 4, such as 0, 1, 2 or 3 or such as 0, 1 or 2.
- m is 0 or 1.
- R 1 and R 2 are independently selected from the group consisting of OR 3 , SR 5 , S(O)R 5 , S(O) 2 R 5 , NR 3 , NR 3 C(O)R 9 , wherein
- R 3 and/or R 5 is selected from the group consisting of H, C 1-8 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl.
- R 3 is selected from the group consisting of H, C 1-6 -alkyl and C 3-7 -cycloalkyl.
- R 3 is selected from the group consisting of H, C 1-6 -alkyl, such as from the group consisting of H and C 1-4 -alkyl.
- R 3 is selected from the group consisting of H and CH 3 .
- R 1 and R 2 are independently selected from the group consisting of H, C 1-8 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl.
- C 1-8 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR 9 —CO—R 10 , —N(R 10 ) 2 —SO 2 —R 12 , —CO—NR 9 R 10 , —SO 2 —NR 9 R 10 , —R 13 —O—R 11 , NR 9 R 10 , —S(O)R 12 , S(O) 2 R 12 , cyano, O—R 11 , fluorinated C 1-3 -alkyl, nitro and halo.
- R 9 , R 10 and R 11 are independently selected from H, C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl whereas R 12 is selected from C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl It is appreciated that R 1 is different from R 2 .
- R 1 is selected from the group consisting of H and —CH 3 . In a more preferred embodiment R 1 is H.
- R 1 is H and R 2 is selected from the group consisting of H, C 1-8 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl.
- C 1-8 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR 9 —CO—R 10 , —N(R 10 ) 2 —SO 2 —R 12 , —CO—NR 9 R 10 , —SO 2 —NR 9 R 10 , —R 13 —O—R 11 , NR 9 R 10 , —S(O)R 12 , S(O) 2 R 12 , cyano, O—R 11 , fluorinated C 1-3 -alkyl, nitro and halo, wherein R 9 , R 10 and R 11 are independently selected from H, C 1-4 -alk(en/yn)yl and C
- R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alk(en)yl, C 3-6 -cycloalk(en)yl, wherein said C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl may be substituted with up to two substituents selected from the group consisting of —NR 9 —CO—R 10 , —N(R 10 ) 2 —SO 2 —R 12 , —CO—NR 9 R 10 , —SO 2 —NR 9 R 10 , —R 13 —O—R 11 , NR 9 R 10 , —S(O)R 12 , S(O) 2 R 12 , cyano, O—R 11 , fluorinated C 1-3 -alkyl, nitro and halo, wherein R 9 , R 10 and R 11 are independently selected from H, C 1-4 -alk(en/yn)yl and C
- R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alkyl, C 3-6 -cycloalkyl and amino-C 1-4 -alkyl, wherein said C 1-4 -alkyl and C 3-6 -cycloalkyl may be substituted with O—R 11 , wherein R 11 is as defined above.
- R 11 is —CH 3 .
- R 1 and R 2 are independently selected from the group consisting of H and CH 3 .
- R 1 is H and R 2 is selected from the group consisting of H, C 1-6 -alkyl and C 3-7 -cycloalkyl.
- R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alkyl and C 3-5 -cycloalkyl.
- R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alkyl.
- R 1 is H and R 2 is selected from the group consisting of H, —CH 3 , —CH(CH 3 ) 2 and cyclopropyl.
- R 1 is H and R 2 is —CH(CH 3 ) 2 .
- R 2 is —CH(CH 3 )CH 2 —O—CH 3 .
- R 1 is H and R 2 is —CH(CH 3 )CH 2 —O—CH 3 .
- the compound is the S-enantiomer with respect to the C-atom to which R 2 is bound.
- R 1 and R 2 are in one embodiment linked to form a C 3-6 -cycloalk(en)yl or a halo-C 3-6 -cycloalk(en)yl.
- R 1 and R 2 are linked to form a C 3-5 -cycloalk(en)yl or a halo-C 3-5 -cycloalk(en)yl.
- R 1 and R 2 are linked to form a C 3-4 -cycloalk(en)yl or a halo-C 3-4 -cycloalk(en)yl.
- R 1 and R 2 are linked to form a cyclopropyl or a halo-cyclopropyl.
- R 1 and R 2 are linked to form a cyclopropyl.
- the invention relates to a composition
- a composition comprising a compound of Formula (II.4):
- R 1 is H and R 2 is —CH(CH 3 ) 2 and wherein said compound is the S-enantiomer with respect to the C-atom to which R 2 is bound as shown in formula
- X 1 is N
- X 2 is N
- X 3 is N
- R 4 may for example be selected from the group consisting of H, halo, cyano, —CHO, C 1-4 -alk(en)yl, halo-C 1-4 -alk(en)yl, —O—C 1-4 -alk(en)yl
- n is 0, 1 or 2. In one embodiment m is 0 or 1. For example m is 1.
- the invention relates to a compound of Formula (III.4):
- R 2 is C 1-6 -alkyl or C 3-7 -cycloalkyl.
- A is a monocyclic ring such as a phenyl. It is preferred that R 4 is in ortho- or meta position.
- the invention relates to a compound of Formula (IV.4):
- R 2 and R 4 are as defined above.
- the invention relates to a compound of Formula (V.4):
- the compound of Formula (V) is further defined by Formula (VI):
- R 4 is as defined above. It is preferred the R 4 is in ortho- or meta position.
- the invention relates to a compound of Formula (VI.4):
- the invention relates to a compound of Formula (VII.4):
- Formula (VII) is further defined by Formula (VIII)
- Y is O.
- R 2 is selected from the group consisting of H and C 1-4 -alkyl.
- R 4 is in one embodiment selected from the group consisting of H, —CH 3 and halogen.
- the invention relates to a compound of Formula (VIII.4):
- the invention relates to a compound of Formula (IX.4):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH(CH 3 )CH 2 —O—CH 3 , —CH 2 —CH 2 —CH 3 , —CH 2 —NH 2 , —CH 2 —CHF 2 , —CH 2 —CF 3 , —CH 2 —NH—CO—CH 3 and —CH 2 —NH—SO 2 —CH 3 and cyclopropyl, and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- R 2 is —CH 3 or —CH(CH 3 ) 2 ; and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- R 2 is —CH(CH 3 ) 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- the invention relates to a compound of Formula (X.4):
- the invention relates to a compound of Formula (XI.4):
- the invention relates to a compound of Formula (XII.4):
- the invention relates to a compound of Formula (XIII.4):
- the invention relates to a compound of Formula (XIV.4):
- the invention relates to a compound of Formula (XIV.4):
- Formula (VII) is further defined by any one of Formulas (XI) to (XXVI II):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- R 2 is —CH 3 or —CH(CH 3 ) 2 ; and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- R 2 is —CH 3 or —CH(CH 3 ) 2 and R 4 is selected from the group consisting of H, Br, Cl and F. It is further preferred that the compound of Formula (X) is the S-enantiomer with respect to the C-atom to which R 2 is bound.
- This embodiment is exemplified by Formulas (XXIII) and (XXIV), where R 2 is —CH 3 and R 4 is Cl or Br.
- Y is SO 2 .
- the compound of Formula (VII) can be further defined by Formula (XXXII):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- R 2 is —CH 3 or —CH(CH 3 ) 2 ; and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- R 2 is —CH 3 or —CH(CH 3 ) 2 and R 4 is selected from the group consisting of H, Br, Cl and F.
- R 2 and X 1 are as defined above; and R 4 and R′ 4 are independently selected from the group consisting of H, halo, cyano, hydroxy, —CHO, C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, O—C 1-6 -alk(en/yn)yl.
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 .
- R 2 is CH 3 or —CH(CH 3 ) 2 . It is preferred that R 4 and R′ 4 are individually selected from the group consisting of H, Br, Cl, F and I. In another preferred embodiment R 4 and/or R′ 4 are H. It is further preferred that X 1 is N or C.
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 ;
- X 1 is N or C; and
- R 4 and R′ 4 are individually selected from the group consisting of H, Br, Cl, F and I.
- Formula (XXXIV) is further defined by Formula (XXXV):
- the compound of Formula (I) is further defined by any one of Formulas (XXXVI) to (LIX):
- the compound is selected from the group consisting of:
- the invention relates to the use of the following compounds in treating, ameliorating and/or preventing a neuromuscular disorder. In one aspect, the invention relates to the use of the following compounds in reversing and/or ameliorating a neuromuscular blockade.
- Another aspect of the present invention relates to a compound of Formula (I):
- A is a monocyclic or bicyclic aromatic or heteroaromatic ring.
- A can be a five-membered or six-membered aromatic ring.
- A is phenyl, or naphthyl.
- the invention concerns a compound of Formula (I.3.4):
- the invention relates to a compound of Formula (I.3.4), wherein:
- the invention concerns a compound of Formula (I.3.4):
- the invention concerns a compound of Formula (I.3.4):
- the compound of Formula (I) is further defined by Formula (II):
- R 1 is selected from the group consisting of H and —CH 3 . In a particular embodiment R 1 is H.
- R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alk(en)yl, C 3-6 -cycloalk(en)yl, wherein said C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl may be substituted with up to two substituents selected from the group consisting of —NR 9 —CO—R 10 , —N(R 10 ) 2 —SO 2 —R 12 , —CO—NR 9 R 10 , —SO 2 —NR 9 R 10 , —R 13 —O—R 11 , NR 9 R 10 , —S(O)R 12 , S(O) 2 R 12 , cyano, O—R 11 , fluorinated C 1-3 -alkyl, nitro and halo, wherein R 9 , R 10 and R 11 are independently selected from H, C 1-4 -alk(en/yn)yl and
- R 1 is H and R 2 is selected from the group consisting of H, C 1-6 -alkyl and C 3-7 -cycloalkyl.
- R 1 is H and R 2 is selected from the group consisting of H, —CH 3 , —CH(CH 3 ) 2 and cyclopropyl.
- R 1 is H and R 2 is —CH(CH 3 ) 2 .
- R 1 is different from R 2 .
- the compound as defined herein is the S-enantiomer with respect to the C-atom to which R 2 is bound.
- the invention relates to a compound of Formula (II.4):
- R 1 is H and R 2 is C 1-6 -alkyl or C 3-7 -cycloalkyl and wherein said compound is the S-enantiomer with respect to the C-atom to which R 2 is bound as shown in Formula (III):
- R 4 is selected from the group consisting of H, halo, cyano, —CHO, C 1-4 -alk(en)yl, halo-C 1-4 -alk(en)yl, —O—C 1-4 -alk(en)yl.
- n 0, 1 or 2.
- m is 1.
- X 1 is N
- X 2 is N or X 3 is N.
- X1, X 2 and X 3 is C.
- the invention relates to a compound of Formula (III.4):
- the compound may in one embodiment be defined by Formula (I), which is further defined by Formula (IV):
- the invention relates to a compound of Formula (IV.4):
- R 2 and R 4 are as defined above. It is preferred that R 2 is C 1-6 -alkyl or C 3-7 -cycloalkyl.
- the invention relates to a compound of Formula (V.4):
- the compound of Formula (V) is further defined by Formula (VI):
- R 4 is as defined above.
- R 4 is in ortho- or meta position.
- the invention relates to a compound of Formula (VI.4):
- the compound of Formula (I) is further defined by Formula (VII):
- the invention relates to a compound of Formula (VII.4):
- the compound of Formula (VII) is further defined by Formula (VIII)
- the invention relates to a compound of Formula (VIII.4):
- Y is O. It is further preferred that R 2 is selected from the group consisting of H and C 1-4 -alkyl. Preferably, R 4 is selected from the group consisting of H, —CH 3 and halogen. Thus, in one embodiment the compound is further defined by Formula (IX):
- the invention relates to a compound of Formula (IX.4):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH(CH 3 )CH 2 —O—CH 3 , —CH 2 —CH 2 —CH 3 , —CH 2 —NH 2 , —CH 2 —CHF 2 , —CH 2 —CF 3 , —CH 2 —NH—CO—CH 3 and —CH 2 —NH—SO 2 —CH 3 and cyclopropyl, and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- the invention relates to a compound of Formula (X.4):
- the invention relates to a compound of Formula (XI.4):
- the invention relates to a compound of Formula (XII.4):
- the invention relates to a compound of Formula (XIII.4):
- the invention relates to a compound of Formula (XIV.4):
- the invention relates to a compound of Formula (XIV.4):
- the compound of Formula (VII) is further defined by any one of Formulas (XI) to (XXVIII) as defined herein.
- Another embodiment of the present invention relates to a compound of Formula (VII) that is further defined by Formula (XXIX):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- the compound of Formula (VII) is further defined by Formula (XXXI):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- the compound of Formula (XXXII) is further defined by Formula (XXXIII):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 ;
- X 1 is N or C; and
- R 4 and R′ 4 are individually selected from the group consisting of H, Br, Cl, F and I.
- Formula (XXXIV) can be further defined by Formula (XXXV):
- the compound of Formula (I) is further defined by any one of Formulas (XXXVI) to (LIX) and compounds A-1 to A-29.
- the compound or the compound for use according to the present invention has been modified in order to increase its half-life when administered to a patient, in particular its plasma half-life.
- the compound or the compound for use according to the present invention further comprises a moiety conjugated to said compound, thus generating a moiety-conjugated compound.
- said moiety-conjugated compound has a plasma and/or serum half-life being longer than the plasma and/or serum half-life of the non-moiety conjugated compound.
- the moiety conjugated to the compound or compound for use according to the present invention is one or more type(s) of moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments
- compositions and compounds of the present invention are used for treating, ameliorating and/or preventing a neuromuscular disorder, or reversing neuromuscular blockade caused by non-depolarizing neuromuscular blocker or antibiotic agent.
- the inventors of the present invention have shown that inhibition of CIC-1 channels recovers neuromuscular transmission. CIC-1 function may therefore contribute to muscle weakness in conditions of compromised neuromuscular transmission.
- composition for use as described herein inhibits CIC-1 channels.
- compounds of Formula (I) inhibit CIC-1 channels.
- the neuromuscular disorder may also include neuromuscular dysfunctions.
- Neuromuscular disorders include for example disorders with symptoms of muscle weakness and fatigue. Such disorders may include conditions with reduced neuromuscular transmission safety factor.
- the neuromuscular disorders are motor neuron disorders.
- Motor neuron disorders are disorders with reduced safety in the neuromuscular transmission.
- motor neuron disorders are selected from the group consisting of amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), X-linked spinal and bulbar muscular atrophy, Kennedy's disorder, multifocal motor neuropathy, Guillain-Barré syndrome, poliomyelitis and post-polio syndrome.
- ALS amyotrophic lateral sclerosis
- SMA spinal muscular atrophy
- X-linked spinal and bulbar muscular atrophy Kennedy's disorder
- multifocal motor neuropathy Guillain-Barré syndrome
- poliomyelitis post-polio syndrome.
- the neuromuscular disorder is ALS.
- the neuromuscular disorder is SMA.
- the neuromuscular disorder is Charcot-Marie tooth disease (CMT).
- the neuromuscular disorder is sarcopenia.
- the neuromuscular disorder is critical illness myopathy (CIM).
- neuromuscular disorders include for example disorders with symptoms of muscle weakness and fatigue.
- Such disorder may for example include diabetes.
- the composition of the present invention is used to prevent neuromuscular disorder.
- the composition may for example be used prophylactically against nerve gas that is known to cause symptoms of muscle weakness and fatigue.
- the neuromuscular disorders is chronic fatigue syndrome.
- Chronic fatigue syndrome is the common name for a medical condition characterized by debilitating symptoms, including fatigue that lasts for a minimum of six months in adults.
- CFS may also be referred to as systemic exertion intolerance disorder (SEID), myalgic encephalomyelitis (ME), post-viral fatigue syndrome (PVFS), chronic fatigue immune dysfunction syndrome (CFIDS), or by several other terms.
- SEID systemic exertion intolerance disorder
- ME myalgic encephalomyelitis
- PVFS post-viral fatigue syndrome
- CIDS chronic fatigue immune dysfunction syndrome
- Symptoms of CFS include malaise after exertion; unrefreshing sleep, widespread muscle and joint pain, physical exhaustion, and muscle weakness.
- the neuromuscular disorder is a critical illness polyneuropathy or CIM.
- Critical illness polyneuropathy and CIM are overlapping syndromes of widespread muscle weakness and neurological dysfunction developing in critically ill patients.
- the neuromuscular disorder may also include metabolic myopathy and mitochondrial myopathy.
- Metabolic myopathies result from defects in biochemical metabolism that primarily affects muscle. These may include glycogen storage disorders, lipid storage disorder and 3-phosphocreatine stores disorder.
- Mitochondrial myopathy is a type of myopathy associated with mitochondrial disorder. Symptoms of mitochondrial myopathies include muscular and neurological problems such as muscle weakness, exercise intolerance, hearing loss and trouble with balance and coordination.
- the neuromuscular disorder is a myasthenic condition.
- Myasthenic conditions are characterized by muscle weakness and neuromuscular transmission failure.
- Congenital myasthenia gravis is an inherited neuromuscular disorder caused by defects of several types at the neuromuscular junction.
- Myasthenia gravis 3 and Lambert-Eaton syndrome are also examples of myasthenic condition.
- Myasthenia gravis is either an autoimmune or congenital neuromuscular disorder that leads to fluctuating muscle weakness and fatigue.
- Lambert-Eaton myasthenic syndrome also known as LEMS, Lambert-Eaton syndrome, or Eaton-Lambert syndrome
- LEMS Lambert-Eaton myasthenic syndrome
- Eaton-Lambert syndrome is a rare autoimmune disorder that is characterized by muscle weakness of the limbs. It is the result of an autoimmune reaction in which antibodies are formed against presynaptic voltage-gated calcium channels, and likely other nerve terminal proteins, in the neuromuscular junction.
- the neuromuscular disorder is myasthenia gravis.
- the neuromuscular disorder is Lambert-Eaton syndrome.
- Neuromuscular blockade is used in connection with surgery under general anaesthesia. Reversing agents are used for more rapid and safer recovery of muscle function after such blockade. Complications with excessive muscle weakness after blockade during surgery can result in delayed weaning from mechanical ventilation and respiratory complications after the surgery. Since such complications have pronounced effects on outcome of the surgery and future quality of life of patients, there is a need for improved reversing agents.
- the neuromuscular disorder is muscle weakness caused by neuromuscular blockade after surgery.
- the composition is used for reversing and/or ameliorating neuromuscular blockade after surgery.
- one aspect of the present invention relates to a composition comprising a compound of Formula
- the invention concerns a compound of Formula (I.3.4):
- the invention relates to a compound of Formula (I.3.4), wherein:
- the invention concerns a compound of Formula (I):
- the invention concerns a compound of Formula (I):
- the invention relates to a compound of Formula (II.4):
- the invention relates to a compound of Formula (III.4):
- the invention relates to a compound of Formula (IV.4):
- the invention relates to a compound of Formula (V.4):
- the invention relates to a compound of Formula (VI.4):
- the invention relates to a compound of Formula (VII.4):
- the invention relates to a compound of Formula (VIII.4):
- the invention relates to a compound of Formula (IX.4):
- the invention relates to a compound of Formula (X.4):
- the invention relates to a compound of Formula (XI.4):
- the invention relates to a compound of Formula (XII.4):
- the invention relates to a compound of Formula (XIII.4):
- the invention relates to a compound of Formula (XIV.4):
- the invention relates to a compound of Formula (XIV.4):
- the compound for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade is selected from the group consisting of:
- the compound or the compound for use according to the present invention has been modified in order to increase its half-life when administered to a patient, in particular its plasma half-life.
- the compound or the compound for use according to the present invention further comprises a moiety conjugated to said compound, thus generating a moiety-conjugated compound.
- said moiety-conjugated compound has a plasma and/or serum half-life being longer than the plasma and/or serum half-life of the non-moiety conjugated compound.
- the moiety conjugated to the compound or compound for use according to the present invention is one or more type(s) of moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- Another aspect of the invention relates to a method of reversing and/or ameliorating a neuromuscular blockade after surgery, said method comprising administering a therapeutically effective amount of the composition as defined in any one of the embodiments herein below to a person in need thereof.
- the present invention relates to use of a composition as defined herein, for the manufacture of a medicament for reversing and/or amelioration of a neuromuscular blockade after surgery.
- composition of the present invention may comprise further active ingredients/agents or other components to increase the efficiency of the composition.
- composition further comprises at least one further active agent.
- active agent is suitable for treating, preventing or ameliorating said neuromuscular disorder.
- the active agent is in a preferred embodiment an acetylcholine esterase inhibitor.
- Said acetylcholine esterase inhibitor may for example be selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives, galantamine, caffeine—noncompetitive, piperidines, donepezil, tacrine, edrophonium, huperzine, ladostigil, ungeremine and lactucopicrin.
- the acetylcholine esterase inhibitor is selected from the group consisting of neostigmine, physostigmine and pyridostigmine. It is preferred that the acetylcholine esterase inhibitor is neostigmine or pyridostigmine.
- the active agent may also be an immunosuppressive drug.
- limmunosuppressive drugs are drugs that suppress or reduce the strength of the body's immune system. They are also known as anti-rejection drugs.
- Immunosuppressive drugs include but are not limited to glucocorticoids, corticosteroids, cytostatics, antibodies and drugs acting on immunophilins.
- the active agent is prednisone.
- the active agent may also be an agent that is used in anti-myotonic treatment.
- agents include for example blockers of voltage gated Na + channels, and aminoglycosides.
- the active agent may also be an agent for reversing a neuromuscular blockade after surgery.
- agents include for example neostigmine or suggammadex.
- the active agent may also be an agent for increasing the Ca 2+ sensitivity of the contractile filaments in muscle.
- Such agent includes tirasemtiv.
- the active agent may also be an agent for increasing ACh release by blocking voltage gated K + channels in the pre-synaptic terminal.
- agent includes 3,4-aminopyridine.
- combination therapy using C8 and 3,4-diaminopyridine resulted in an unexpected synergistic effect on recovery of neuromuscular transmission.
- compositions comprising the compound or the compound for use, according to the present invention.
- the composition according to the present invention is used for treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- the compositions and compounds described herein are pharmaceutically acceptable.
- the composition as described herein is in the form of a pharmaceutical formulation.
- the composition as described herein further comprises a pharmaceutically acceptable carrier.
- the present invention further provides a pharmaceutical formulation, which comprises a compound as disclosed herein and a pharmaceutically acceptable salt or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof, as herein defined, and a pharmaceutically acceptable carrier.
- a pharmaceutical formulation which comprises a compound as disclosed herein and a pharmaceutically acceptable salt or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof, as herein defined, and a pharmaceutically acceptable carrier.
- the composition of the present invention further comprises a pharmaceutically acceptable carrier.
- the pharmaceutical formulations may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practice of Pharmacy 2005, Lippincott, Williams & Wilkins.
- the pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier can be one or more excipients which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, wetting agents, tablet disintegrating agents, or an encapsulating material.
- solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- compositions of the present invention may be formulated for parenteral administration and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers, optionally with an added preservative.
- the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
- oily or non-aqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
- compositions of the present invention is formulated for oral administration.
- Oral administration forms include solid form preparations including powders, tablets, drops, capsules, cachets, lozenges, and dispersible granules.
- Other forms suitable for oral administration may include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, toothpaste, gel dentrifrice, chewing gum, or solid form preparations which are intended to be converted shortly before use to liquid form preparations, such as solutions, suspensions, and emulsions.
- the carrier is a finely divided solid which is a mixture with the finely divided active component.
- the composition as described herein is formulated in a tablet or capsule.
- the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
- Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- Drops according to the present invention may comprise sterile or non-sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent.
- suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
- Emulsions may be prepared in solutions in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia.
- Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents.
- Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- compositions of the present invention may also be formulated in a wide variety of formulations for parenteral administration.
- the formulations may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol.
- the composition may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.
- the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules, vials, pre-filled syringes, infusion bags, or can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
- oily or non-aqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters, and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents.
- the formulations for injection will typically contain from about 0.5 to about 25% by weight of the active ingredient in solution.
- Regions for topical administration include the skin surface and also mucous membrane tissues of the vagina, rectum, nose, mouth, and throat.
- the topical composition will typically include a pharmaceutically acceptable carrier adapted for topical administration.
- the composition may take the form of a suspension, solution, ointment, lotion, sexual lubricant, cream, foam, aerosol, spray, suppository, implant, inhalant, tablet, capsule, dry powder, syrup, balm or lozenge, for example. Methods for preparing such compositions are well known in the pharmaceutical industry.
- the compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base.
- the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin or a fatty acid.
- the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
- suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
- Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
- Lotions according to the present invention also include those suitable for application to the eye.
- An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide.
- Formulations for use in nasal, pulmonary and/or bronchial administration are normally administered as aerosols in order to ensure that the aerosolized dose actually reaches the mucous membranes of the nasal passages, bronchial tract or the lung.
- aerosol particle is used herein to describe the liquid or solid particle suitable for nasal, bronchial or pulmonary administration, i.e., that will reach the mucous membranes.
- aerosols are administered by use of a mechanical devices designed for pulmonary and/or bronchial delivery, including but not limited to nebulizers, metered dose inhalers, and powder inhalers.
- any form of aerosolization known in the art including but not limited to spray bottles, nebulization, atomization or pump aerosolization of a liquid formulation, and aerosolization of a dry powder formulation, can be used.
- Liquid Aerosol Formulations in general contain a compound of the present invention in a pharmaceutically acceptable diluent.
- Pharmaceutically acceptable diluents include but are not limited to sterile water, saline, buffered saline, dextrose solution, and the like.
- Formulations for dispensing from a powder inhaler device will normally comprise a finely divided dry powder containing pharmaceutical composition of the present invention (or derivative) and may also include a bulking agent, such as lactose, sorbitol, sucrose, or mannitol in amounts which facilitate dispersal of the powder from the device.
- Dry powder formulations for inhalation may also be formulated using powder-filled capsules, in particularly capsules the material of which is selected from among the synthetic plastics.
- the formulation is formulated to the type of device employed and may involve the use of an appropriate propellant material, in addition to the usual diluents, adjuvants and/or carriers useful in therapy and known to the person skilled in the art.
- the propellant may be any propellant generally used in the art. Specific non-limiting examples of such useful propellants are a chlorofluorocarbon, a hydrofluorocarbon, a hydrochlorofluorocarbon, or a hydrocarbon.
- the formulations of the present embodiment may also include other agents useful for pH maintenance, solution stabilization, or for the regulation of osmotic pressure.
- the formulations of the present embodiment may also include other agents useful for pH maintenance, solution stabilization, or for the regulation of osmotic pressure.
- Transdermal administration typically involves the delivery of a pharmaceutical agent for percutaneous passage of the drug into the systemic circulation of the patient.
- the skin sites include anatomic regions for transdermally administering the drug and include the forearm, abdomen, chest, back, buttock, mastoidal area, and the like.
- Transdermal delivery is accomplished by exposing a source of the complex to a patient's skin for an extended period of time.
- Transdermal patches have the added advantage of providing controlled delivery of a pharmaceutical agent-chemical modifier complex to the body.
- dosage forms can be made by dissolving, dispersing, or otherwise incorporating the pharmaceutical agent-chemical modifier complex in a proper medium, such as an elastomeric matrix material.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.
- a simple adhesive patch can be prepared from a backing material and an acrylate adhesive.
- administration forms include but are not limited to oral, parental, topical, enteral, rectal or buccal administration.
- the composition is administered or adapted for administration enterally, topically, parenterally or as part of a sustained release implant.
- the parenteral administration may for example be intravenous, subcutaneous, intramuscular, intracranial or intraperitoneal.
- the parental administration is intramuscular.
- Enteral administration includes oral, rectal, or buccal administration and may be sustained release, long acting or immediate relase.
- topical administration is dermal, epicutaneous, vaginal, intravesical, pulmonary, intranasal, intratracheal or as eye drops.
- composition is administered or adapted for administration subcutaneously or intravenously.
- composition of the present invention comprises at least 30 wt. % compound, such as at least 25 wt. % compound, such as for example at least 20 wt. % compound, at least 15 wt. % compound, such as at least 25 wt. % compound, such as for example at least 20 wt. % compound, at least 15 wt. % compound, such as at least 10 wt. % compound, such as for example at least 8 wt. % compound, at least 5 wt. % compound, such as at least 4 wt. % compound, such as for example at least 3 wt. % compound, at least 2 wt. % compound, such as at least 1 wt. % compound, such as for example at least 0.5 wt. % compound or at least 0.5 wt. % compound.
- Wt. % is an abbreviation for weight percent.
- the compound is any compound defined by Formula (I).
- the active ingredient can be any of the compounds defined by the formulas or embodiments presented herein.
- the compound as described herein is to be administered in a dosage of from 1 ⁇ g/kg-30,000 ⁇ g/kg body weight, such as 1 ⁇ g/kg-7,500 ⁇ g/kg, such as 1 ⁇ g/kg-5,000 ⁇ g/kg, such as 1 ⁇ g/kg-2,000 ⁇ g/kg, such as 1 ⁇ g/kg-1,000 ⁇ g/kg, such as 1 ⁇ g/kg-700 ⁇ g/kg, such as 5 ⁇ g/kg-500 ⁇ g/kg, such as 10 ⁇ g/kg to 100 ⁇ g/kg bodyweight.
- 1 ⁇ g/kg-30,000 ⁇ g/kg body weight such as 1 ⁇ g/kg-7,500 ⁇ g/kg, such as 1 ⁇ g/kg-5,000 ⁇ g/kg, such as 1 ⁇ g/kg-2,000 ⁇ g/kg, such as 1 ⁇ g/kg-1,000 ⁇ g/kg, such as 1 ⁇ g/kg-700 ⁇ g/kg, such as 5 ⁇ g/kg-
- the compound as described herein is to be administered in a dosage of from 1 ⁇ g/kg-1,000 ⁇ g/kg body weight, such as 1 ⁇ g/kg-500 ⁇ g/kg, such as 1 ⁇ g/kg-250 ⁇ g/kg, such as 1 ⁇ g/kg-100 ⁇ g/kg, such as 1 ⁇ g/kg-50 ⁇ g/kg, such as 1 ⁇ g/kg to 10 ⁇ g/kg bodyweight.
- the compound as described herein is to be administered in a dosage of from 10 ⁇ g/kg-30,000 ⁇ g/kg body weight, such as 10 ⁇ g/kg-7,500 ⁇ g/kg, such as 10 ⁇ g/kg-5,000 ⁇ g/kg, such as 10 ⁇ g/kg-2,000 ⁇ g/kg, such as 10 ⁇ g/kg-1,000 ⁇ g/kg, such as 10 ⁇ g/kg-700 ⁇ g/kg, such as 10 ⁇ g/kg-500 ⁇ g/kg, such as 10 ⁇ g/kg to 100 ⁇ g/kg bodyweight.
- the administration of the composition as described herein is repeated at least 1, 2, 3, 4, 5 or 6 times weekly.
- the administration is repeated at least 1-3 times weekly, such as 2-5 times weekly, such as 3-6 times weekly.
- the administration is repeated daily.
- the administration of the composition may for example be repeated 1, 2, 3, 4, 5, 6, 7 or 8 times daily.
- the administration is repeated 1 to 8 times daily, such as 2 to 5 times daily.
- the compound as defined herein can be modified in order to increase its half-life when administered to a patient, in particular its plasma half-life.
- half-life is the time it takes for the compound to lose one-half of its pharmacologic activity.
- plasma half-life is the time that it takes the compound to lose one-half of its pharmacologic activity in the blood plasma.
- Modification of the compound to increase its half-life may for example include conjugation of a moiety that increases the half-life of the compound.
- the compound further comprises a moiety conjugated to said compound, thus generating a moiety-conjugated compound. It is preferred that the moiety-conjugated compound has a plasma and/or serum half-life being longer than the plasma and/or serum half-life of the non-moiety conjugated compound.
- the moiety conjugated to the compound can for example be one or more type(s) of moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- the present invention relates to a method of treating, preventing and/or ameliorating a neuromuscular disorder, said method comprising administering a therapeutically effective amount of the compositions and compounds as defined herein to a person in need thereof.
- the present invention relates to a method of reversing and/or ameliorating a neuromuscular blockade, said method comprising administering a therapeutically effective amount of the compound or the compound for use as defined herein to a person in need thereof.
- the present invention relates to a method for recovery of neuromuscular transmission, said method comprising administering a therapeutically effective amount of the compound or the compound for use as defined herein to a person in need thereof.
- the person in need thereof may be a person having a neuromuscular disorder or a person at risk of developing a neuromuscular disorder or a person having symptoms of muscle weakness and/or fatigue.
- the person in need thereof is a person with reduced neuromuscular transmission safety with prolonged recovery after neuromuscular blockade. Types of neuromuscular disorders are defined herein above.
- the person has, amyotrophic lateral sclerosis, spinal muscular atrophy, myasthenia gravis or Lambert-Eaton syndrome.
- a therapeutically effective amount is an amount that produces a therapeutic response or desired effect in the person taking it.
- Administration routes, formulations, forms and dosages are as defined herein above and throughout this specification.
- the method of treatment may be combined with other methods that are known to treat, prevent and/or ameliorate neuromuscular disorders.
- the treatment method may for example be combined with administration of any of the agents mentioned herein above.
- the treatment is combined with administration of acetylcholine esterase inhibitor such as for example neostigmine or pyridostigmine.
- Another aspect of the invention relates to use of a composition as defined herein, for the manufacture of a medicament for the treatment, prevention and/or amelioration of a neuromuscular disorder.
- compositions as defined herein for the manufacture of a medicament or a reversal agent for reversing and/or ameliorating a neuromuscular blockade after surgery.
- the present invention relates to methods of manufacturing compounds or compounds for use according to formula (I).
- One method for manufacturing the compounds or compounds for use according to the present invention comprises the steps of
- a second method for manufacturing the compounds or compounds for use according to the present invention comprises the steps of
- the compounds of formula (I) may be administered as a prodrug to modify the distribution, duration of efficacy or other properties. Conversion of the carboxylic acid group of compounds of formula (I) to an ester using ethanol to form the ethyl ester is an example of such prodrug.
- Preferred alcohols include low molecular weight alcohols, phenols and other aromatic alcohols, and fluorinated alcohols. In some cases, it is preferable to use an enol as the alcohol, for example 4-hydroxy-pent-3-ene-2-one.
- the prodrug may be the corresponding aldehyde, or an imine thereof. Again, these precursors can be expected to transform to the carboxylic acid in vivo.
- the prodrugs are administered using the same formulations and in the same dosage ranges as the compounds of formula (I).
- said prodrug is defined by Formula (LX):
- R 14 is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, pyrimidyl, pyridinyl, thiazolyl, oxadiazolyl and quinolyl, all aromatic and heteroaromatic groups optionally substituted by one or more R 4
- R 14 is a phenyl substituted with methoxy, nitro, cyano, Cl, Br, I and/or F.
- Formula (LX) is further defined by Formula (LXI):
- the prodrug is defined by Formula (LXII):
- the prodrug can also be defined by Formula (LXIII):
- Embodiment 1 is a composition comprising a compound of Formula (I):
- Embodiment 2 is a composition according to embodiment 1, wherein A is a monocyclic or bicyclic aromatic or heteroaromatic ring.
- Embodiment 3 composition according to embodiments 1 and 2, wherein A is five-membered or six-membered aromatic ring.
- Embodiment 4 composition according to embodiment 1 to 3, wherein A is phenyl, or naphthyl.
- Embodiment 5 composition according to any of the preceding embodiments, wherein said compound is a compound of Formula (II):
- Embodiment 6 is a composition for use according to any one of the preceding embodiments, wherein R 1 is selected from the group consisting of H and —CH 3 .
- Embodiment 7 is a composition according to any one of the preceding embodiments, wherein R 1 is H.
- Embodiment 8 is a composition for use according to any of the preceding embodiments, wherein R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alk(en)yl, C 3-6 -cycloalk(en)yl, wherein said C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl may be substituted with up to two substituents selected from the group consisting of —NR 9 —CO—R 10 , —N(R 10 ) 2 —SO 2 —R 12 , —CO—NR 9 R 10 , —SO 2 —NR 9 R 10 , —R 13 —O—R 11 , —NR 9 R 10 , —S(O)R 12 , —S(O) 2 R 12 , cyano, —O—R 11 , fluorinated C 1-3 -alkyl, nitro and halo, wherein R 9 , R 10
- Embodiment 9 is a composition for use according to any of the preceding embodiments, wherein R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alkyl, C 3-6 -cycloalkyl and amino-C 1-4 -alkyl, wherein said C 1-4 -alkyl and C 3-6 -cycloalkyl may be substituted with O—R 11 , wherein R 11 is selected from H, C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl.
- Embodiment 10 is a composition for use according to embodiment 9, wherein R 11 is —CH 3 .
- Embodiment 11 is a composition for use according to embodiment 9, wherein R 2 is —CH(CH 3 )CH 2 —O—CH 3 .
- Embodiment 12 is a composition for use according to any of embodiments 1 to 7, wherein R 1 is H and R 2 is selected from the group consisting of H, C 1-6 -alkyl and C 3-7 -cycloalkyl.
- Embodiment 13 is a composition for use according to any of the preceding embodiments, wherein R 1 is H and R 2 is selected from the group consisting of H, —CH 3 , —CH(CH 3 ) 2 and cyclopropyl.
- Embodiment 14 is a composition for use according to any of the preceding embodiments, wherein R 1 is H and R 2 is —CH(CH 3 ) 2 .
- Embodiment 15 is composition for use according to any one of the preceding embodiments, wherein R 1 is different from R 2 .
- Embodiment 16 is a composition for use according to any one of the preceding embodiments, wherein said compound is an S-enantiomer with respect to the C-atom to which R 2 is bound.
- Embodiment 17 is a composition for use according to any embodiments 1 to 16, wherein R 1 is H and R 2 is C 1-6 -alkyl or C 3-7 -cycloalkyl and wherein said compound is an S-enantiomer with respect to the C-atom to which R 2 is bound as shown in Formula (III):
- Embodiment 18 is a composition for use according to any one of the preceding embodiments wherein R 4 is selected from the group consisting of H, halo, cyano, —CHO, C 1-4 -alk(en)yl, halo-C 1-4 -alk(en)yl, —O—C 1-4 -alk(en)yl.
- Embodiment 19 is a composition for use according to any one of the preceding embodiments wherein m is 0, 1 or 2.
- Embodiment 20 is a composition for use according to any one of the preceding embodiments wherein m is 1.
- Embodiment 21 is a composition for use according to any embodiments, wherein X 1 is N, X 2 is N or X 3 is N.
- Embodiment 22 is a composition for use according to any one of embodiments 5 to 20, wherein X 1 , X 2 and X 3 is C.
- Embodiment 23 is a composition for use according to any one of embodiments 1 to 4, wherein the compound of Formula (I) is further defined by Formula (IV):
- Embodiment 24 is a composition for use according to embodiment 23, wherein the compound of Formula (IV) is further defined by Formula (V):
- Embodiment 25 is a composition for use according to embodiments 23, wherein R 2 is C 1-6 -alkyl or C 3-7 -cycloalkyl.
- Embodiment 26 is a composition for use according embodiment 25, wherein the compound of
- Embodiment 27 is a composition for use according to any one of embodiments 24 to 26, wherein R 4 is in ortho- or meta position.
- Embodiment 28 is a composition for use according to embodiment 1, wherein the compound of Formula (I) is further defined by Formula (VII):
- Embodiment 29 is a composition for use according to embodiment 28, wherein the compound of Formula (VII) is further defined by Formula (VIII)
- Embodiment 30 is a composition for use according to any one of embodiment 5 to 29, wherein Y is O.
- Embodiment 31 is a composition for use according to any one of embodiments 28 to 30, wherein R 2 is selected from the group consisting of H and C 1-4 -alkyl.
- Embodiment 32 is a composition for use according to any one of embodiments 28 to 31, wherein R 4 is selected from the group consisting of H, —CH 3 and halogen.
- Embodiment 33 is a composition for use according to embodiment 32, wherein said compound is further defined by Formula (IX):
- Embodiment 34 is a composition for use according to embodiment 28, wherein the compound of Formula (VII) is further defined by Formula (X):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH(CH 3 )CH 2 —O—CH 3 , —CH 2 —CH 2 —CH 3 , —CH 2 —NH 2 , —CH 2 —CHF 2 , —CH 2 —CF 3 , —CH 2 —NH—CO—CH 3 and —CH 2 —NH—SO 2 —CH 3 and cyclopropyl, and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 35 is a composition for use according to embodiment 28, wherein the compound of Formula (VII) is further defined by any one of Formulas (XI) to (XXVIII):
- Embodiment 36 is a composition for use according to embodiment 28, wherein the compound of Formula (VII) is further defined by Formula (XXIX):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 37 is a composition for use according to embodiment 36, wherein the compound of Formula (XXIX) is further defined by Formula (XXX):
- Embodiment 38 is a composition for use according to embodiment 28, wherein the compound of Formula (VII) is further defined by Formula (XXXI):
- Embodiment 39 is a composition for use according to embodiment 28, wherein the compound of Formula (VII) is further defined by Formula (XXXII):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 40 is a composition for use according to embodiment 39, wherein the compound of Formula (XXXII) is further defined by Formula (XXXIII):
- Embodiment 41 is a composition for use according to embodiment 1, wherein the compound of Formula (I) is further defined by Formula (XXXIV):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 ;
- X 1 is N or C; and
- R 4 and R′ 4 are independently selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 42 is a composition for use according to embodiment 41, wherein Formula (XXXIV) is further defined by Formula (XXXV):
- Embodiment 43 is a composition for use according to embodiment 1, wherein the compound of Formula (I) is further defined by any one of Formulas (XXXVI) to (LIX)
- Embodiment 44 is a composition for use according to any one of the preceding embodiments wherein said prodrug is defined by Formula (LX):
- Embodiment 45 is a prodrug according to embodiment 44, wherein R 14 is a phenyl substituted with methoxy, nitro, cyano, Cl, Br, I and/or F.
- Embodiment 46 is a prodrug according to embodiment 44, wherein Formula (LX) is further defined by Formula (LXI):
- Embodiment 47 is a composition for use according to any one of embodiments 1 to 43, wherein said prodrug is defined by Formula (LXII):
- Embodiment 48 is a composition for use according to any one of embodiments 1 to 43,
- Embodiment 49 is a composition for use according to any one of embodiments 1 to 43, wherein said prodrug is defined by Formula (LXIV):
- Embodiment 50 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is myasthenia gravis.
- Embodiment 51 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is autoimmune myasthenia gravis.
- Embodiment 52 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is congenital myasthenia gravis.
- Embodiment 53 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is Lambert-Eaton Syndrome.
- Embodiment 54 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is critical illness myopathy.
- Embodiment 55 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
- Embodiment 56 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is spinal muscular atrophy (SMA).
- SMA spinal muscular atrophy
- Embodiment 57 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is critical illness myopathy (CIM).
- CCM critical illness myopathy
- Embodiment 58 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is reversal diabetic polyneuropathy.
- Embodiment 59 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder is selected from the group consisting of Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, and critical illness polyneuropathy.
- the neuromuscular disorder is selected from the group consisting of Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, and critical illness polyneuropathy.
- Embodiment 60 is a composition for use according to any one of the preceding embodiments, wherein the composition is for use in the treatment of symptoms of an indication selected from the group consisting of myasthenia gravis (such as autoimmune and congenital myasthenia gravis), Lambert-Eaton Syndrome, critical illness myopathy, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), critical illness myopathy (CIM), reversal diabetic polyneuropathy, Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, and critical illness polyneuropathy.
- myasthenia gravis such as autoimmune and congenital myasthenia gravis
- Lambert-Eaton Syndrome critical illness myopathy
- ALS amyotrophic lateral sclerosis
- SMA spinal muscular atrophy
- CCM critical illness myopathy
- reversal diabetic polyneuropathy Guillain-Barré syndrome
- poliomyelitis post-polio syndrome
- Embodiment 61 is a composition for use according to any one of the preceding embodiments wherein the neuromuscular disorder has been induced by a neuromuscular blocking agent.
- Embodiment 62 is a composition for use according to any one of the preceding embodiments further comprising a pharmaceutically acceptable carrier.
- Embodiment 63 is a composition for use according to any one of the preceding embodiments further comprising at least one further active agent.
- Embodiment 64 is a composition for use according to any one of the preceding embodiments wherein said further active agent is suitable for treating, preventing or ameliorating said neuromuscular disorder.
- Embodiment 65 is a composition for use according to any one of the preceding embodiments, wherein said further active agent is an acetylcholine esterase inhibitor.
- Embodiment 66 is a composition for use according to embodiment 65, wherein said acetylcholine esterase inhibitor is selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives, galantamine, caffeine—noncompetitive, piperidines, donepezil, tacrine, edrophonium, huperzine, ladostigil, ungeremine and lactucopicrin.
- said acetylcholine esterase inhibitor is selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives, galantamine, caffeine—
- Embodiment 67 is a composition for use according embodiment 65, wherein said acetylcholine esterase inhibitor is neostigmine or pyridostigmine.
- Embodiment 68 is a composition for use according to any one of the preceding embodiments, wherein said further active agent is suggamadex.
- Embodiment 69 is a composition for use according to any one of the preceding embodiments, wherein said further active agent is tirasemtiv.
- Embodiment 70 is a composition for use according to any one of the preceding embodiments, wherein said further active agent is 3,4-aminopyridine.
- Embodiment 71 is a composition for use according to any one of the preceding embodiments, wherein the composition is administered or adapted for administration enterally, topically, parenterally or as part of a sustained release implant.
- Embodiment 72 is a composition for use according to any one of the preceding embodiments, wherein the parenteral administration is intravenous, subcutaneous, intramuscular, intracranial or intraperitoneal.
- Embodiment 73 is a composition for use according to any one of the preceding embodiments, wherein the enteral administration is oral, rectal, or buccal.
- Embodiment 74 is a composition for use according to any one of the preceding embodiments, wherein the topical administration is dermal, epicutaneous, vaginal, intravesical, pulmonary, intranasal, intratracheal or as eye drops.
- Embodiment 75 is a composition for use according to any one of the preceding embodiments, wherein the composition is administered or adapted for administration subcutaneously or intravenously.
- Embodiment 76 is a composition for use according to any one of the preceding embodiments, wherein the composition is formulated for oral administration.
- Embodiment 77 is a composition for use according to any one of the preceding embodiments, wherein the composition is formulated in a tablet or capsule.
- Embodiment 78 is a composition for use according to any one of the preceding embodiments, wherein said composition is to be administered in a dosage of from 1 ⁇ g/kg-10,000 ⁇ g/kg body weight, such as 1 ⁇ g/kg-7,500 ⁇ g/kg, such as 1 ⁇ g/kg-5,000 ⁇ g/kg, such as 1 ⁇ g/kg-2,000 ⁇ g/kg, such as 1 ⁇ g/kg-1,000 ⁇ g/kg, such as 1 ⁇ g/kg-700 ⁇ g/kg, such as 5 ⁇ g/kg-500 ⁇ g/kg, such as 10 ⁇ g/kg to 100 ⁇ g/kg bodyweight.
- 1 ⁇ g/kg-10,000 ⁇ g/kg body weight such as 1 ⁇ g/kg-7,500 ⁇ g/kg, such as 1 ⁇ g/kg-5,000 ⁇ g/kg, such as 1 ⁇ g/kg-2,000 ⁇ g/kg, such as 1 ⁇ g/kg-1,000 ⁇ g/kg, such as 1
- Embodiment 79 is a composition for use according to any one of the preceding embodiments, wherein said administration is repeated daily.
- Embodiment 80 is a composition for use according to any one of the preceding embodiments, wherein said administration is repeated at least 1-3 times weekly, such as 2-5 times weekly, such as 3-6 times weekly.
- Embodiment 81 is a composition for use according to any one of the preceding embodiments, wherein said administration is repeated 1 to 8 times daily, such as 2 to 5 times daily.
- Embodiment 82 is a composition for use according to any one of the preceding embodiments, wherein said compound further has been modified in order to increase its half-life when administered to a patient, in particular its plasma half-life.
- Embodiment 83 is a composition for use according to any one of the preceding embodiments, wherein said compound further comprises a moiety conjugated to said compound, thus generating a moiety-conjugated compound.
- Embodiment 84 is a composition for use according to any one of the preceding embodiments, wherein the moiety-conjugated compound has a plasma and/or serum half-life being longer than the plasma and/or serum half-life of the non-moiety conjugated compound.
- Embodiment 85 is a composition for use according to any one of the preceding embodiments, wherein the moiety conjugated to the compound is one or more type(s) of moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- the moiety conjugated to the compound is one or more type(s) of moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- Embodiment 86 is a method of treating, preventing and/or ameliorating a neuromuscular disorder, said method comprising administering a therapeutically effective amount of the composition as defined in any one of the preceding embodiment to a person in need thereof.
- Embodiment 87 is a method of using a composition as defined in any one of embodiments 1 to 85, for the manufacture of a medicament for the treatment, prevention and/or amelioration of a neuromuscular disorder.
- Embodiment 88 is a composition comprising a compound of Formula (I):
- Embodiment 89 is a method of reversing and/or ameliorating a neuromuscular blockade after surgery, said method comprising administering a therapeutically effective amount of the composition as defined in embodiment 88 to a person in need thereof.
- Embodiment 90 is a method for recovery of neuromuscular transmission, said method comprising administering a therapeutically effective amount of the composition as defined in embodiment 88 to a person in need thereof.
- Embodiment 91 is a method of using a composition as defined in embodiment 88, for the manufacture of a medicament for recovery of neuromuscular transmission.
- Embodiment 92 is a compound of Formula (I):
- Embodiment 93 is a compound according to embodiment 92, wherein A is a monocyclic or bicyclic aromatic or heteroaromatic ring.
- Embodiment 94 is a compound according to any of embodiments 92 and 93, wherein A is five-membered or six-membered aromatic ring.
- Embodiment 95 is a compound according to any one of embodiments 92 to 93, wherein A is phenyl, or naphthyl.
- Embodiment 96 is a compound according to any of embodiments 92 to 95, wherein said compound is a compound of Formula (II):
- Embodiment 97 is a compound according to any one of embodiments 92 to 96, wherein R 1 is selected from the group consisting of —H and —CH 3 .
- Embodiment 98 is a compound according to any one of embodiments 92 to 96, wherein R 1 is H.
- Embodiment 99 is a compound according to any of embodiments 92 to 98, wherein R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alk(en)yl, C 3-6 -cycloalk(en)yl, wherein said C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl may be substituted with up to two substituents selected from the group consisting of —NR 9 —CO—R 10 , —N(R 10 ) 2 —SO 2 —R 12 , —CO—NR 9 R 10 , —SO 2 —NR 9 R 10 , —R 13 —O—R 11 , —NR 9 R 10 , —S(O)R 12 , S(O) 2 R 12 , cyano, —O—R 11 , fluorinated C 1-3 -alkyl, nitro and halo, wherein R 9 , R 10 , and
- Embodiment 100 is a compound according to any of embodiments 92 to 98, wherein R 1 is H and R 2 is selected from the group consisting of H, C 1-4 -alkyl, C 3-6 -cycloalkyl and amino-C 1-4 -alkyl, wherein said C 1-4 -alkyl and C 3-6 -cycloalkyl may be substituted with O—R 11 , wherein R 11 is selected from H or C 1-4 -alk(en/yn)yl and C 3-6 -cycloalk(en)yl.
- Embodiment 101 is a compound according to embodiment 100, wherein R 11 is —CH 3 .
- Embodiment 102 is a compound according to embodiment 100, wherein R 2 is —CH(CH 3 )CH 2 —O—CH 3 .
- Embodiment 103 is a compound according to any of embodiments 92 to 102, wherein R 1 is H and R 2 is selected from the group consisting of H, C 1-6 -alkyl and C 3-7 -cycloalkyl.
- Embodiment 104 is a compound according to any of embodiments 92 to 102, wherein R 1 is H and R 2 is selected from the group consisting of H, —CH 3 , —CH(CH 3 ) 2 and cyclopropyl.
- Embodiment 105 is a compound according to any one of embodiments 92 to 104, wherein R 1 is H and R 2 is —CH(CH 3 ) 2 .
- Embodiment 106 is a compound according to any one of embodiments 92 to 105, wherein R 1 is different from R 2 .
- Embodiment 107 is a compound according to any one of embodiments 92 to 106, wherein said compound is an S-enantiomer with respect to the C-atom to which R 2 is bound.
- Embodiment 108 is a compound according to any embodiments 92 to 107, wherein R 1 is H and R 2 is C 1-6 -alkyl or C 3-7 -cycloalkyl and wherein said compound is an S-enantiomer with respect to the C-atom to which R 2 is bound as shown in Formula (III):
- Embodiment 109 is a compound according to any one of embodiments 92 to 108, wherein R 4 is selected from the group consisting of H, halo, cyano, —CHO, C 1-4 -alk(en)yl, halo-C 1-4 -alk(en)yl, —O—C 1-4 -alk(en)yl.
- Embodiment 110 is a compound according to any one of embodiments 92 to 109, wherein m is 0, 1 or 2.
- Embodiment 111 is a compound according to any one of embodiments 92 to 110, wherein m is 1.
- Embodiment 112 is a compound according to any one of embodiments 92 to 111, wherein X 1 is N, X 2 is N or X 3 is N.
- Embodiment 113 is a compound according to any one of embodiments 92 to 111, wherein X 1 , X 2 and X 3 is C.
- Embodiment 114 is a compound according to any one of embodiments 92 to 113, wherein the compound of Formula (I) is further defined by Formula (IV):
- Embodiment 115 is a compound according to embodiment 114, wherein the compound of Formula (IV) is further defined by Formula (V):
- R 2 and R 4 are as defined above.
- Embodiment 116 is a compound according to embodiment 114 or embodiment 115, wherein R 2 is C 1-6 -alkyl or C 3-7 -cycloalkyl.
- Embodiment 117 is a compound according embodiment 115, wherein the compound of Formula (V) is further defined by Formula (VI):
- R 4 is as defined above
- Embodiment 118 is a compound according to any one of embodiments 115 to 117, wherein R 4 is in ortho- or meta position.
- Embodiment 119 is a compound according to embodiment 92, wherein the compound of Formula (I) is further defined by Formula (VII):
- Embodiment 120 is a compound according to embodiment 119, wherein the compound of Formula (VII) is further defined by Formula (VIII)
- Embodiment 121 is a compound according to any one of embodiments 92 to 120, wherein Y is O.
- Embodiment 122 is a compound according to any one of embodiments 92 to 121, wherein R 2 is selected from the group consisting of H and C 1-4 -alkyl.
- Embodiment 123 is a compound according to any one of embodiments 92 to 122, wherein R 4 is selected from the group consisting of H, —CH 3 and halogen.
- Embodiment 124 is a compound according to any one of embodiments 92 to 123, wherein said compound is further defined by Formula (IX):
- Embodiment 125 is a compound according to embodiment 119, wherein the compound of Formula (VII) is further defined by Formula (X):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH(CH 3 )CH 2 —O—CH 3 , —CH 2 —CH 2 —CH 3 , —CH 2 —NH 2 , —CH 2 —CHF 2 , —CH 2 —CF 3 , —CH 2 —NH—CO—CH 3 and —CH 2 —NH—SO 2 —CH 3 and cyclopropyl, and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 126 is a compound se according to embodiment 119, wherein the compound of Formula (VII) is further defined by any one of Formulas (XI) to (XXVIII) as defined in embodiment 35.
- Embodiment 127 is a compound according to embodiment 119, wherein the compound of Formula (VII) is further defined by Formula (XXIX):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 128 is a compound according to embodiment 127, wherein the compound of Formula (XXIX) is further defined by Formula (XXX):
- Embodiment 129 is a compound according to embodiment 119, wherein the compound of Formula (VII) is further defined by Formula (XXXI):
- Embodiment 130 is a compound according to embodiment 119, wherein the compound of Formula (VII) is further defined by Formula (XXXII):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 and R 4 is selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 131 is a compound according to embodiment 130, wherein the compound of Formula (XXXII) is further defined by Formula (XXXIII):
- Embodiment 132 is a compound according to embodiment 92, wherein the compound of Formula (I) is further defined by Formula (XXXIV):
- R 2 is selected from the group consisting of —CH 3 , —CH 2 —CH 3 , —CH(CH 3 ) 2 , —C(CH 3 ) 3 , —CH 2 —CH 2 —CH 3 and —CH 2 —NH 2 ;
- X 1 is N or C; and
- R 4 and R′ 4 are independently selected from the group consisting of H, Br, Cl, F and I.
- Embodiment 133 is a compound according to embodiment 132, wherein Formula (XXXIV) is further defined by Formula (XXXV):
- Embodiment 134 is a compound according to embodiment 92, wherein the compound of Formula (I) is further defined by any one of Formulas (XXXVI) to (LIX) as defined in embodiment 43.
- Embodiment 135 is a compound of Formula (I.3.4):
- Embodiment 136 is a compound according to any one of the preceding embodiments, wherein R 2 is a 5-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 137 is a compound according to any one of the preceding embodiments, wherein R 2 is a 6-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 138 is a compound according to any one of the preceding embodiments, wherein R 2 is an 8-membered bicyclic heterocycle which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 139 is a compound according to any one of the preceding embodiments, wherein R 2 is a 9-membered bicyclic heterocycle which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 140 is a compound according to any one of the preceding embodiments, wherein R 2 is a 10-membered bicyclic heterocycle which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 141 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole, isoxazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,5-thiadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole, 1,3,4-thiadiazole, dihydrofuran, dihydrothiophene, 3-pyrroline, 2-pyrroline, 2-imidazoline, 2-pyrazolidine, dihydro-oxazole, dihydro-thiazole, dihydro-isoxazole, dihydro-isothiazole, dihydro-1,2,3-tri
- Embodiment 142 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole, isoxazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-oxadiazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1,2,5-thiadiazole, 1,2,3-thiadiazole, 1,2,4-thiadiazole and 1,3,4-thiadiazole.
- Embodiment 143 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of thiophene, pyrrole, isoxazole, 1,2,4-oxadiazole and 1,3,4-oxadiazole.
- Embodiment 144 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of isoxazol-5-yl and isoxazol-3-yl.
- Embodiment 145 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of pyridine, pyrazine, pyrimidine, pyridazine, tetrahydropyran, thiane, piperidine, 1, 4-dioxane, morpholine, 1,4-oxathiane, 1,4-diathiane and piperazine, wherein each of which may be optionally substituted with one or more, identical or different, substituents R 6 .
- R 2 is selected from the group consisting of pyridine, pyrazine, pyrimidine, pyridazine, tetrahydropyran, thiane, piperidine, 1, 4-dioxane, morpholine, 1,4-oxathiane, 1,4-diathiane and piperazine, wherein each of which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 146 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of tetrahydro-4H-cyclopent[d]isoxazole, hexahydro-1H-pyrrolizine, 1,4-dihydropyrrolo[3,2-b]pyrrole, 1,6-dihydropyrrolo[2,3-b]pyrrole, 6H-furo[2,3-b]pyrrole, 4H-furo[3,2-b]pyrrole, 6H-thieno[2,3-b]pyrrole and 4H-thieno[3,2-b]pyrrole, wherein each of which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 147 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of benzofuran, benzothiophene, indole, benzimidazole, indazole, benzothiazole, benzoxazole, 1,2-benzisoxazole, 1,2-benzisothiazole, benzotriazole, pyrrolopyridine, pyrazolopyridine and imidazopyridine, wherein each of which may be optionally substituted with one or more, identical or different, substituents R 6 .
- R 2 is selected from the group consisting of benzofuran, benzothiophene, indole, benzimidazole, indazole, benzothiazole, benzoxazole, 1,2-benzisoxazole, 1,2-benzisothiazole, benzotriazole, pyrrolopyridine, pyrazolopyridine and imidazopyridine, wherein each of which may be optionally substitute
- Embodiment 148 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine and naphthyridine, wherein each of which may be optionally substituted with one or more, identical or different, substituents R 6 .
- Embodiment 149 is a compound according to any one of the preceding embodiments, wherein R 2 is selected from the group consisting of isoxazole, oxazole oxadiazole, benzothiazole, thiazole, imidazole, tetrahydrofuran, triazole, pyrazole, thiophene, wherein each of which may be optionally substituted with one or more, identical or different, substituents R 6
- Embodiment 150 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (II.4):
- Embodiment 151 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (III.4):
- Embodiment 152 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (IV.4):
- Embodiment 153 is a compound according to any one of the preceding embodiment, wherein the compound is of Formula (V.4):
- Embodiment 154 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (VI.4):
- Embodiment 155 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (VII.4):
- Embodiment 156 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (VIII.4):
- Embodiment 157 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (IX.4):
- Embodiment 158 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (X.4):
- Embodiment 159 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (XI.4):
- Embodiment 160 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (XII.4):
- Embodiment 161 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (XIII.4):
- Embodiment 162 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (XIV.4):
- Embodiment 163 is a compound according to any one of the preceding embodiments, wherein the compound is of Formula (XV.4):
- Embodiment 164 is a compound according to any of the preceding embodiments, wherein R 2 is pyridine-2-yl.
- Embodiment 165 is a compound according to any of the preceding embodiments, wherein R 2 is 3aH,4H,5H,6H,6aH-cyclopenta[d][1,2]oxazol-3-yl.
- Embodiment 166 is a compound according to any of the preceding embodiments, wherein R 2 is 4,5-dihydro-1,2-oxazol-5-yl.
- Embodiment 167 is a compound according to any of the preceding embodiments, wherein R 2 is 1H-imidazol-4-yl.
- Embodiment 168 is a compound according to any of the preceding embodiments, wherein R 2 is 4H-1,2,4-triazol-3-yl.
- Embodiment 169 is a compound according to any of the preceding embodiments, wherein n is 0.
- Embodiment 170 is a compound according to any of the preceding embodiments, wherein n is 1.
- Embodiment 171 is a compound according to any of the preceding embodiments, wherein n is 2.
- Embodiment 172 is a compound according to any one of the preceding embodiments, wherein R 3 is deuterium or tritium.
- Embodiment 173 is a compound according to any one of the preceding embodiments, wherein R 3 is F, Cl, Br or I.
- Embodiment 174 is a compound according to any one of the preceding embodiments, wherein R 3 is F.
- Embodiment 175 is a compound according to any one of the preceding embodiments, wherein R 4 is C 1-5 alkyl optionally substituted with one or more, identical or different, substituents R 7 .
- Embodiment 176 is a compound according to any one of the preceding embodiments, wherein R 4 is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, 1-ethylpropyl, 2-methylbutyl, pentyl, allyl, homo-allyl, vinyl, crotyl, butenyl, pentenyl, butadienyl, pentadienyl, ethynyl, propynyl, butynyl, pentynyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclopentenyl optionally substituted with one or more, identical or different, substituents R 7 .
- R 4 is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl
- Embodiment 177 is a compound according to any one of the preceding embodiments, wherein R 4 is methyl, ethyl, n-propyl or isopropyl, optionally substituted with one or more, identical or different, substituents R 7 .
- Embodiment 178 is a compound according to any one of the preceding embodiments, wherein R 4 is methyl.
- Embodiment 179 is a compound according to any one of the preceding embodiments, wherein R 4 is ethyl.
- Embodiment 180 is a compound according to any one of the preceding embodiments, wherein R 4 is n-propyl or isopropyl.
- Embodiment 181 is a compound according to any one of the preceding embodiments, wherein R 4 is C 1-5 alkyl substituted with one or more F.
- Embodiment 182 is a compound according to any one of the preceding embodiments, wherein R 4 is selected from the group consisting of —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CH 2 F, —CH 2 CHF 2 and —CH 2 CF 3 .
- Embodiment 183 is a compound according to any one of the preceding embodiments, wherein R 4 is —CH 2 F.
- Embodiment 184 is a compound according to any one of the preceding embodiments, wherein R 5 is hydrogen.
- Embodiment 185 is a compound according to any one of the preceding embodiments, wherein R 5 is C 1-5 alkyl.
- Embodiment 186 is a compound according to any one of the preceding embodiments, wherein R 5 is methyl or tert-butyl.
- Embodiments 187 is a compound according to any one of the preceding embodiments, wherein m is 0.
- Embodiment 188 is a compound according to any one of the preceding embodiments, wherein m is 1.
- Embodiment 189 is a compound according to any one of the preceding embodiments, wherein m is 2.
- Embodiment 190 is a compound according to any one of the preceding embodiments, wherein R 6 is selected from the group consisting of C 1-5 alkyl, C 1-5 alkenyl, C 1-5 alkynyl, C 3-5 cycloalkyl and C 5 cycloalkenyl, each of which may be optionally substituted with one or more halogens.
- Embodiment 191 is a compound according to any one of the preceding embodiments, wherein R 6 is C 1-5 alkyl.
- Embodiment 192 is a compound according to any one of the preceding embodiments, wherein R 6 is methyl or isopropyl.
- Embodiment 193 is a compound according to any one of the preceding embodiments, wherein R 6 is C 1-5 alkenyl.
- Embodiment 194 is a compound according to any one of the preceding embodiments, wherein R 6 is C 1-5 alkynyl.
- Embodiment 195 is a compound according to any one of the preceding embodiments, wherein R 6 is C 3-5 cycloalkyl.
- Embodiment 196 is a compound according to any one of the preceding embodiments, wherein R 6 is cyclopropyl.
- Embodiment 197 is a compound according to any one of the preceding embodiments, wherein R 6 is C 1-5 cycloalkenyl.
- Embodiment 198 is a compound according to any one of the preceding embodiments, wherein R 6 is C 1-5 alkyl substituted with one or more F.
- Embodiment 199 is a compound according to any one of the preceding embodiments, wherein R 6 is C 1-5 alkenyl substituted with one or more F.
- Embodiment 200 is a compound according to any one of the preceding embodiments, wherein R 6 is C 1-5 alkynyl substituted with one or more F.
- Embodiment 201 is a compound according to any one of the preceding embodiments, wherein R 6 is C 3-5 cycloalkyl substituted with one or more F.
- Embodiment 202 is a compound according to any one of the preceding embodiments, wherein R 6 is C 5 cycloalkenyl substituted with one or more F.
- Embodiment 203 is a compound according to any one of the preceding embodiments, wherein the compound is selected from the group consisting of:
- Embodiment 204 is a compound according to any one of the preceding embodiments, wherein the compound is selected from the group consisting of:
- Embodiment 205 is a compound according to any one of the preceding embodiments, wherein the compound has activity on CIC-1 receptor.
- Embodiment 206 is a compound according to any one of the preceding embodiments, wherein the compound is an inhibitor of the CIC-1 ion channel.
- Embodiment 207 is a compound according to any one of the preceeding embodiments, wherein the EC 50 ⁇ 50 ⁇ M, preferably ⁇ 40 ⁇ M, more preferably ⁇ 30 ⁇ M, more preferably ⁇ 20 ⁇ M, more preferably ⁇ 15 ⁇ M, even more preferably ⁇ 10 ⁇ M and most preferably ⁇ 5 ⁇ M.
- Embodiment 208 is a compound according to any one of the preceding embodiments, wherein the recovery of force in muscles with neuromuscular dysfunction is >5%, preferably >10%, more preferably >15%, more preferably >20%, more preferably >25%, even more preferably >30% and most preferably >35%.
- Embodiment 209 is a compound according to any one of the preceding embodiments, wherein the compound improves the recovered force in isolated rat soleus muscles after exposure to tubocurarine.
- Embodiment 210 is a composition comprising the compound according to any one of the preceding embodiments.
- Embodiment 211 is a composition according to any one of the preceding embodiments, wherein the composition is a pharmaceutical composition.
- Embodiment 212 is a compound or the composition according to any one of the preceding embodiments, for use as a medicament.
- Embodiment 213 is a composition according to any one of the preceding embodiments, wherein the composition further comprises a pharmaceutically acceptable carrier.
- Embodiment 214 is a composition according to any one of the preceding embodiments, wherein the composition further comprises at least one further active agent.
- Embodiment 215 is a composition according to any one of the preceding embodiments, wherein said further active agent is suitable for treating, preventing or ameliorating said neuromuscular disorder.
- Embodiment 216 is a composition according to any one of the preceding embodiments, wherein said further active agent is an acetylcholine esterase inhibitor.
- Embodiment 217 is a composition according to any one of the preceding embodiments, wherein said acetylcholine esterase inhibitor is selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives, galantamine, caffeine—noncompetitive, piperidines, donepezil, tacrine, edrophonium, huperzine, ladostigil, ungeremine and lactucopicrin.
- said acetylcholine esterase inhibitor is selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives, galant
- Embodiment 218 is a composition according to any one of the preceding embodiments, wherein said acetylcholine esterase inhibitor is neostigmine or pyridostigmine.
- Embodiment 219 is a composition according to any one of the preceding embodiments, wherein said further active agent is suggamadex.
- Embodiment 220 is a composition according to any one of the preceding embodiments, wherein said further active agent is tirasemtiv or CK-2127107.
- Embodiment 221 is a composition according to any one of the preceding embodiments, wherein said further active agent is 3,4-aminopyridine.
- Embodiment 222 is a method for manufacturing the compound according to any one of the preceding embodiments, the method comprising the steps of
- Embodiment 223 is a method for manufacturing the compound according to any one of the preceding embodiments, the method comprising the steps of
- Embodiment 224 is a method for manufacturing the compound according to any one of the preceding embodiments, the method comprising the steps of
- Embodiment 225 is a compound according to any one of the preceding embodiments for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a
- Embodiment 226 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is myasthenia gravis.
- Embodiment 227 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is autoimmune myasthenia gravis.
- Embodiment 228 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is congenital myasthenia gravis.
- Embodiment 229 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is Lambert-Eaton Syndrome.
- Embodiment 230 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is critical illness myopathy.
- Embodiment 231 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
- Embodiment 232 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is spinal muscular atrophy (SMA).
- SMA spinal muscular atrophy
- Embodiment 233 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is critical illness myopathy (CIM).
- CCM critical illness myopathy
- Embodiment 234 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is Charcot-Marie tooth disease (CMT).
- CMT Charcot-Marie tooth disease
- Embodiment 235 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is sarcopenia.
- Embodiment 236 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is reversal diabetic polyneuropathy.
- Embodiment 237 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder is selected from the group consisting of Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, and critical illness polyneuropathy.
- the neuromuscular disorder is selected from the group consisting of Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, and critical illness polyneuropathy.
- Embodiment 238 is a compound for use according to any one of the preceding embodiments, wherein the compound is for use in the treatment of symptoms of an indication selected from the group consisting of myasthenia gravis (such as autoimmune and congenital myasthenia gravis), Lambert-Eaton Syndrome, critical illness myopathy, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), critical illness myopathy (CIM), reversal diabetic polyneuropathy, Guillain-Barré syndrome, poliomyelitis, post-polio syndrome, chronic fatigue syndrome, and critical illness polyneuropathy.
- myasthenia gravis such as autoimmune and congenital myasthenia gravis
- Lambert-Eaton Syndrome critical illness myopathy
- ALS amyotrophic lateral sclerosis
- SMA spinal muscular atrophy
- CCM critical illness myopathy
- reversal diabetic polyneuropathy Guillain-Barré syndrome
- poliomyelitis post-polio syndrome
- Embodiment 239 is a compound for use according to any one of the preceding embodiments wherein the neuromuscular disorder has been induced by a neuromuscular blocking agent.
- Embodiment 240 is a compound for use according to any one of the preceding embodiments, wherein the neuromuscular blockade is neuromuscular blockade after surgery.
- Embodiment 241 is a compound for use according to any one of the preceding embodiments, wherein the neuromuscular blockade is drug induced.
- Embodiment 242 is a compound for use according to any one of the preceding embodiments, wherein the drug is an antibiotic.
- Embodiment 243 is a compound for use according to any one of the preceding embodiments, wherein the drug is a non-depolarizing neuromuscular blocker.
- Embodiment 244 is a compound for use according to any one of the preceding embodiments, wherein said compound further has been modified in order to increase its half-life when administered to a patient, in particular its plasma half-life.
- Embodiment 245 is a compound for use according to any one of the preceding embodiments, wherein said compound further comprises a moiety conjugated to said compound, thus generating a moiety-conjugated compound.
- Embodiment 246 is a compound for use according to any one of the preceding embodiments, wherein the moiety-conjugated compound has a plasma and/or serum half-life being longer than the plasma and/or serum half-life of the non-moiety conjugated compound.
- Embodiment 247 is a compound for use according to any one of the preceding embodiments, wherein the moiety conjugated to the compound is one or more type(s) of moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- the moiety conjugated to the compound is one or more type(s) of moieties selected from the group consisting of albumin, fatty acids, polyethylene glycol (PEG), acylation groups, antibodies and antibody fragments.
- Embodiment 248 is a compound for use according to any one of the preceding embodiments, wherein said compound is comprised in a composition.
- Embodiment 249 is a compound for use according to any one of the preceding embodiments, wherein the composition is a pharmaceutical composition.
- Embodiment 250 is a compound for use according to any one of the preceding embodiments, wherein the composition further comprises a pharmaceutically acceptable carrier.
- Embodiment 251 is a compound for use according to any one of embodiments, wherein the composition further comprises at least one further active agent.
- Embodiment 252 is a compound for use according to any one of the preceding embodiments, wherein said further active agent is suitable for treating, preventing or ameliorating said neuromuscular disorder.
- Embodiment 253 is a compound for use according to any one of the preceding embodiments, wherein said further active agent is an acetylcholine esterase inhibitor.
- Embodiment 254 is a compound for use according to any one of the preceding embodiments, wherein said acetylcholine esterase inhibitor is selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives, galantamine, caffeine—noncompetitive, piperidines, donepezil, tacrine, edrophonium, huperzine, ladostigil, ungeremine and lactucopicrin.
- said acetylcholine esterase inhibitor is selected from the group consisting of delta-9-tetrahydrocannabinol, carbamates, physostigmine, neostigmine, pyridostigmine, ambenonium, demecarium, rivastigmine, phenanthrene derivatives,
- Embodiment 255 is a compound for use according to any one of the preceding embodiments, wherein said acetylcholine esterase inhibitor is neostigmine or pyridostigmine.
- Embodiment 256 is a compound for use according to any one of the preceding embodiments, wherein said further active agent is suggamadex.
- Embodiment 257 is a compound for use according to any one of the preceding embodiments, wherein said further active agent is tirasemtiv.
- Embodiment 258 is a compound for use according to any one of the preceding embodiments, wherein said further active agent is 3,4-aminopyridine.
- Embodiment 259 is a method of treating, preventing and/or ameliorating a neuromuscular disorder, said method comprising administering a therapeutically effective amount of the compound as defined in any one of the preceding embodiments to a person in need thereof.
- Embodiment 260 is a method of using a compound as defined in any one of the preceding embodiments, for the manufacture of a medicament for the treatment, prevention and/or amelioration of a neuromuscular disorder, and/or for reversing and/or ameliorating of a neuromuscular blockade.
- Embodiment 261 is a method of reversing and/or ameliorating a neuromuscular blockade, said method comprising administering a therapeutically effective amount of the compound as defined in any one of the preceding embodiments to a person in need thereof.
- Embodiment 262 is a method for recovery of neuromuscular transmission, said method comprising administering a therapeutically effective amount of the compound as defined in any one of the preceding embodiments to a person in need thereof.
- Embodiment 262 is a method for recovering neuromuscular transmission, the method comprising administering a compound as defined in any one of the preceding embodiments to an individual in need thereof.
- the product was analysed by Waters 2695 HPLC consisting of a Waters 996 photodiode array detector, Kromasil Eternity C18, 5 ⁇ m, 4.6 ⁇ 150 mm column. Flow rate: 1 mL/minute, run time 20 minutes. Solvent A: methanol; solvent B: 0.1% formic acid in water. Gradient 0-100% Solvent B over 15 minutes with monitoring at 280 nm.
- step K To a 0° C. solution of the product of step K in methanol, a catalytic amount of acetyl chloride was added. The mixture was heated under reflux for 3-9 h and the solvent was evaporated. The residue was extracted with a solvent like methyl-tert-butyl ether or DCM. The organic layer was evaporated.
- step L To a solution of the product of step L in methanol, 10% Pd/C was added and hydrogenated under ambient pressure for 24 h. The mixture was filtered through silica gel and evaporated.
- the thioether obtained by Method A or B in a suitable solvent like DCM or ethyl acetate is treated with m-CPBA or another peracid at room temperature for 1-48 h and the reaction is monitored by TLC. After aqueous workup, the product is purified by chromatography.
- the protected compound obtained from Step C in a suitable solvent like DCM is treated with TFA at room temperature for 1-18 h. After evaporation, the product is purified by reversed-phase chromatography with an HCl containing eluent.
- the acid obtained by the previous methods in a suitable solvent like DCM or acetonitrile is treated DCC and the desired phenol, like p-nitrophenol, with a suitable catalyst like DMAP at room temperature for 1-48 h. After aqueous workup at acidic pH, the product is purified by rapid chromatography.
- the ester obtained by the previous methods in a suitable solvent like toluene is treated DIBAL-H at ⁇ 78° C. for 1 h. After aqueous workup, the product is purified by rapid chromatography.
- the aldehyde obtained by the step F in a suitable solvent like DCM is treated at room temperature with the desired primary amine like 2-aminoethanol. Evaporation, redilution with DCM and re-evaporation yielded the desired product.
- Compound (X) in the case where Y ⁇ O is a phenol, is available either commercially or synthetically (see below), and can be converted into an ether (XI) by methods which include Mitsunobu reaction conditions.
- This ether contains an ester functionality —CO 2 R 11 , which can be hydrolysed under a range of standard conditions, involving treatment with acid or base, to provide the carboxylic acid structure (XII), Y ⁇ O.
- Standard conditions for hydrolysis of the ester can also for example involve an enzymatic hydrolysis, employing for example an esterase or lipase.
- an ester molecule (XI) comprises for example a (CH 3 ) 3 SiCH 2 CH 2 O— group as —OR 11 , then a fluoride ion source such as tetra-n-butylammonium fluoride can be employed to convert (XI) into the corresponding carboxylic acid (XII).
- Substituted phenols of general formula (X), Y ⁇ O can be prepared by a variety of standard methods, for example by an ester rearrangement in the Fries rearrangement, by a rearrangement of N-phenylhydroxylamines in the Bamberger rearrangement, by hydrolysis of phenolic esters or ethers, by reduction of quinones, by replacement of an aromatic amine or by a hydroxyl group with water and sodium bisulfide in the Bucherer reaction.
- Other methods include hydrolysis of diazonium salts, by rearrangement reaction of dienones in the dienone phenol rearrangement, by the oxidation of aryl silanes or by the Hock process.
- Carboxylic acids of Formula (X) (which is the same as Formula (I) in which R 4 is H) can also be prepared by the procedure illustrated as General Method B.
- a phenolic ether of formula (XI) can be prepared by displacement of a suitable leaving group Q in (XIII) with the nucleophilic YH in (IX) (wherein Y ⁇ O).
- Q can for example be a halogen such as fluorine or iodine, and the ether product of formula (XI) can be converted into the carboxylic acid derivative (XII) by one of a range of methods outlined in General Method A, involving hydrolysis of the ester functionality.
- Carboxylic acids of Formula (X) (which is the same as Formula (I) in which R 4 is H) can be prepared by the procedure illustrated as General Method C.
- a phenolic ether of formula (XV) can be prepared by utilising e.g. Mitsunobu conditions when (X) is a phenol structure, i.e. Y ⁇ O, and (XIV) is a suitable secondary alcohol, i.e. Z ⁇ OH, and —R 12 is a suitable protecting group, such as a silyl-containing moiety.
- the primary alcohol in (XVI) can be oxidised to a carboxylic acid under standard conditions involving potassium permanganate, Jones oxidation conditions, the Heyns oxidation, ruthenium tetroxide or TEMPO, generating (XII).
- the product (1.4) was analysed by LCMS (Agilent Infinity, X-Select, Waters X-Select C18, 2.5 ⁇ m, 4.6 ⁇ 30 mm, Basic (0.1% Ammonium Bicarbonate) 4 min method, 5-95% MeCN/water): m/z 312.150 (M+H-Na)+ (ES+); 334.053, (M+H)+ (ES+); 312.061 (M ⁇ H) ⁇ (ES ⁇ ), at 1.312 min, 100% purity @ 254 nm.
- LCMS Alent Infinity, X-Select, Waters X-Select C18, 2.5 ⁇ m, 4.6 ⁇ 30 mm, Basic (0.1% Ammonium Bicarbonate) 4 min method, 5-95% MeCN/water
- N-Chlorosuccinimide (220 mg, 1.650 mmol) followed by 1 drop of 1 M hydrochloric acid were added to a stirred solution of (E)-5-bromo-2-hydroxybenzaldehyde oxime (2.2) (300 mg, 1.375 mmol) in DMF (6 mL) at room temperature. After 2 hours ethynylcyclopropane (0.140 mL, 1.650 mmol) was added followed by triethylamine (0.249 mL, 1.787 mmol) and the mixture maintained at room temp for 16 hours.
- the product was analysed by LCMS (Waters Acquity UPLC, X-Select, Waters X-Select UPLC C18, 1.7 ⁇ m, 2.1 ⁇ 30 mm, Acidic (0.1% Formic acid) 3 min method, 5-95% MeCN/water) m/z 280/282 (M+H) + (ES + ); 278/280 (M ⁇ H) ⁇ (ES ⁇ ), at 1.753 min, 85% purity (diode array).
- LCMS Waters Acquity UPLC, X-Select, Waters X-Select UPLC C18, 1.7 ⁇ m, 2.1 ⁇ 30 mm, Acidic (0.1% Formic acid) 3 min method, 5-95% MeCN/water) m/z 280/282 (M+H) + (ES + ); 278/280 (M ⁇ H) ⁇ (ES ⁇ ), at 1.753 min, 85% purity (diode array).
- Table B illustrates Example compounds defined by the general Formula (I.3.4).
- the HPLC System is one of the methods as defined in the Materials and methods section.
- G m ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ channels and for this reason an effect of a compound on G m predominantly reflects alterations in CIC-1 function.
- recordings were in some cases repeated in the presence of the CIC-1 inhibitor 9-AC (100 ⁇ M) to quantify for effects of the compounds on K + channels.
- affinity of CIC-1 channels for a particular compound G m was plotted against compound concentration and a Boltzmann sigmoidal function was fitted to the data to obtain Kd of the compound (Table 2).
- EPPs endplate potentials
- tubocurarine was injected. Animals that failed to respond to tubocurarine were not used on the next day of experimentation. On the second day, the animals were first allowed to run on the rotarod, and all animals performed normally. This shows that effects of the tubocurarine that had been injected on the day before had completely disappeared.
- the aim was to find compounds that by inhibition of CIC-1 channels can recover nerve-stimulated force under conditions of fatigue including conditions where fatigue is caused by compromised neuromuscular transmission.
- Neuromuscular transmission dysfunction can develop because of both pre- and/or post-synaptic complications in connection with a disorder or as part of neuromuscular blockade during/after surgery.
- FIG. 1 Experiments shown in FIG. 1 were performed to confirm that tubocurarine and elevated extracellular Mg 2+ specifically suppressed neuromuscular transmission without affecting the capacity of the muscle fibers to generate force.
- the experiments also illustrate that field stimulation of the entire nerve-muscle preparation selectively activates the motor nerve when short-duration pulses (0.02 vs 0.2 ms) were used.
- the preparation was stimulated either via field stimulation or via nerve-stimulation using a suction electrode. With the suction electrode only the nerve could be stimulated.
- a submaximal concentration of the ACh receptor antagonist tubocurarine 0.2 ⁇ M
- FIG. 1 B shows that only with short-duration pulses did tubocurarine cause a decline in peak force and fading.
- FIG. 1C shows that also elevated extracellular Mg 2+ primarily affected nerve-stimulated force while it did not affect force when the muscle was stimulated directly. Elevated extracellular Mg 2+ could thus be used to partially block neuromuscular transmission and thus be used as a model of conditions with compromised pre-synaptic function (Lambert Eaton syndrome, amyotrophic lateral sclerosis, spinal muscular atrophy).
- CIC-1 ion channels can be used to recover contractile force in muscle with reduced neuromuscular transmission
- isolated nerve-muscle preparations were first exposed to either tubocurarine ( FIG. 2A ) or elevated Mg 2+ ( FIG. 2B ) and then a specific CIC-1 inhibitor (9-AC) was added. It can be seen that CIC-1 inhibition caused a marked recovery of both force and M-wave signal in both conditions. This demonstrates the novel concept that CIC-1 channel inhibition can alleviate loss of force induced by compromised neuromuscular transmission. Similar observations were seen in EDL and diaphragm muscles from both young and adult rats (data not shown). 9-AC does not have the potential to be used as a pharmaceutical.
- FIG. 3A shows representative nerve-stimulated force in two muscles during such an experiment before and during exposure to tubocurarine.
- 50 ⁇ M of a test compound (C8) was added after 40 mins in tubocurarine.
- grey trace For comparison with the muscle only exposed to tubocurarine (grey trace), the two traces have been overlaid.
- FIG. 3B shows average AUC observations of force during experiments in which muscles at tubocurarine were exposed to C8. For comparison, muscles only exposed to tubocurarine have been included. The dotted line indicates the recovery of force with C8 when compared to the force production before its addition.
- AUC force was first determined after 40 min in tubocurarine (column 3) and related to nerve-stimulated force prior to addition of tubocurarine.
- the AUC at the different concentrations of compounds (columns 4-6) is the % change in AUC compared to the AUC before addition (column 3).
- ACh receptors were inhibited using 2 ⁇ M rocuronium, which is a clinically used neuromuscular blocking agent. Under these conditions the nerve-stimulated force was reduced to 51 ⁇ 5% of force before rocuronium. When 50 ⁇ M C8 was subsequently added nerve-stimulated contractile force was significantly recovered to 81 ⁇ 4% of force before rocuronium (p ⁇ 0.01). This illustrates the potential of these compounds to be used as reversal agents.
- Kd values for compounds when tested in human muscle using an approach identical to that in rat muscle are also included.
- CIC-1 is a novel target in treatment of neuromuscular complications and it was therefore explored whether this approach for symptomatic treatment could be used in combination with existing symptomatic treatment approaches.
- myasthenia gravis which in isolated muscles was mimicked by tubocurarine, the symptoms of muscle fatigue are most commonly treated with inhibitors of acethylcholineesterase of which neostigmine and pyridostigmine are examples.
- neostigmine is the most commonly used reversal agent of neuromuscular blocked after surgery.
- FIG. 5A-D show recordings of nerve-stimulated force production at different tubocurarine concentrations when tested under the four experimental conditions. It can be seen that C8 ( FIG. 5B ) and neostigmine ( FIG.
- tubocurarine mimics conditions with reduced neuromuscular transmission due to post-synaptic dysfunction (myasthenia gravis, neuromuscular blockade)
- the experiments with elevated extracellular Mg 2+ mimics conditions with pre-synaptic dysfunction akin to a range of neuromuscular disorders including Lambert Eaton syndrome, motor neuron disorders and polyneuropathy.
- Patients with Lambert Eaton syndrome are commonly treated with inhibitors of voltage gated K + channels such as 3,4-diaminopyridine (3,4-AP). Based on this it was determined whether recovery of nerve-stimulated force at elevated extracellular Mg 2+ with CIC-1 inhibiting compounds could be added to force recovery with 3,4-AP.
- FIG. 6A-D show recordings of nerve-stimulated force production at different Mg 2+ concentrations when tested under these four experimental conditions. It can be seen that with both 3,4-AP and CIC-1 inhibitor did the nerve-stimulated force at elevated Mg 2+ remain elevated when compared to control. The force was, however, best maintained when the combination of both 3,4-AP and CIC-1 inhibitor was used.
- Example 10 CIC-1 Inhibition can Recover Contractile Force in Human Muscles Under Conditions that Mimic Critical Illness Myopathy
- Critical illness myopathy is a condition that develops in around 30% of critically ill patients in intensive care units. The condition is diagnosed from a loss of muscle excitability as evaluated from reduction in compound muscle action potentials. The associated muscle weakness prevents patients from weaning from mechanical ventilation and therefore increases the stay in intensive care units.
- CIM is associated with loss of NaV1.4 function and muscle fibers become depolarized.
- depolarization and loss of NaV1.4 function in CIM were mimicked in experiments with isolated human muscles. Fibers were depolarized by raised extracellular K + , and loss of NaV1.4 function was induced by a small dose of NaV1.4 inhibitor TTX. As shown by FIG.
- tubocurarine (0.13 mg/kg) in animals that had been familiarized to running on the rotarod.
- tubocurarine was injected I.P. and the running performance of the animal was tested 21 minutes after this injection.
- the animals first performed a test run to ensure that they were no longer affected by the tubocurarine injected the day before. Then C8 (20 mg/kg) or sham treatment were injected I.P. and allowed to act for 2 hrs before again injecting tubocurarine. Animals were again tested 21 minutes after this second tubocurarine treatment.
- FIG. 9C shows the number of animals in the two groups (sham and C8) that had a performance increase of at least 100% on the second day.
- CIC-1 Cl ⁇ ion channels generate around 80% of the total membrane conductance (G m ) in resting skeletal muscle fibres of most animals including rat and human. Other ion channels that contribute to G m can therefore be considered negligible, and it is possible to evaluate whether a compound inhibits CIC-1 in rat muscle by comparing G m measurements before and after exposure to a compound. CIC-1 inhibition would in such recordings be reflected by a reduction of G m .
- G m was measured in individual fibres of whole rat soleus muscles using a three micro-electrodes technique described in this example and in full detail elsewhere. Briefly, intact rat soleus muscles were dissected out from 12-14 week old Wistar rats and placed in an experimental chamber that was perfused with a standard Krebs Ringer solution containing 122 mM NaCl, 25 mM NaHCO 3 , 2.8 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 1.3 mM CaC 2 , 5.0 mM D-glucose. During experiments, the solution was kept at approx. 30° C.
- the experimental chamber was placed in Nikon upright microscope that was used to visualize individual muscle fibres and the three electrodes (glass pipettes filled with 2 M potassium citrate).
- the electrodes were inserted into the same fibre with known inter-electrode distances of 0.35-0.5 mm (V1-V2, X1) and 1.1-1.5 mm (V1-V3, X3) ( FIG. 1A ).
- the membrane potential of the impaled muscle fibre was recorded by all electrodes.
- Two of the electrodes were furthermore used to inject 50 ms current pulses of ⁇ 30 nA.
- G m was first determined in 10 muscle fibres in the absence of compound and then at four increasing compound concentrations with G m determinations in 5-10 fibres at each concentration. The average G m values at each concentration were plotted against compound concentration and the data was fitted to sigmoidal function to obtain an EC 50 value ( FIG. 1C ).
- Table 7 shows the EC 50 values for a range of compounds with n values referring to number of experiments that each reflect recordings from around 50 fibres.
- this example demonstrates that the compounds of the present invention have an EC 50 value in the range of 1-12 ⁇ M.
- the current invention relates to compounds that inhibit CIC-1 ion channels and increase muscle excitability and thereby improve muscle function in clinical conditions where muscle activation is failing. Such conditions result in loss of contractile function of skeletal muscle, weakness and excessive fatigue.
- the compounds were tested for their ability to restore contractile function of isolated rat muscle when the neuromuscular transmission had been compromised akin to neuromuscular disorders.
- the contractile function of the muscle was initially assessed under the control conditions ( FIG. 2A ).
- Sub-maximal concentration of tubocurarine 115 nM
- tubocurarine an acetylcholine receptors antagonist
- the experimental condition mimics the failing neuromuscular transmission in a range of neuromuscular disorders.
- the contractile force declined over the next 90 mins to 10-50% of the control force.
- 50 ⁇ M of the test compound was then added and the contractile force recovered despite the continued presence of tubocurarine.
- the percentage of the initial force that was restored was determined after 40 mins of compound exposure ( FIG. 2B ) and the point increase is reported in Table 8.
- this example demonstrates that the compounds of the present invention are able to increase muscle excitability and thereby improve muscle function in clinical conditions.
- the muscle contractility was recovered by 15-40% points, which meant almost complete restoration of the force.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- m is 0, 1, 2, 3, 4 or 5;
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1, X2 and X3 are independently selected from the group consisting of CH and N;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a C3-6-cycloalk(en)yl or a halo-C3-6-cycloalk(en)yl;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3, nitro and halo; or R1 and R2 are linked to form a ring;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl;
for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade after surgery.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-6 membered heterocycle or an 8-10 membered bicyclic heterocycle each of which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof,
for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5 membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof, with the proviso that when R2 is 3-thienyl, R1 is H, n=0 and R5 is CH3 then R4 is not CH3.
- wherein:
-
- The term “C1-8-alkyl” refers to a branched or unbranched alkyl group having from one to eight carbon atoms, including but not limited to methyl, ethyl, prop-1-yl, prop-2-yl, 2-methyl-prop-1-yl, 2-methyl-prop-2-yl, 2,2-dimethyl-prop-1-yl, but-1-yl, but-2-yl, 3-methyl-but-1-yl, 3-methyl-but-2-yl, pent-1-yl, pent-2-yl, pent-3-yl, hex-1-yl, hex-2-yl, hex-3-yl, 2-methyl-4,4-dimethyl-pent-1-yl and hept-1-yl;
- The term “C2-8-alkenyl” refers to a branched or unbranched alkenyl group having from two to eight carbon atoms and one double bond, including but not limited to ethenyl, propenyl, and butenyl; and
- The term “C2-8-alkynyl” refers to a branched or unbranched alkynyl group having from two to eight carbon atoms and one triple bond, including but not limited to ethynyl, propynyl and butynyl.
-
- The term “C3-6-cycloalkyl” refers to a group having three to six carbon atoms including a monocyclic or bicyclic carbocycle, including but not limited to cyclopropyl, cyclopentyl, cyclopropylmethyl and cyclohexyl;
- The term “C3-6-cycloalkenyl” refers to a group having three to six carbon atoms including a monocyclic or bicyclic carbocycle having three to six carbon atoms and at least one double bond, including but not limited to cyclobutenylmethyl, cyclopentenyl, cyclohexenyl.
- The term “C3-6-cycloalkyl” refers to a group having three to six carbon atoms including a monocyclic or bicyclic carbocycle, including but not limited to cyclopropyl, cyclopentyl, cyclopropylmethyl and cyclohexyl;
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- wherein
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl
- for use in treating, ameliorating and/or preventing a neuromuscular disorder.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-6 membered heterocycle or an 8-10 membered bicyclic heterocycle each of which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof, with the proviso that when R2 is 3-thienyl, R1 is H, n=0 and R5 is CH3 then R4 is not CH3.
- wherein:
-
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer - or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof, with the proviso that when R2 is 3-thienyl, R1 is H, n=0 and R5 is CH3 then R4 is not CH3.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 6-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is an 8-10 membered bicyclic heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1, X2 and X3 are selected from the group consisting of, CH and N;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a C3-6-cycloalk(en)yl or a halo-C3-6-cycloalk(en)yl;
- R4 is as defined in
embodiment 1 below; - m is as defined in
embodiment 1 below; - R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3, nitro and halo;
R9, R10 and R11 are independently selected from H, C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl whereas R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl for use in treating, ameliorating and/or preventing a neuromuscular disorder.
Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2. Thus Y may be O, NH, N—CH3, CH2, CH2—O, S or SO2. In one preferred embodiment Y is selected from the group consisting of O, NH, CH2, S, and SO2. In a particular embodiment Y is O.
X1, X2 and X3 are selected from the group consisting of, CH and N. In one embodiment X1 is N, X2 is N or X3 is N. In another preferred embodiment X1 is N. In particular embodiment X2 is N.
R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo, wherein R9, R10 and R11 are independently selected from H, C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl whereas R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
-
- R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo; and
- R9, R10 and R11 are independently selected from H, C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl whereas R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein, m, Y, X1, X2 and X3 and R4 are as defined above. For example X1 is N, X2 is N or X3 is N. In another embodiment X1, X2 and X3 is C. R4 may for example be selected from the group consisting of H, halo, cyano, —CHO, C1-4-alk(en)yl, halo-C1-4-alk(en)yl, —O—C1-4-alk(en)yl
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein A, R2 and R4 are as defined above. In one embodiment R2 is C1-6-alkyl or C3-7-cycloalkyl. For example A is a monocyclic ring such as a phenyl. It is preferred that R4 is in ortho- or meta position.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens; F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein m is 2 and X1, X2, Y, R2 and R4 are as defined above.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer - or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein m, X2, Y, R2 and R4 are as defined above. For example, in a preferred embodiment Y is O. Further, it is preferred that R2 is selected from the group consisting of H and C1-4-alkyl. R4 is in one embodiment selected from the group consisting of H, —CH3 and halogen.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH(CH3)CH2—O—CH3, —CH2—CH2—CH3, —CH2—NH2, —CH2—CHF2, —CH2—CF3, —CH2—NH—CO—CH3 and —CH2—NH—SO2—CH3 and cyclopropyl, and R4 is selected from the group consisting of H, Br, Cl, F and I. In a preferred embodiment R2 is —CH3 or —CH(CH3)2; and R4 is selected from the group consisting of H, Br, Cl, F and I. In particular, R2 is —CH(CH3)2 and R4 is selected from the group consisting of H, Br, Cl, F and I.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I. In a preferred embodiment R2 is —CH3 or —CH(CH3)2; and R4 is selected from the group consisting of H, Br, Cl, F and I. In another preferred embodiment R2 is —CH3 or —CH(CH3)2 and R4 is selected from the group consisting of H, Br, Cl and F. It is further preferred that the compound of Formula (X) is the S-enantiomer with respect to the C-atom to which R2 is bound. This embodiment is exemplified by Formulas (XXIII) and (XXIV), where R2 is —CH3 and R4 is Cl or Br.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I. In a preferred embodiment R2 is —CH3 or —CH(CH3)2; and R4 is selected from the group consisting of H, Br, Cl, F and I. In another preferred embodiment R2 is —CH3 or —CH(CH3)2 and R4 is selected from the group consisting of H, Br, Cl and F.
or a salt or tautomer thereof;
wherein R2 and X1 are as defined above; and R4 and R′4 are independently selected from the group consisting of H, halo, cyano, hydroxy, —CHO, C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl, O—C1-6-alk(en/yn)yl. In a preferred embodiment R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2. Preferably R2 is CH3 or —CH(CH3)2. It is preferred that R4 and R′4 are individually selected from the group consisting of H, Br, Cl, F and I. In another preferred embodiment R4 and/or R′4 are H. It is further preferred that X1 is N or C.
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- wherein
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-6 membered heterocycle or an 8-10 membered bicyclic heterocycle each of which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer - or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof, with the proviso that when R2 is 3-thienyl, R1 is H, n=0 and R5 is CH3 then R4 is not CH3
- wherein:
-
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer - or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof, with the proviso that when R2 is 3-thienyl, R1 is H, n=0 and R5 is CH3 then R4 is not CH3.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 6-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is an 8-10 membered bicyclic heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1, X2 and X3 are selected from the group consisting of, CH and N;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a C3-6-cycloalk(en)yl or a halo-C3-6-cycloalk(en)yl;
- R4 is as defined in
embodiment 1 below; - m is as defined in
embodiment 1 below; - R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3, nitro and halo; or R1 and R2 are linked to form a ring;
- R9, R10 and R11 are independently selected from H, C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl whereas R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl; for use in treating, ameliorating and/or preventing a neuromuscular disorder.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein, Y, X1, X2 and X3 and R4 are as defined above.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein A, R2 and R4 are as defined above.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein m is 2 and X1, X2, Y, R2 and R4 are as defined above.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein m, X2, Y, R2 and R4 are as defined above.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH(CH3)CH2—O—CH3, —CH2—CH2—CH3, —CH2—NH2, —CH2—CHF2, —CH2—CF3, —CH2—NH—CO—CH3 and —CH2—NH—SO2—CH3 and cyclopropyl, and R4 is selected from the group consisting of H, Br, Cl, F and I.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer - or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof.
- wherein:
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2; X1 is N or C; and R4 and R′4 are individually selected from the group consisting of H, Br, Cl, F and I.
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- wherein
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl
- for use in reversing and/or ameliorating a neuromuscular blockade after surgery.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-6 membered heterocycle or an 8-10 membered bicyclic heterocycle each of which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer - or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 6-membered heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer - or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is an 8-10 membered bicyclic heterocycle which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof for use in for use in treating, ameliorating and/or preventing a neuromuscular disorder, and/or for use in reversing and/or ameliorating a neuromuscular blockade.
- wherein:
-
- a. reacting a compound having formula (IX)
-
- wherein R4 is as defined herein and R11 is a protecting group, such as selected from the group consisting of alkyl, alkenyl, akynyl, cycloalkyl, cycloalkenyl, aromatic ring, heteroaromatic ring and -alkylene-Si-alkyl, with first a reagent capable of converting the alcohol (OH) into a leaving group and secondly with a compound having formula (X)
-
- wherein R1, R2, R3 and n are as defined herein and Y is O to generate a compound having formula (XI)
-
- b. reacting the product compound of a) with an ester hydrolysing reagent thus generating a compound as defined herein.
-
- a. reacting a compound having formula (XII)
-
- wherein R1, R2, R3 and n are as defined herein and Q is a leaving group, such as selected from the group consisting of fluorine and iodine, with a compound having formula (IX)
-
- wherein R4 is as defined herein, and R11 a protecting group, such as selected from the group consisting of alkyl, alkenyl, akynyl, cycloalkyl, cycloalkenyl, aromatic ring, heteroaromatic ring and -alkylene-Si-alkyl wherein Y is O to generate a compound having formula (XI)
-
- wherein Y is O; and
- b. reacting the product compound of a) with an ester hydrolysing reagent thus generating a compound as defined herein.
-
- a. reacting a compound having formula (XIII)
-
- wherein R4 is as defined herein, Z is OH and R12 is a protecting group, such as an —Si-alkyl, with first a reagent capable of converting the alcohol (Z) into a leaving group and secondly with a compound having formula (X)
-
- wherein R1, R2, R3 and n are as defined herein, and Y is O to generate a compound having formula (XIV)
-
- b. reacting the product compound of a) with an ether cleaving reagent to generate a compound having formula (XV)
-
- c. reacting the product compound of b) with an oxidising agent thus generating a compound as defined herein.
Prodrugs
- c. reacting the product compound of b) with an oxidising agent thus generating a compound as defined herein.
or a salt of tautomer thereof
wherein m, A, Z, R1, R2 and R4 are as defined above and wherein R14 is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, pyrimidyl, pyridinyl, thiazolyl, oxadiazolyl and quinolyl, all aromatic and heteroaromatic groups optionally substituted by one or more R4
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof, wherein m, A, Z, R1, R2 and R4 are as defined above.
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof;
- wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- wherein
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl for use in treating, ameliorating and/or preventing a neuromuscular disorder.
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof;
- wherein
- m is 0, 1, 2, 3, 4 or 5;
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1, X2 and X3 are independently selected from the group consisting of CH and N;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a C3-6-cycloalk(en)yl or a halo-C3-6-cycloalk(en)yl;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3, nitro and halo; or R1 and R2 are linked to form a ring;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl;
- for use in treating, ameliorating and/or preventing a neuromuscular disorder.
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof;
- wherein Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1, X2 and X3 are selected from the group consisting of, CH and N;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof;
-
- wherein A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- R2 is selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo.
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
-
- wherein
- R2 is selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-5-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
-
- Formula (V) is further defined by Formula (VI):
-
- wherein R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
-
- m is 2;
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1 and X2 are independently selected from the group consisting of CH and N;
- R2 is selected from the group consisting of —OR3, —SR5, —S(O)R5, —S(O)2R5, —NR3, —NR3C(O)R9 or —R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo; R2 is selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
-
- m is 2;
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X2 is selected from the group consisting of, CH and N;
- R2 is selected from the group consisting of —OR3, —SR5, —S(O)R5, —S(O)2R5, —NR3, —NR3C(O)R9 or —R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo; R2 is selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH(CH3)CH2—O—CH3, —CH2—CH2—CH3, —CH2—NH2, —CH2—CHF2, —CH2—CF3, —CH2—NH—CO—CH3 and —CH2—NH—SO2—CH3 and cyclopropyl, and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2; X1 is N or C; and R4 and R′4 are independently selected from the group consisting of H, Br, Cl, F and I.
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo; R2 is selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R1, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo.
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
- R14 is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, pyrimidyl, pyridinyl, thiazolyl, oxadiazolyl and quinolyl, all aromatic and heteroaromatic groups optionally substituted by one or more R4.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof, wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-5-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-5-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof, wherein
-
- wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl
- wherein
-
- wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- B is a 5- to 7-membered heterocyclic.
- wherein
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof;
- wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- wherein
- R1 and R2 are independently selected from the group consisting of —OR3, —SR5, —S(O)R5, —S(O)2R5, —NR3, —NR3C(O)R9 or —R3, wherein R3 is selected from the group consisting of —H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of —H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, —O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from —H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl
- for use in reversing and/or ameliorating a neuromuscular blockade after surgery.
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- m is 0, 1, 2, 3, 4 or 5;
- Z is a 2-5 atom chain comprising at least one carbon atom and optionally one heteroatom or substituted heteroatom, wherein the heteroatom or substituted heteroatom is selected from the group consisting of O, N, NC(O)R3, S, S(O)R5 and S(O)2R5, wherein each atom of said 2-5 atom chain is optionally substituted with R1 and R2;
- wherein
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, —O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-5-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, O—R11, fluorinated C1-3-alkyl, nitro and halo;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
- m is 0, 1, 2, 3, 4 or 5;
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1, X2 and X3 are independently selected from the group consisting of CH and N;
- R1 and R2 are independently selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a C3-6-cycloalk(en)yl or a halo-C3-6-cycloalk(en)yl;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3, nitro and halo; or R1 and R2 are linked to form a ring;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein
-
- or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof;
- wherein
- m is 0, 1, 2, 3, 4 or 5
- Y is selected from the group consisting of O, NH, N—CH3, CH2, CH2—O, S and SO2;
- X1, X2 and X3 are independently selected from the group consisting of CH and N;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo, wherein R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl; R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl and R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3, nitro and halo; or R1 and R2 are linked to form a ring;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
-
- A is an aromatic or heteroaromatic ring selected from the group consisting of phenyl, naphthyl, biphenyl, quinolinyl, isoquinolinyl, imidazolyl, thiazolyl, thiadiazolyl, triazolyl, oxazolyl, pyridinyl, pyrimidinyl, pyrazyl, and pyridazinyl;
- R2 is selected from the group consisting of OR3, SR5, S(O)R5, S(O)2R5, NR3, NR3C(O)R9 or R3, wherein R3 is selected from the group consisting of H, C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2—SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3-alkyl, nitro and halo; or R1 and R2 are linked to form a ring;
- R4 is selected from the group consisting of H, C1-6-alk(en/yn)yl, C3-6-cycloalk(en)yl, —NR9—CO—R10, —NR10—SO2—R11, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, cyano, O—R11, fluorinated C1-3, nitro and halo, wherein R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl; R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl and R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl;
- R5 is selected from the group consisting of C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl, wherein said C1-8-alk(en/yn)yl and C3-6-cycloalk(en)yl may be substituted with up to three substituents selected from the group consisting of —NR9—CO—R10, —N(R10)2SO2—R12, —CO—NR9R10, —SO2—NR9R10, —R13—O—R11, —NR9R10, —S(O)R12, —S(O)2R12, cyano, —O—R11, fluorinated C1-3, nitro and halo; or R1 and R2 are linked to form a ring;
- R9, R10, R11 are independently selected from H or C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R12 is selected from C1-4-alk(en/yn)yl and C3-6-cycloalk(en)yl;
- R13 is selected from C1-4-alk(an/en/yn)diyl and C3-6-cycloalk(an/en)diyl.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein m is 2 and X1, X2, Y, R2 and R4 are as defined above.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein m, X2, Y, R2 and R4 are as defined above.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH(CH3)CH2—O—CH3, —CH2—CH2—CH3, —CH2—NH2, —CH2—CHF2, —CH2—CF3, —CH2—NH—CO—CH3 and —CH2—NH—SO2—CH3 and cyclopropyl, and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2 and R4 is selected from the group consisting of H, Br, Cl, F and I.
or a pharmaceutically acceptable salt, solvate, polymorph, or tautomer thereof; wherein R2 is selected from the group consisting of —CH3, —CH2—CH3, —CH(CH3)2, —C(CH3)3, —CH2—CH2—CH3 and —CH2—NH2; X1 is N or C; and R4 and R′4 are independently selected from the group consisting of H, Br, Cl, F and I.
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R2 is a 5-6 membered heterocycle or an 8-10 membered bicyclic heterocycle each of which may be optionally substituted with one or more, identical or different, substituents R6;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- n is an
integer
- or a pharmaceutically acceptable salt, hydrate, polymorph, tautomer, or solvate thereof, with the proviso that when R2 is 3-thienyl, R1 is H, n=0 and R5 is CH3 then R4 is not CH3.
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
-
- wherein:
- R1 is selected from the group consisting of H, deuterium, F, Cl, Br and I;
- R3 is selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, CF3, CCl3, CHF2, CHCl2, CH2F, CH2Cl, OCF3, OCCl3 and isocyanide;
- R4 is selected from the group consisting of C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C cycloalkenyl, each of which may be optionally substituted with one or more, identical or different, substituents R7;
- R5 is selected from the group consisting of H, C1-5 alkyl, C1-5 alkenyl and C1-5 alkynyl;
- R6 is independently selected from the group consisting of H, deuterium, tritium, F, Cl, Br, I, CN, isocyanide, C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl, and wherein C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C3-5 cycloalkyl, C5 cycloalkenyl, O—C1-5 alkyl, O—C1-5 alkenyl, O—C1-5 alkynyl, O—C3-5 cycloalkyl, O—C5 cycloalkenyl, —C(═O)—C1-5 alkyl, —C(═O)—C1-5 alkenyl, —C(═O)—C1-5 alkynyl, —C(═O)—C3-5 cycloalkyl, —CH2—O—C1-3 alkyl and —CH2—S—C1-3 alkyl may be optionally substituted with one or more halogens;
- R7 is independently selected from the group consisting of deuterium, tritium, F, Cl, Br, I, CN, isocyanide, O—C1-3 alkyl, S—C1-3 alkyl, CH2—O—C1-3 alkyl and CH2—S—C1-3 alkyl;
- m is an
integer - n is an
integer
- wherein:
- (2S)-2-[4-bromo-2-(1,2-oxazol-5-yl)phenoxy]butanoic acid;
- (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]butanoic acid;
- (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]-3-methylbutanoic acid;
- (2S)-2-{4-bromo-2-[3-(propan-2-yl)-1,2-oxazol-5-yl]phenoxy}propanoic acid;
- (2S)-2-[4-bromo-2-(4-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-chloro-6-(1,2-oxazol-3-yl)phenoxy]propanoic acid;
- (2S)-2-[4-chloro-2-(pyridin-2-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-(5-methyl-1,2-oxazol-3-yl)phenoxy]propanoic acid;
- (2S)-2-[4-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenoxy]propanoic acid;
- (2S)-2-(2-{3aH,4H,5H,6H,6aH-cyclopenta[d][1,2]oxazol-3-yl}-4-bromophenoxy)propanoic acid;
- (2S)-2-[4-bromo-2-(5-cyclopropyl-1,2-oxazol-3-yl)phenoxy]propanoic acid;
- (2S)-2-[2-(1,3-benzothiazol-2-yl)-4-bromophenoxy]propanoic acid;
- (2S)-2-[4-chloro-2-(1,3-thiazol-2-yl)phenoxy]propanoic acid;
- (2S)-2-{4-bromo-2-[(5S)-3-methyl-4,5-dihydro-1,2-oxazol-5-yl]phenoxy}propanoic acid;
- (2S)-2-{4-bromo-2-[(5R)-3-methyl-4,5-dihydro-1,2-oxazol-5-yl]phenoxy}propanoic acid;
- (2S)-2-[4-bromo-2-(1,2-oxazol-3-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-(3-methyl-1,2-oxazol-5-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-(1H-imidazol-2-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-(1H-imidazol-4-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-(oxolan-3-yl)phenoxy]propanoic acid;
- (2R)-2-[4-bromo-2-(1,2-oxazol-5-yl)phenoxy]-3-fluoropropanoic acid;
- (2S)-2-[4-chloro-2-(1,3-dimethyl-1H-pyrazol-4-yl)phenoxy]propanoic acid;
- (2S)-2-[4-chloro-2-(1H-pyrazol-3-yl)phenoxy]propanoic acid;
- (2S)-2-[4-chloro-2-(thiophen-2-yl)phenoxy]propanoic acid;
- (2S)-2-[4-chloro-2-(1,2-oxazol-5-yl)phenoxy]propanoic acid;
- (2S)-2-[4-chloro-2-(1-methyl-1H-pyrazol-4-yl)phenoxy]propanoic acid;
- (2S)-2-[2-(1,3-benzothiazol-2-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-(1,3,4-oxadiazol-2-yl)phenoxy]propanoic acid;
- (2S)-2-[4-bromo-2-(1,2-oxazol-5-yl)phenoxy]propanoic acid; and
- (2S)-2-[4-chloro-2-(1H-pyrazol-1-yl)phenoxy]propanoic acid.
-
- a. reacting a compound having a formula of
-
- wherein R4 is as defined in any one of the preceding embodiments and R11 is selected from the group consisting of alkyl, alkenyl, akynyl, cycloalkyl, cycloalkenyl, aromatic ring, heteroaromatic ring and -alkylene-Si-alkyl, with first a reagent capable of converting the alcohol (OH) into a leaving group and secondly with a compound having a formula of
-
- wherein R1, R2, R3 and n are as defined in any one of the preceding embodiments and Y is O to generate a compound having a formula of
-
- b. reacting the product compound of a) with an ester hydrolysing reagent thus generating a compound according to any one of embodiments 135 to 204
-
- a. reacting a compound having a formula of
-
- wherein R1, R2, R3 and n are as defined in any one of the preceding embodiments and Q is a leaving group selected from the group consisting of fluorine and iodine, with a compound having a formula of
-
- wherein R4 is as defined in any one of the preceding embodiments and R11 is selected from the group consisting of alkyl, alkenyl, akynyl, cycloalkyl, cycloalkenyl, aromatic ring, heteroaromatic ring and -alkylene-Si-alkyl wherein Y is O to generate a compound having a formula of
-
- wherein Y is O; and
- b. reacting the product compound of a) with an ester hydrolysing reagent thus generating a compound according to any one of the preceding embodiments.
-
- a. reacting a compound having a formula of
-
- wherein R4 is as defined in any one of the preceding embodiments, Z is OH and R12 is selected from the group consisting of —Si-alkyl, with first a reagent capable of converting the alcohol (Z) into a leaving group and secondly with a compound having a formula of
-
- wherein R1, R2, R3 and n are as defined in any one of the preceding embodiments and Y is O to generate a compound having a formula of
-
- b. reacting the product compound of a) with an ether cleaving reagent to generate a compound having a formula of
-
- c. reacting the product compound of b) with an oxidising agent thus generating a compound according to any one of embodiments 135 to 204.
TABLE A |
Synthesis of compounds |
Compounds of formula (I) may be synthesized by one of |
Synthetic Methods A to H, as shown in the below. |
Example | Preparation | ||
number | IUPAC name | method | NMR |
C1 | (2S)-2-(4- | A | 1H-NMR (400 MHz, DMSO- |
chlorophenoxy) | d6): δ 13.2 (s, 1H), 7.35 (m, | ||
propanoic | 2H), 6.9 (m, 2H), 4.85 (q, | ||
acid | 1H), 1.45 (d, 3H). | ||
C2 | (2S)-2-[(4- | B | 1H-NMR (500 MHz, DMSO- |
chlorophenyl) | d6): δ 7.15 (m, 2H), 6.58 | ||
amino] | (m, 2H), 3.95 (q, 1H), 1.35 | ||
propanoic acid | (d, 3H). | ||
C3 | 2- | B | 1H-NMR (400 MHz, CDCl3): |
(benzyloxy) | δ 9.8 (s, 1H), 7.35 (m, 5H), | ||
propanoic | 4.7 (d, 1H), 4.5 (d, 1H), 4.05 | ||
acid | (q, 1H), 1.47(d, 3H). | ||
C4 | 2-(4-fluoro- | A | 1H-NMR (400 MHz, DMSO- |
phenoxy) | d6): δ 12.68 (s, 1H), 6.9 (m, | ||
propanoic | 4H), 4.68 (q, 1H), 1.62 (d, | ||
acid | 3H). | ||
C5 | (2S)-2- | B | 1H-NMR (400 MHz, CDCl3): |
(benzyloxy) | δ 11.3 (bs, 1H), 7.4 (m, 5H), | ||
propanoic | 4.71 (d, 1H), 4.52 (d, 1H), | ||
acid | 4.08 (q, 1H), 1.47 (d, 3H). | ||
C6 | 2-(4- | D | 1H-NMR (500 MHz, DMSO- |
fluoro- | d6): δ 13.4 (s, 1H), 7.96 (m, | ||
benzene- | 2H), 7.51 (m, 2H), 4.38 (q, | ||
sulfonyl) | 1H), 1.35 (d, 3H). | ||
propanoic | |||
acid | |||
C7 | 2-(4- | A | 1H-NMR (400 MHz, DMSO- |
chlorophen- | d6): δ 12.72 (bs, 1H), 7.23 | ||
oxy)butanoic | (m, 2H), 6.83 (m, 2H), 4.52 | ||
acid | (m, 1H), 1.9 (m, 2H), 1.05 | ||
(m, 3H). | |||
C8 | (2S)-2-(4- | A | 1H-NMR (300 MHz, CDCl3): |
bromophen- | δ 8.42 (bs, 1H), 7.35 (m, | ||
oxy)propanoic | 2H), 6.78 (m, 2H), 4.71 (q, | ||
acid | 1H), 1.62 (d, 3H). | ||
C9 | 3-amino-2- | E | 1H-NMR (400 MHz, DMSO- |
(4- | d6): δ 13.7 (bs, 1H), 8.25 (s, | ||
fluorophen- | 2H), 7.18 (m, 2H), 7.02 (m, | ||
oxy)propanoic | 2H), 5.05 (q, 1H), 3.15 (bs, | ||
acid | 2H). | ||
hydrochloride | |||
C10 | (2S)-2-[(4- | A | 1H-NMR (400 MHz, DMSO- |
chloronaph- | d6): δ 13.2 (bs, 1H), 8.25 (d, | ||
thalen-1- | 1H), 8.0 (d, 1H), 7.6 (m, | ||
yl)oxy] | 3H), 6.90 (d, 1H), 4.98 (q, | ||
propanoic acid | 1H), 1.58 (d, 3H). | ||
C11 | 4- | F | 1H-NMR (300 MHz, |
chlorophenyl | DMSO/CCl4): δ 7.41 (m, | ||
2-(4- | 2H), 7.08 (m, 6H), 5.14 (m, | ||
chloro- | 1H), 1.71 (d, 3H). | ||
phenoxy) | |||
propanoate | |||
C12 | (2S)-2-(5- | C | 1H-NMR (300 MHz, CDCl3): |
bromopyrim- | δ 9.65 (bs, 1H), 8.42 (m, | ||
idin-2-yl)-3- | 2H), 5.05 (dd, 1H), 2.44 (m, | ||
methylbutano | 1H), 1.2 (m, 6H). | ||
ic acid | |||
C13 | 2-[(1S)-1-(4- | H | 1H-NMR (300 MHz, CDCl3): |
chlorophenoxy) | δ 7.24 (m, 2H), 6.9 (m, 2H), | ||
ethyl]-1,3- | 4.62 (m, 1H), 4.41 (m, 1H), | ||
oxazolidine | 3.8 (m, 2H), 3.3 (m, 1H), 3.1 | ||
(m, 1H), 1.4 (m, 3H). | |||
C14 | 2-(4- | B | 1H-NMR (500 MHz, DMSO- |
bromophen- | d6): δ 13.1 (s, 1H), 7.48 (m, | ||
oxy)-2-cyclo- | 2H), 6.8 (m, 2H), 4.08 (d, | ||
propylactic | 1H), 1.12 (m,1H), 0.5 (m, | ||
acid | 4H). | ||
C15 | 2-(4- | B | 1H-NMR (500 MHz, DMSO- |
bromophen- | d6): δ 13.3 (s, 1H), 8.15 (s, | ||
oxy)-3 | 1H), 7.48 (m, 2H), 6.85 (m, | ||
acetamido- | 2H), 4.70 (q, 1H), 3.61 (m, | ||
propanoic | 1H), 3.31 (m, 1H), 1.72 (s, | ||
acid | 3H). | ||
C16 | 2-(4- | B | 1H-NMR (500 MHz, DMSO- |
bromophen- | d6): δ 13.4 (bs, 1H), 7.5 (m, | ||
oxy)-3- | 3H), 6.92 (m, 2H), 4.85 (m, | ||
methane- | 1H), 3.52 (m, 1H), 3.35 (m, | ||
sulfonamido- | 1H) 2.9 (s, 3H). | ||
propanoic acid | |||
C17 | (2S)-2-(4- | G | 1H-NMR (300 MHz, CDCl3): |
chloro- | δ 9.7 (d, 1H), 7.25 (m, 2H), | ||
phenoxy) | 6.81 (m, 2H), 4.61 (q, 1H), | ||
propanal | 1.45 (m, 3H). | ||
C18 | 4-nitrophenyl | F | 1H-NMR (300 MHz, CDCl3): |
(2S)-2-(4- | δ 8.28 (m, 2H), 7.25 (m, 4H), | ||
chlorophen- | 6.84 (m, 2H), 5.02 (m, 1H), | ||
oxy) | 1.82 (m, 3H). | ||
propanoate | |||
C19 | 4-meth- | F | 1H-NMR (300 MHz, CDCl3): |
oxyphenyl | δ 7.3 (m, 2H), 6.92 (m, 6H), | ||
(2S)-2-(4- | 4.9 (q, 1H), 3.81 (s, 3H), | ||
chloro- | 1.78 (dd, 3H). | ||
phenoxy) | |||
propanoate | |||
C20 | 2-(4- | B | 1H-NMR (400 MHz, DMSO- |
bromophen- | d6): δ 13.1 (bs, 1H), 7.42 | ||
oxy)-2-(3- | (m, 2H), 6.81 (m, 2H), 4.65 | ||
ethoxycyclo- | (dd, 1H), 3.44 (m, 1H), 3.30 | ||
butyl)acetic | (m, 1H), 3.24 (m, 3H), 2.36 | ||
acid | (m, 1H), 0.9 (dd, 3H). | ||
C21 | 2-(4- | B | 1H-NMR (400 MHz, DMSO- |
bromophen- | d6): δ 13.1 (s, 1H), 7.42 (m, | ||
oxy)-4- | 2H), 6.82 (m, 2H), 4.61 (d, | ||
methoxy-3- | 1H), 3.80 (m, 1H), 3.28 (m, | ||
methyl- | 2H), 2.31 (m , 3H), 1.80 (m, | ||
butanoic acid | 2H), 1.05 (t, 3H). | ||
C22 | (2S)-2-(4- | A | 1H-NMR (500 MHz, CDCl3): |
bromo- | δ 7.41 (m, 2H), 6.78 (m, 2H), | ||
phenoxy)- | 4.41 (d, 1H), 2.38 (q, 1H), | ||
3methyl- | 1.11 (d, 6H). | ||
butanoic acid | |||
TABLE B |
Illustrative Examples of the Invention |
HPLC | ||||
Cpd | retention | Synthesis | ||
Number | IUPAC name | 1H NMR | time | method |
A-1 | (2S)-2[4-bromo-2- | 1H NMR (500 MHz, DMSO-d6) | 4.066 | I |
(1,2-oxazol-5- | δ 13.29 (s, 1H), 8.71 (d, J = 1.9 | |||
yl)phenoxy] | Hz, 1H), 7.98 (d, J = 2.5 Hz, | |||
butanoic | 1H), 7.64 (dd, J = 8.9, 2.6 Hz, | |||
acid | 1H), 7.08 (d, J = 9.0 Hz, 1H), | |||
7.02 (d, J = 1.9 Hz, 1H), 5.06 | ||||
(dd, J = 6.3, 4.9 Hz, 1H), 2.07 - | ||||
1.94 (m, 2H), 1.00 (t, J = 7.4 Hz, | ||||
3H). | ||||
A-2 | (2S)-2[4-bromo-2- | 1H NMR (500 MHz, DMSO-d6) | 4.025 | I |
(1,2-oxazol-3- | δ 13.25 (s, 1H), 9.02 (d, J = 1.7 | |||
yl)phenoxy] | Hz, 1H), 7.89 (d, J = 2.6 Hz, | |||
butanoic | 1H), 7.63 (dd, J = 8.9, 2.6 Hz, | |||
acid | 1H), 7.07 - 7.04 (m, 2H), 4.99 | |||
(dd, J = 6.3, 4.9 Hz, 1H), 1.99 - | ||||
1.88 (m, 2H), 0.96 (t, J = 7.4 Hz, | ||||
3H). | ||||
A-3 | (2S)-2-[4-bromo-2- | 1H NMR (500 MHz, DMSO-d6) | 4.391 | I |
(1,2-oxazol-3- | δ 13.25 (s, 1H), 9.03 (d, J = 1.7 | |||
yl)phenoxy]-3- | Hz, 1H), 7.85 (d, J = 2.6 Hz, | |||
methylbutanoic | 1H), 7.63 (dd, J = 8.9, 2.6 Hz, | |||
acid | 1H), 7.04 (d, J = 9.0 Hz, 1H), | |||
7.01 (d, J = 1.7 Hz, 1H), 4.84 (d, | ||||
J = 4.3 Hz, 1H), 2.32 - 2.24 (m, | ||||
1H), 1.00 (d, J = 6.9 Hz, 6H). | ||||
A-4 | (2S)-2-{4-bromo- | 1H NMR (500 MHz, Chloroform- | 4.790 | I |
2-[3-(propan-2- | d) δ 8.08 (d, J = 2.5 Hz, 1H), | |||
yl)-1,2-oxazol-5- | 7.45 (dd, J = 8.8, 2.5 Hz, 1H), | |||
yl]phenoxy} | 6.82 (s, 1H), 6.77 (d, J = 8.9 Hz, | |||
propanoic acid | 1H), 4.95 (q, J = 6.8 Hz, 1H), | |||
3.12 (p, J = 7.0 Hz, 1H), 1.76 (d, | ||||
J = 6.8 Hz, 3H), 1.34 (d, J = 7.0 | ||||
Hz, 6H). | ||||
A-5 | (2S)-2-[4-bromo- | 1H NMR (500 MHz, DMSO-d6) | 3.707 | I |
2-(4-methyl- | δ 13.21 (s, 1H), 8.74 (q, J = 1.0 | |||
1,2-oxazol-3- | Hz, 1H), 7.66 (dd, J = 8.9, 2.6 | |||
yl)phenoxy] | Hz, 1H), 7.47 (d, J = 2.6 Hz, | |||
propanoic | 1H), 6.94 (d, J = 9.0 Hz, 1H), | |||
acid | 4.94 (q, J = 6.8 Hz, 1H), 1.98 (d, | |||
J = 1.1 Hz, 3H), 1.43 (d, J = 6.8 | ||||
Hz, 3H). | ||||
A-6 | (2S)-2[4-bromo- | 1H NMR (500 MHz, DMSO-d6) | 4.064 | I |
2-chloro-6-(1,2- | δ 13.02 (s, 1H), 9.07 (d, J = 1.7 | |||
oxazol-3- | Hz, 1H), 7.95 (d, J = 2.5 Hz, | |||
yl)phenoxy] | 1H), 7.87 (d, J = 2.4 Hz, 1H), | |||
propanoic | 7.04 (d, J = 1.7 Hz, 1H), 4.67 (q, | |||
acid | J = 6.7 Hz, 1H), 1.28 (d, J = 6.8 | |||
Hz, 3H). | ||||
A-7 | (2S)-2-[4-chloro- | 1H NMR (500 MHz, DMSO-d6) | 1.63 | I |
2-(pyridin-2- | δ 13.44 (s, 1H), 8.68 (ddd, J = | |||
yl)phenoxy] | 4.8, 1.8, 1.0 Hz, 1H), 8.10 (dt, J | |||
propanoic acid | = 8.0, 1.0 Hz, 1H), 7.87 (ddd, J | |||
= 8.0, 7.6, 1.9 Hz, 1H), 7.77 (d, | ||||
J = 2.8 Hz, 1H), 7.42 (dd, J = | ||||
8.8, 2.8 Hz, 1H), 7.37 (ddd, J = | ||||
7.5, 4.8, 1.1 Hz, 1H), 7.05 (d, J | ||||
= 9.0 Hz, 1H), 5.03 (q, J = 6.8 | ||||
Hz, 1H), 1.50 (d, J = 6.8 Hz, | ||||
3H). | ||||
A-8 | (2S)-2-[4-bromo- | 1H NMR (500 MHz, DMSO-d6) | 3.975 | I |
2-(5-methyl- | δ 13.23 (s, 1H), 7.86 (d, J = 2.6 | |||
1,2-oxazol-3- | Hz, 1H), 7.60 (dd, J = 8.9, 2.6 | |||
yl)phenoxy] | Hz, 1H), 7.02 (d, J = 9.0 Hz, | |||
propanoic | 1H), 6.77 (s, 1H), 5.04 (q, J = | |||
acid | 6.7 Hz, 1H), 2.47 (d, J = 0.9 Hz, | |||
3H), 1.55 (d, J = 6.7 Hz, 3H). | ||||
A-9 | (2S)-2-[4-chloro- | 1H NMR (500 MHz, DMSO-d6) | 3.34 | I |
2-(3-methyl-1,2,4- | δ 13.24 (s, 1H), 7.95 (d, J = 2.7 | |||
oxadiazol-5- | Hz, 1H), 7.67 (dd, J = 9.0, 2.8 | |||
yl)phenoxy] | Hz, 1H), 7.15 (d, J = 9.1 Hz, | |||
propanoic | 1H), 5.09 (q, J = 6.8 Hz, 1H), | |||
acid | 2.42 (s, 3H), 1.56 (d, J = 6.8 Hz, | |||
3H). | ||||
A-10 | (2S)-2-(2- | 1HNMR (500 MHz, DMSO-d6) δ | 4.05 | I |
{3aH,4H,5H, | 13.20 (s, 1H), 7.70 (d, J = 2.6 | and | ||
6H,6aH- | Hz, 0.4H)7.68 (d, J = 2.6 Hz, | 4.14 | ||
cyclopenta[d][1,2] | 0.6H), 7.58 - 7.54 (m, 1H), 6.94 | |||
oxazol-3-y1}-4- | (app t, J = 8.7 Hz, 1H), 5.15 - | |||
bromophenoxy) | 5.12 (m, 1H), 5.02 (p, J = 6.6 | |||
propanoic | Hz, 1H), 4.42 - 4.37 (m, 1H), | |||
acid | 1.93 (dd, J = 13.8, 6.3 Hz, 1H), | |||
1.77 - 1.58 (m, 4H), 1.54 (app | ||||
dd, J = 6.7, 2.6 Hz, 3H), 1.32 - | ||||
1.21 (m, 1H). | ||||
A-11 | (2S)-2-[4-bromo- | 1H NMR (500 MHz, DMSO-d6) | 4.603 | I |
2-(5-cyclo- | δ 13.25 (s, 1H), 7.84 (d, J = 2.6 | |||
propyl-1,2- | Hz, 1H), 7.60 (dd, J = 8.9, 2.6 | |||
oxazol-3- | Hz, 1H), 7.02 (d, J = 9.0 Hz, | |||
yl)phenoxy] | 1H), 6.73 (s, 1H), 5.03 (q, J = | |||
propanoic | 6.8 Hz, 1H), 2.22 (tt, J = 8.4, 5.0 | |||
acid | Hz, 1H), 1.55 (d, J = 6.7 Hz, | |||
3H), 1.13 - 1.07 (m, 2H), 0.96 - | ||||
0.89 (m, 2H). | ||||
A-12 | (2S)-2-[2-(1,3- | 1H NMR (500 MHz, DMSO-d6) | 5.284 | I |
benzothiazol- | δ 13.35 (s, 1H), 8.55 (d, J = 2.6 | |||
2-y1)-4-bromo- | Hz, 1H), 8.17 (dt, J = 7.9, 0.9 | |||
phenoxy] | Hz, 1H), 8.11 (dt, J = 8.2, 0.9 | |||
propanoic acid | Hz, 1H), 7.69 (dd, J = 8.9, 2.6 | |||
Hz, 1H), 7.57 (ddd, J = 8.3, 7.1, | ||||
1.3 Hz, 1H), 7.48 (ddd, J = 8.2, | ||||
7.1, 1.2 Hz, 1H), 7.13 (d, J = 9.0 | ||||
Hz, 1H), 5.29 (q, J = 6.8 Hz, | ||||
1H), 1.77 (d, J = 6.8 Hz, 3H). | ||||
A-13 | (2S)-2-[4-chloro-2- | 1H NMR (500 MHz, DMSO-d6) | 3.790 | I |
(1,3-thiazol-2- | δ 13.28 (s, 1H), 8.26 (d, J = 2.8 | |||
yl)phenoxy] | Hz, 1H), 7.98 (d, J = 3.2 Hz, | |||
propanoic acid | 1H), 7.86 (d, J = 3.2 Hz, 1H), | |||
7.46 (dd, J = 8.9, 2.8 Hz, 1H), | ||||
7.10 (d, J = 9.0 Hz, 1H), 5.24 - | ||||
5.17 (m, 1H), 1.69 (d, J = 6.8 | ||||
Hz, 3H). | ||||
A-14 | (2S)-2-{4-bromo-2- | 1H NMR (400 MHz, DMSO-d6) | 3.103 | I |
[(5S)-3-methyl-4,5- | δ 13.16 (s, 1H), 7.43 (dd, J = | |||
dihydro-1,2- | 8.7, 2.6 Hz, 1H), 7.36 (d, J = 2.5 | |||
oxazol-5- | Hz, 1H), 6.87 (d, J = 8.8 Hz, | |||
yl]phenoxy} | 1H), 5.63 (dd, J = 11.1, 7.2 Hz, | |||
propanoic acid | 1H), 4.93 (q, J = 6.8 Hz, 1H), | |||
3.43 (ddd, J = 17.4, 11.1, 1.3 | ||||
Hz, 1H), 2.89 (ddd, J = 17.3, | ||||
7.3, 1.1 Hz, 1H), 1.92 (s, 3H), | ||||
1.50 (d, J = 6.8 Hz, 3H). | ||||
A-15 | (2S)-2-{4-bromo-2- | 1H NMR (400 MHz, DMSO-d6) | 3.198 | I |
[(5R)-3-methyl-4,5- | δ 13.04 (s, br, 1H), 7.42 (dd, J = | |||
dihydro-1,2- | 8.7, 2.6 Hz, 1H), 7.35 (d, J = 2.6 | |||
oxazol-5-yl] | Hz, 1H), 6.84 (d, J = 8.8 Hz, | |||
phenoxy} | 1H), 5.64 (dd, J = 11.0, 6.8 Hz, | |||
propanoic acid | 1H), 4.94 (q, J = 6.8 Hz, 1H), | |||
3.48 (ddd, J = 17.5, 11.0, 1.3 | ||||
Hz, 1H), 2.92 (dd, J = 17.7, 6.8 | ||||
Hz, 1H), 1.93 (s, 3H), 1.52 (d, J | ||||
= 6.8 Hz, 3H). | ||||
A-16 | (2S)-2[4-bromo-2- | 1H NMR (400 MHz, DMSO-d6) | 3.622 | I |
(1 ,2-oxazol-3- | δ 13.24 (s, 1H), 9.01 (d, J = 1.7 | |||
yl)phenoxy] | Hz, 1H), 7.91 (d, J = 2.6 Hz, | |||
propanoic acid | 1H), 7.63 (dd, J = 8.9, 2.6 Hz, | |||
1H), 7.11 (d, J = 1.7 Hz, 1H), | ||||
7.06 (d, J = 9.0 Hz, 1H), 5.09 (q, | ||||
J = 6.7 Hz, 1H), 1.55 (d, J = 6.7 | ||||
Hz, 3H). | ||||
A-17 | (2S)-2-[4-bromo- | 1H NMR (400 MHz, Chloroform- | 2.168 | 1 |
2-(3-methyl-1,2- | d) δ 8.10 (d, J = 2.5 Hz, 1H), | |||
oxazol-5- | 7.45 (dd, J = 8.9, 2.5 Hz, 1H), | |||
yl)phenoxy] | 6.76 (t, J = 4.4 Hz, 2H), 4.96 (q, | |||
propanoic acid | J = 6.8 Hz, 1H), 2.36 (s, 3H), | |||
1.76 (d, J = 6.8 Hz, 3H). | ||||
A-18 | (2S)-2[4-bromo-2- | 1H NMR (500 MHz, DMSO-d6) | 0.677 | I |
(1H-imidazol-2- | δ 8.12 (d, J = 2.6 Hz, 1H), 7.57 | (3 minute | ||
yl)phenoxy] | (dd, J = 8.9, 2.6 Hz, 1H), 7.39 | method) | ||
propanoic acid | (s, 2H), 7.19 (d, J = 9.0 Hz, 1H), | |||
5.10 (q, J = 6.8 Hz, 1H), 1.62 (d, | ||||
J = 6.8 Hz, 3H). | ||||
A-19 | (2S)-2[4-bromo-2- | 1H NMR (400 MHz, Methanol- | 1.179 | I |
(1H-imidazol-4- | d4) δ 8.12 (s, 1H), 7.85(d, J = | |||
yl)phenoxy] | 2.4 Hz, 1H), 7.72 (s, 1H), 7.37 | |||
propanoic acid | (dd, J = 8.8, 2.4 Hz, 1H), 6.97 | |||
(d, J = 8.9 Hz, 1H), 4.72 (q, J = | ||||
6.7 Hz, 1H), 1.62 (d, J = 6.7 Hz, | ||||
3H). | ||||
A-20 | (2S)-2[4-bromo-2- | 1H NMR (400 MHz, DMSO-d6) | 3.434 | I |
(oxolan-3- | δ 13.16 (s, 1H), 7.34 (m, 2H), | and | ||
yl)phenoxy] | 6.84-6.76 (m, 1H), 4.89 (m, | 3.532 | ||
propanoic acid | 1H), 4.05 - 3.93 (m, 1H), 3.89 | |||
(m, 1H), 3.79 (q, J = 7.5 Hz, | ||||
1H), 3.60 (m, 2H), 2.21 (m, 1H), | ||||
2.09 - 1.95 (m, 1H), 1.52 (d, J = | ||||
6.7 Hz, 3H). | ||||
A-21 | (2R)-2-[4-bromo- | 1H NMR (400 MHz, DMSO-d6) | 3.537 | K |
2-(1,2-oxazol-5- | δ 8.72 (d, J = 1.9 Hz, 1H), 8.00 | |||
yl)phenoxy]-3- | (d, J = 2.6 Hz, 1H), 7.65 (dd, J = | |||
fluoropropanoic | 9.0, 2.5 Hz, 1H), 7.18 (d, J = 9.0 | |||
acid | Hz, 1H), 7.04 (d, J = 1.9 Hz, | |||
1H), 5.53 (dt, J = 30.6, 2.8 Hz, | ||||
1H), 4.98 (dqd, J = 48.1, 10.7, | ||||
2.8 Hz, 2H). | ||||
A-22 | (2S)-244-bromo- | 1H NMR (400 MHz, DMSO-d6) δ | 3.667 | I |
2-(1,2-oxazol-5- | 8.66 (d, J = 1.9 Hz, 1H); 7.90 (d, | |||
yl)phenoxy] | J = 2.6 Hz, 1H); 7.52 (dd, J = | |||
propanoic | 9.0, 2.6 Hz, 1H); 7.21 (d, J = 1.9 | |||
acid | Hz, 1H); 6.95 (d, J = 9.0 Hz, | |||
1H); 4.47(q, J = 6.6 Hz, 1H); | ||||
1.47 (d, J = 6.6 Hz, 3H). | ||||
A-23 | (2S)-2-[4-chloro-2- | 1H NMR (400 MHz, DMSO-d6) | 3.186 | I |
(1,3-dimethyl-1H- | δ 13.15 (s, 1H), 7.82 (s, 1H), | |||
pyrazol-4- | 7.25 (dq, J = 5.6, 2.7 Hz, 2H), | |||
yl)phenoxy] | 6.94 - 6.80 (m, 1H), 4.86 (q, J = | |||
propanoic acid | 6.7 Hz, 1H), 3.79 (s, 3H), 2.20 | |||
(s, 3H), 1.48 (d, J = 6.7 Hz, 3H). | ||||
A-24 | (2S)-2-[4-chloro- | 1H NMR (400 MHz, DMSO-d6) | 3.183 | I |
2-(1H-pyrazol-3- | δ 13.19 (s, 2H), 7.89 (d, J = 2.8 | |||
yl)phenoxy] | Hz, 1H), 7.71 (s, 1H), 7.30 (dd, J | |||
propanoic | = 8.8, 2.7 Hz, 1H), 6.99 (d, J = | |||
acid | 8.9 Hz, 1H), 6.92 (d, J = 2.1 Hz, | |||
1H), 5.01 (q, J = 6.7 Hz, 1H), | ||||
1.57 (d, J = 6.7 Hz, 3H). | ||||
A-25 | (2S)-2-[4-chloro- | 1H NMR (400 MHz, DMSO-d6) | 4.606 | I |
2-(thiophen-2- | δ 13.27 (s, 1H), 7.78 (d, J = 2.6 | |||
yl)phenoxy] | Hz, 1H), 7.74 (dd, J = 3.8, 1.2 | |||
propanoic acid | Hz, 1H), 7.62 (dd, J = 5.1, 1.2 | |||
Hz, 1H), 7.29 (dd, J = 8.8, 2.6 | ||||
Hz, 1H), 7.14 (dd, J = 5.2, 3.7 | ||||
Hz, 1H), 6.96 (d, J = 8.9 Hz, | ||||
1H), 5.04 (q, J = 6.7 Hz, 1H), | ||||
1.62 (d, J = 6.7 Hz, 3H). | ||||
A-26 | (2S)-2-[4-chloro- | 1H NMR (400 MHz, DMSO-d6) | 3.533 | I |
2-(1,2-oxazol-5- | δ 13.28 (br. s, 1H), 8.71 (d, J = | |||
yl)phenoxy] | 1.9 Hz, 1H), 7.87 (d, J = 2.7 Hz, | |||
propanoic acid | 1H), 7.52 (dd, J = 9.0, 2.7 Hz, | |||
1H), 7.20 - 7.03 (m, 2H), 5.15 | ||||
(q, J = 6.7 Hz, 1H), 1.60 (d, J = | ||||
6.7 Hz, 3H). | ||||
A-27 | (2S)-2-[4-chloro- | 1H NMR (400 MHz, DMSO-d6) | 3.130 | I |
2-(1-methyl-1H- | δ 13.16 (s, 1H), 8.23 (s, 1H), | |||
pyrazol-4- | 8.02 (d, J = 0.7 Hz, 1H), 7.65 (d, | |||
yl)phenoxy] | J = 2.7 Hz, 1H), 7.17 (dd, J = | |||
propanoic | 8.8, 2.7 Hz, 1H), 6.91 (d, J = 8.9 | |||
acid | Hz, 1H), 4.98 (q, J = 6.7 Hz, | |||
1H), 3.88 (s, 3H), 1.59 (d, J = | ||||
6.7 Hz, 3H). | ||||
A-28 | (2S)-2-[2-(1,3- | 1H NMR (400 MHz, DMSO-d6) | 4.227 | I |
benzothiazol-2- | δ 13.22 (s, 1H), 8.47 (dd, J = | |||
yl)phenoxy] | 7.9, 1.8 Hz, 1H), 8.19 - 8.02 (m, | |||
propanoic | 2H), 7.60 - 7.40 (m, 3H), 7.23 - | |||
acid | 7.06 (m, 2H), 5.25 (q, J = 6.7 | |||
Hz, 1H), 1.77 (d, J = 6.7 Hz, | ||||
3H). | ||||
A-29 | (2S)-2[4-bromo-2- | 1H NMR (400 MHz, DMSO-d6) | 1.088 | I |
(1,3,4-oxadiazol-2- | δ 13.20 (s, 1H), 9.39 (s, 1H), | |||
yl)phenoxy] | 7.99 (d, J = 2.6 Hz, 1H), 7.76 | |||
propanoic acid | (dd, J = 9.0, 2.6 Hz, 1H), 7.09 | |||
(d, J = 9.0 Hz, 1H), 5.06 (q, J = | ||||
6.7 Hz, 1H), 1.54 (d, J = 6.8 Hz, | ||||
3H). | ||||
A-30 | (2S)-2-[4-chloro- | 1H NMR (500 MHz, DMSO-d6) | 3.22 | I |
2-(1H-pyrazol-1- | δ 13.32 (s, 1H), 8.45 (dd, J = | |||
yl)phenoxy] | 2.5, 0.5 Hz, 1H), 7.75 (dd, J = | |||
propanoic acid | 1.7, 0.5 Hz, 1H), 7.73 (d, J = 2.7 | |||
Hz, 1H), 7.35 (dd, J = 8.9, 2.7 | ||||
Hz, 1H), 7.17 (d, J = 9.0 Hz, | ||||
1H), 6.53 (dd, J = 2.5, 1.8 Hz, | ||||
1H), 5.11 (q, J = 6.7 Hz, 1H), | ||||
1.53 (d, J = 6.8 Hz, 3H). | ||||
Description of Pharmacological Methods and Drawings
Isolation of Muscles from Rats and Human, Ethical Approval, Dissection of Muscles, Solutions, and Chemicals
TABLE 1 |
Recovery of nerve-stimulated force by some compounds in isolated |
rat soleus muscles exposed to sub-maximal tubocurarine concentration. |
AUC force was first determined after 40 min in tubocurarine |
(column 3) and related to nerve-stimulated force prior to addition |
of tubocurarine. The AUC at the different concentrations of |
compounds (columns 4-6) is the % change in AUC compared to |
the AUC before addition (column 3). |
Force | ||||||
before | ||||||
|
50 |
150 |
500 μM | |||
of | % | % | % | |||
compound | change | change | change | |||
% of | after | after | after | |||
IUPAC | control | addition | addition | addition | n | |
C5 | (2S)-2-(benzyl- | 24 | −7 | 1 | 42 | 2 | |
oxy)propanoic | |||||||
acid | |||||||
C6 | 2-(4-fluoro- | 39 | −11 | −8 | 9 | 5 | |
benzenesulfonyl) | |||||||
propanoic acid | |||||||
C7 | 2-(4-chloro- | 41 | −12 | 0 | 40 | 2 | |
phenoxy)butanoic | |||||||
acid | |||||||
C8 | (2S)-2-(4-bromo- | 36 | 16 | 23 | |
10 | |
phenoxy)propanoic | |||||||
acid | |||||||
C9 | 3-amino-2-(4-fluoro- | 57 | −14 | −13 | 5 | 2 | |
phenoxy)propanoic | |||||||
acid hydrochloride | |||||||
C11 | 4-chlorophenyl | 38 | 46 | 54 | |
4 | |
2-(4-fluoro- | |||||||
phenoxy)propanoate | |||||||
C21 | 2-(4-bromophenoxy)- | 54 | −3 | 7 | 36 | 2 | |
4-methoxy-3- | |||||||
methylbutanoic acid | |||||||
C22 | (2S)-2-(4- | ||||||
bromophenoxy)- | 42 | 16 | | NT | 2 | ||
3methylbutanoic acid | |||||||
NT: Not Tested |
TABLE 2 |
Recovery of nerve-stimulated force with |
compounds in isolated rat soleus muscles |
exposed to 3.5 mM Mg2+. AUC force was first |
determined after 70 min at elevated extracellular |
Mg2+ (column 3) and related to nerve-stimulated |
force prior to addition of additional Mg2+. The |
AUC at the different concentrations of compounds |
( |
compared to the AUC before Mg2+ elevation |
(column 3). As in experiments with tubocurarine, |
please note that force kept dropping |
in muscles only exposed to elevated Mg2+. |
Force | |||||
before | |||||
addition of | 50 |
100 μM | |||
compound | % change | % change | |||
% of | after | after | |||
IUPAC | control | addition | addition | n | |
C8 | (2S)-2-(4- | 38 ± 6 | 13 ± 4 | 26 ± 5 | 2 |
bromophenoxy) | |||||
propanoic acid | |||||
TABLE 3 |
Effect of different compounds on |
Gm in isolated rat and human muscles. |
Gm | Kd for | |||
No | ClC-1 | |||
Compound | inhibition | |||
C8 | 642 ± 25, n = 33 | 9 μM | ||
Rat | ||||
C8 | 430 ± 41, n = 5 | 5.5 μM | ||
Human | ||||
C22 | 642 ± 25, n = 33 | 4.1 μM | ||
rat | ||||
TABLE 4 |
Effect of neostigmine, pyridostigmine, CIC-1 inhibitor, and |
combination of neostigmine or pyridostigmine and |
CIC-1 inhibitor on Kd,tub. |
Compound | Compound | |||||
(50 μM) + | (50 μM) + | |||||
Neo- | Pyrido- | Com- | Neo- | Pyrido- | ||
Com- | stigmine | stigmine | pound | stigmine | stigmine | |
pound | Control | (10 nM) | (100 nM) | (50 μM) | (10 nM) | (100 nM) |
C8 | 118 ± 5 | 166 ± 13 | 177 ± 7 | 218 ± 18 | ||
nM | nM*,** | nM*,** | nM* | |||
C8 | 118 ± 5 | 127 ± 15 | 177 ± 7 | 186 ± 5 | ||
nM | nM | nM*,** | nM* | |||
*Indicates significantly different from control. | ||||||
**Significantly different from the combination of neostigmine and compound. |
TABLE 5 |
Effect of 3,4-AP, ClC-1 inhibitor and combination of |
3,4-AP and ClC-1 inhibitor on Kd, Mg2+ |
Compound | ||||||
Com- | (50 μM) + | |||||
Com- | 3,4- | pound | 3,4-AP | |||
pound | IUPAC | Control | (10 μM) | (50 μM) | (10 μM) | |
C8 | (2S)-2-(4- | 3.5 ± 0.1 | 5.8 ± 0.3 | 4.0 ± 0.1 | 7.8 ± 0.5 | |
bromophenoxy) | mM | mM*, ** | mM*, ** | mM* | ||
propanoic acid | n = 6 | n = 3 | n = 7 | n = 4 | ||
*Indicates significantly different from control. | ||||||
**Significantly different from the combination of 3,4-AP and compound. |
TABLE 6 |
PK parameters for C8 tested in rats. |
Parameter | Unit | Value | ||
t1/2 | h | 3.70 | ||
Tmax | h | 0.5 | ||
Cmax | ng/ml | 44600 | ||
CO | ng/ml | 24533 | ||
AUC 0-t | ng/ml * h | 203635 | ||
AUC 0-inf_obs | ng/ml * h | 205381 | ||
AUC 0-t/0- | 0.9915 | |||
inf_obs | ||||
VD_obs | ml | 259.62 | ||
Cl_obs | ml/h | 48.69 | ||
TABLE 7 |
Inhibition of ClC-1 ion channel |
using compounds of the invention |
Compound investigated | EC50 (μM) | ||
Compound A-2 | 4 | (n = 1) | ||
Compound A-11 | 11.1 | (n = 1) | ||
Compound A-16 | 1.8 ± 1.1 | (n = 4) | ||
Compound A-22 | 7.5 ± 3.0 | (n = 6) | ||
TABLE 8 |
Percentage increase of initial force that was restored |
Compound investigated | Point increase (%) | ||
Compound A-2 | 27 | ||
Compound A-11 | 19 | ||
Compound A-16 | 48 | ||
Compound A-22 | 27 | ||
Claims (19)
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/842,823 US10385028B2 (en) | 2017-12-14 | 2017-12-14 | Compounds for the treatment of neuromuscular disorders |
TW107145017A TWI780281B (en) | 2017-12-14 | 2018-12-13 | Compounds for the treatment of neuromuscular disorders |
KR1020207016720A KR102667838B1 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
PL18819107T PL3724173T3 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
IL274828A IL274828B2 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
SI201830443T SI3724173T1 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
LTEPPCT/EP2018/084989T LT3724173T (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
US16/221,006 US20190183863A1 (en) | 2017-12-14 | 2018-12-14 | Compounds For The Treatment Of Neuromuscular Disorders |
BR112020011850-8A BR112020011850A2 (en) | 2017-12-14 | 2018-12-14 | compounds for the treatment of neuromuscular disorders |
MX2020005545A MX2020005545A (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders. |
ES18819107T ES2899413T3 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
PCT/EP2018/084989 WO2019115781A1 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
JP2020531486A JP7310071B2 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
SG11202004754VA SG11202004754VA (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
CA3085233A CA3085233A1 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
EP18819107.6A EP3724173B1 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
CN201880089425.0A CN111712489B (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
AU2018383006A AU2018383006B2 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
DK18819107.6T DK3724173T3 (en) | 2017-12-14 | 2018-12-14 | Compounds for the treatment of neuromuscular disorders |
ZA2020/02993A ZA202002993B (en) | 2017-12-14 | 2020-05-21 | Compounds for the treatment of neuromuscular disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/842,823 US10385028B2 (en) | 2017-12-14 | 2017-12-14 | Compounds for the treatment of neuromuscular disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/221,006 Continuation-In-Part US20190183863A1 (en) | 2017-12-14 | 2018-12-14 | Compounds For The Treatment Of Neuromuscular Disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
US20190185437A1 US20190185437A1 (en) | 2019-06-20 |
US10385028B2 true US10385028B2 (en) | 2019-08-20 |
Family
ID=66813795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/842,823 Active US10385028B2 (en) | 2017-12-14 | 2017-12-14 | Compounds for the treatment of neuromuscular disorders |
Country Status (1)
Country | Link |
---|---|
US (1) | US10385028B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220306564A1 (en) * | 2019-06-19 | 2022-09-29 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
WO2024068862A1 (en) | 2022-09-30 | 2024-04-04 | Nmd Pharma A/S | Compositions and methods for treating myasthenia gravis |
Citations (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB573476A (en) | 1943-04-21 | 1945-11-22 | Reginald Thomas Foster | Improvements in or relating to the manufacture of chlorinated phenoxy compounds |
GB822199A (en) | 1956-09-18 | 1959-10-21 | Boots Pure Drug Co Ltd | Process for the preparation of alpha-phenoxyalkanoic acids |
CA676827A (en) | 1963-12-24 | The Sherwin-Williams Company Of Canada Limited | Herbicidal compositions | |
FR1451171A (en) | 1961-04-21 | 1966-01-07 | Jacques Logeais Soc D Expl Des | Etherified and esterified derivatives of 2-o-hydroxyphenyl-oxadiazole-1, 3, 4 and process for their preparation |
US3544560A (en) | 1968-07-19 | 1970-12-01 | Carter Wallace | Penicillin compounds |
US3984411A (en) | 1975-04-10 | 1976-10-05 | Societe Generale De Recherches Et D'applications Scientifiques "Sogeras" | Pyrimidines |
US4056628A (en) | 1975-08-08 | 1977-11-01 | Hoffmann-La Roche Inc. | Insecticidal esters of alpha-phenoxy alkanoic acids with substituted benzyl alcohols |
US4283472A (en) | 1980-02-26 | 1981-08-11 | Eastman Kodak Company | Silver halide elements containing blocked pyrazolone magenta dye-forming couplers |
EP0046590A2 (en) | 1980-08-25 | 1982-03-03 | Byk Gulden Lomberg Chemische Fabrik GmbH | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them |
EP0117675A1 (en) | 1983-02-19 | 1984-09-05 | Beecham Group Plc | Benzofuran and benzothiophene-carboxylic-acid derivatives |
FR2551063A1 (en) | 1983-08-22 | 1985-03-01 | Inst Nat Sante Rech Med | New 2,5-dimethylpyrroles, process for preparing them and their therapeutic use |
EP0257378A1 (en) | 1986-08-18 | 1988-03-02 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives, their preparation and medicaments containing these derivatives |
US5025031A (en) | 1989-11-30 | 1991-06-18 | A. H. Robins Co., Inc. | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants |
US5192785A (en) | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
EP0582198A2 (en) | 1992-08-01 | 1994-02-09 | Hoechst Schering AgrEvo GmbH | Substituted (hetero-)aryle compounds, process for their preparation, those containing compositions and their use as safeners |
EP0623605A2 (en) | 1993-05-06 | 1994-11-09 | Bayer Ag | Substituted piperazines as antiretroviral medicaments |
WO2002057222A2 (en) | 2001-01-17 | 2002-07-25 | Guilford Pharmaceuticals Inc. | Thiol-based naaladase inhibitors |
WO2002074768A1 (en) | 2001-03-16 | 2002-09-26 | Smithkline Beecham Plc | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) |
WO2002092087A1 (en) | 2001-05-11 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors |
WO2004089885A1 (en) | 2003-04-07 | 2004-10-21 | Astrazeneca Ab | Novel compounds |
WO2004094386A1 (en) | 2003-03-28 | 2004-11-04 | Eli Lilly And Company | Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b) |
US20050054630A1 (en) | 2003-08-28 | 2005-03-10 | Dolle Roland E. | Fused bicyclic carboxamide derivatives and methods of their use |
WO2005105727A1 (en) | 2004-05-04 | 2005-11-10 | Novartis Ag | Crth2 receptor antagonists |
WO2006037982A2 (en) | 2004-10-05 | 2006-04-13 | Astrazeneca Ab | Modulators of crth2 receptor activity for the treatment of prostaglandin d2 mediated diseases |
US20060211765A1 (en) | 2003-04-07 | 2006-09-21 | Astrazeneca Ab | Novel compounds |
WO2007030885A1 (en) | 2005-09-16 | 2007-03-22 | Nufarm Australia Limited | Agrochemical emulsifiable concentrate |
WO2007062773A1 (en) | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Oxadiazole derivatives with crth2 receptor activity |
WO2007062678A1 (en) | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
WO2008138889A2 (en) | 2007-05-11 | 2008-11-20 | Novartis Ag | 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
WO2012004722A1 (en) | 2010-07-05 | 2012-01-12 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
US8163793B2 (en) | 2009-04-20 | 2012-04-24 | Hoffman-La Roche Inc. | Proline derivatives |
CN102771479A (en) | 2012-08-31 | 2012-11-14 | 广西田园生化股份有限公司 | Herbicide composition containing hexazinone and phenoxy carboxylic acid |
WO2013010082A2 (en) | 2011-07-13 | 2013-01-17 | Microbiotix, Inc. | Inhibitors of bacterial type iii secretion system |
EP2554049A1 (en) | 2011-08-02 | 2013-02-06 | Agro Industrie Recherches Et Developpements (A.R.D.) | Herbicidal composition with improved efficiency, preparation method and use |
US20130197039A1 (en) | 2012-01-31 | 2013-08-01 | Eli Lilly And Company | Novel Benzyl Sulfonamide Derivatives Useful As MOGAT-2 Inhibitors |
US20130261101A1 (en) | 2012-04-02 | 2013-10-03 | Incyte Corporation | Bicyclic azaheterocyclobenzylamines as pi3k inhibitors |
CN104059055A (en) | 2013-12-10 | 2014-09-24 | 常州大学 | 1, 2, 3-triazole compounds and preparation method and use thereof |
JP2015231988A (en) | 2014-05-12 | 2015-12-24 | 大正製薬株式会社 | 2- pyridone compound |
WO2016011019A1 (en) | 2014-07-15 | 2016-01-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
US20160221965A1 (en) | 2013-09-16 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluoromethyl pyrimidinones and their use |
US20160237059A1 (en) | 2013-09-16 | 2016-08-18 | Bayer Pharma Aktiengesellschaft | Heterocyclic substituted trifluoromethyl pyrimidinones and their use |
WO2016202341A1 (en) | 2015-06-15 | 2016-12-22 | Nmd Pharma Aps | Compounds for use in treating neuromuscular disorders |
WO2017106064A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
WO2018124000A1 (en) | 2016-12-27 | 2018-07-05 | 第一三共株式会社 | Pyrimidine derivative |
-
2017
- 2017-12-14 US US15/842,823 patent/US10385028B2/en active Active
Patent Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA676827A (en) | 1963-12-24 | The Sherwin-Williams Company Of Canada Limited | Herbicidal compositions | |
GB573476A (en) | 1943-04-21 | 1945-11-22 | Reginald Thomas Foster | Improvements in or relating to the manufacture of chlorinated phenoxy compounds |
GB822199A (en) | 1956-09-18 | 1959-10-21 | Boots Pure Drug Co Ltd | Process for the preparation of alpha-phenoxyalkanoic acids |
FR1451171A (en) | 1961-04-21 | 1966-01-07 | Jacques Logeais Soc D Expl Des | Etherified and esterified derivatives of 2-o-hydroxyphenyl-oxadiazole-1, 3, 4 and process for their preparation |
US3544560A (en) | 1968-07-19 | 1970-12-01 | Carter Wallace | Penicillin compounds |
US3984411A (en) | 1975-04-10 | 1976-10-05 | Societe Generale De Recherches Et D'applications Scientifiques "Sogeras" | Pyrimidines |
US4056628A (en) | 1975-08-08 | 1977-11-01 | Hoffmann-La Roche Inc. | Insecticidal esters of alpha-phenoxy alkanoic acids with substituted benzyl alcohols |
US4283472A (en) | 1980-02-26 | 1981-08-11 | Eastman Kodak Company | Silver halide elements containing blocked pyrazolone magenta dye-forming couplers |
EP0046590A2 (en) | 1980-08-25 | 1982-03-03 | Byk Gulden Lomberg Chemische Fabrik GmbH | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them |
US4337267A (en) | 1980-08-25 | 1982-06-29 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenalkoxyalkyl- and phenoxyalkyl-substituted oxiranecarboxylic acids, their use and medicaments containing them |
EP0117675A1 (en) | 1983-02-19 | 1984-09-05 | Beecham Group Plc | Benzofuran and benzothiophene-carboxylic-acid derivatives |
FR2551063A1 (en) | 1983-08-22 | 1985-03-01 | Inst Nat Sante Rech Med | New 2,5-dimethylpyrroles, process for preparing them and their therapeutic use |
EP0257378A1 (en) | 1986-08-18 | 1988-03-02 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives, their preparation and medicaments containing these derivatives |
US5192785A (en) | 1989-09-03 | 1993-03-09 | A. H. Robins Company, Incorporated | Sulfamates as antiglaucoma agents |
US5025031A (en) | 1989-11-30 | 1991-06-18 | A. H. Robins Co., Inc. | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants |
EP0582198A2 (en) | 1992-08-01 | 1994-02-09 | Hoechst Schering AgrEvo GmbH | Substituted (hetero-)aryle compounds, process for their preparation, those containing compositions and their use as safeners |
EP0623605A2 (en) | 1993-05-06 | 1994-11-09 | Bayer Ag | Substituted piperazines as antiretroviral medicaments |
WO2002057222A2 (en) | 2001-01-17 | 2002-07-25 | Guilford Pharmaceuticals Inc. | Thiol-based naaladase inhibitors |
WO2002074768A1 (en) | 2001-03-16 | 2002-09-26 | Smithkline Beecham Plc | Piperazine derivatives, their preparation and uses in therapy (5ht1b receptor activity) |
WO2002092087A1 (en) | 2001-05-11 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors |
WO2004094386A1 (en) | 2003-03-28 | 2004-11-04 | Eli Lilly And Company | Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b) |
WO2004089885A1 (en) | 2003-04-07 | 2004-10-21 | Astrazeneca Ab | Novel compounds |
US20060211765A1 (en) | 2003-04-07 | 2006-09-21 | Astrazeneca Ab | Novel compounds |
US20050054630A1 (en) | 2003-08-28 | 2005-03-10 | Dolle Roland E. | Fused bicyclic carboxamide derivatives and methods of their use |
WO2005105727A1 (en) | 2004-05-04 | 2005-11-10 | Novartis Ag | Crth2 receptor antagonists |
WO2006037982A2 (en) | 2004-10-05 | 2006-04-13 | Astrazeneca Ab | Modulators of crth2 receptor activity for the treatment of prostaglandin d2 mediated diseases |
WO2007030885A1 (en) | 2005-09-16 | 2007-03-22 | Nufarm Australia Limited | Agrochemical emulsifiable concentrate |
WO2007062678A1 (en) | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
WO2007062773A1 (en) | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Oxadiazole derivatives with crth2 receptor activity |
WO2008138889A2 (en) | 2007-05-11 | 2008-11-20 | Novartis Ag | 3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors |
US8163793B2 (en) | 2009-04-20 | 2012-04-24 | Hoffman-La Roche Inc. | Proline derivatives |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
WO2012004722A1 (en) | 2010-07-05 | 2012-01-12 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
WO2013010082A2 (en) | 2011-07-13 | 2013-01-17 | Microbiotix, Inc. | Inhibitors of bacterial type iii secretion system |
EP2554049A1 (en) | 2011-08-02 | 2013-02-06 | Agro Industrie Recherches Et Developpements (A.R.D.) | Herbicidal composition with improved efficiency, preparation method and use |
US20130197039A1 (en) | 2012-01-31 | 2013-08-01 | Eli Lilly And Company | Novel Benzyl Sulfonamide Derivatives Useful As MOGAT-2 Inhibitors |
US20130261101A1 (en) | 2012-04-02 | 2013-10-03 | Incyte Corporation | Bicyclic azaheterocyclobenzylamines as pi3k inhibitors |
CN102771479A (en) | 2012-08-31 | 2012-11-14 | 广西田园生化股份有限公司 | Herbicide composition containing hexazinone and phenoxy carboxylic acid |
US20160221965A1 (en) | 2013-09-16 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Disubstituted trifluoromethyl pyrimidinones and their use |
US20160237059A1 (en) | 2013-09-16 | 2016-08-18 | Bayer Pharma Aktiengesellschaft | Heterocyclic substituted trifluoromethyl pyrimidinones and their use |
CN104059055A (en) | 2013-12-10 | 2014-09-24 | 常州大学 | 1, 2, 3-triazole compounds and preparation method and use thereof |
JP2015231988A (en) | 2014-05-12 | 2015-12-24 | 大正製薬株式会社 | 2- pyridone compound |
WO2016011019A1 (en) | 2014-07-15 | 2016-01-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for inhibiting bmp |
WO2016202341A1 (en) | 2015-06-15 | 2016-12-22 | Nmd Pharma Aps | Compounds for use in treating neuromuscular disorders |
WO2017106064A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections |
WO2018124000A1 (en) | 2016-12-27 | 2018-07-05 | 第一三共株式会社 | Pyrimidine derivative |
Non-Patent Citations (151)
Title |
---|
A. Chiriac et al., Quantitative Structure-Activity Relations With the MTD Procedure for Plant Growth-Regulation Optically Active Acetic Acid Derivatives, Revue Roumaine de Chimie, 27(4):561-568, 1982. |
A. Chiriac et al., Quantitiavie Structure-Citostatic Activity Relations for Diketonato-Complexes of Tetravalent Transitional Metals, Universitatea din timisoara, Facultatea de Stiinte ale Naturii, Serie Chimie, 4:1-6, 1989. |
A. I. Karaev et al., About the Injuries Healing Properties of Synthetic Growth Regulators, Reports of the Academy of Sciences of Azerbaijan SSR, IX(1):1-4, Sep. 18, 1952. |
A. Liantonio et al., Investigations of Pharmacologic Properties of the Renal CLCK1 Chloride Channel Co-expressed with Barttin by the Use of 2-(p-Chlorophenoxy)Propionic Acid Derivatives and Other Structurally Unrelated Chloride Channels Blockers, J Am Soc Nephrol. 15:13-20, 2004. |
A. Ramazani et al., Dipotassium Hydrogen Phosphate-Catalyzed Synthesis of Dialkyl 2-(4-Fluoro-Phenoxy)-2-Butendioates from Stabilized Phosphorus Ylides in Solven-Free Conditions, Phosphorus, Sulfur and Silicon, 182:413-417, 2007. |
A. W. Galston et al., The Adaptive Formation and Physiological Signaificance of Indoleacetic Acid Oxidase, American Journal of Botany, 41(5):373-380, May 1954. |
Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. Apr. 2015; 1852(4):615-621. |
Ansar V, Valadi N. Guillain-Barré Syndrome. Prim Care. Jun. 2015;42(2):189-193. |
Aromataris, E.C., Pharmacology of the ClC-1 Chloride Channel, PhD Thesis, Dicipline of Physiology, school of Molecular and Biomedical Science, The University of Adelaide, 2009. |
B. S. Kirkiacharian, No. 293.—Thermal free radicals: study of malonic and cyanoacetic esters, No. 5, 1971. |
B. Sjoberg, Stereochemical studies. X The relationship between optical rotatory dispersion and configuration for some carboxylic acids, Arkiv for Kemi Band 15(5):473-480, 1960. |
B. Sjoberg, Stereochemical studies. XI The relationship between optical rotatory dispersion and configuration for some ketones, Arkiv for Kemi Band 15(5):473-480, 1960. |
Bansagi B, Griffin H, Whittaker RG, Antoniadi T, Evangelista T, Miller J, Greenslade M, Forester N, Duff J, Bradshaw A, Kleinle S, Boczonadi V, Steele H, Ramesh V, Franko E, Pyle A, Lochmüller H, Chinnery PF, Horvath R. Genetic heterogeneity of motor neuropathies. Neurology. 2017. 28;88(13):1226-1234). |
Bettoni, G. et al., J. Med. Chem. 1987, 30, 1267-1270. |
Bettoni, S. et al., Chiral beta-Aryloxy Acetic Acids: Synthesis, Absolute Configuration, Chemical Resolution, and Direct Separation by HPLC, CHIRALITY, 1992, 4:193-203. |
Birk TJ1. Poliomyelitis and the post-polio syndrome: exercise capacities and adaptation—current research, future directions, and widespread applicability. Med Sci Sports Exerc. Apr. 1993;25(4):466-72. |
Burton A. Take your pyridostigmine: that's an (ethical?) order! Lancet Neurol. May 2003;2(5):268. |
C. A. Bache et al., Absence of Phenoxyacid Herbicide Residues in the Milk of Dairy Cows at High Feeding Levels, Journal of Dairy Science, 47(3):298-299, Mar. 1964. |
C. H. Fawcett et al., Investigations on Fungicides, ii. Aryloxy- and Arylthio-Alkanecarboxylic Acids and Their Activity as Fungicides and Systemic Fungicides, Ann. appl. Biol., 45(r): 158-176, 1957. |
C. H. Fawcett et al., Studies on Plant Growth-Regulating Substances, vi. Side-Chain Structure in Relation to Growth-Regulating Activity in the Aryloxyalkylcarboxylic Acids, 40(2):231-243, Jun. 1953. |
C. H. Fawcett et al., Studies on Plant Growth-Regulationg Substances, VIII. The Growth-Promoting Activity of Certain Aryloxy- and Arylthio-Alkeanecarboxylic Acids, Ann. appl. Biol., 43(3): 342-354, 1955. |
C. M. Hill et al., The Synthesis, Propertis and Dehydrohalogenation of Some alpha-Phenoxy and 2,4-Dichlorophenoxy Substituted Acid Chlorides, Phenoxy Substituted Acid Chlorides, 73:1660-1662, Aug. 24, 1950. |
C. Rivalle et al., III.—Study of diversely-substituted α-aryloxy pinacolones, Newsletter of the French Chemistry Society, BSCFAS, 7:2555-3002, 1972. |
C. Stanley, Derivatization of Pesticide-Related Acids and Phenols for Gas Chromatographic Determination, 14(3):321-323, May-Jun. 1966. |
C. Temporini et al., Enantiomeric separation of 2-aryloxyalkyl- and 2-arylalkyl-2-aryloxyacetic acids on a Penicillin G Acylase-based chiral stationary phase: Influence of the chemical structure on retention and enantioselectivity; ESJPBA, ISSN: 0731-7085, 45(2):211-218, 2007. |
C. Zhang et al., Synthesis and Bioactivity of Novel Inhibitors for Type III Secretion System of Pseudomonas aeruginosa PAO1, Chinese Journal of Organic Chemistry, 33:1309-1318, 2013. |
CAMPIANI G, ET AL: "Pyrrolobenzothiazepinones and Pyrrolobenzoxazepinones: Novel and Specific Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Antiviral Activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39, no. 14, 1 January 1996 (1996-01-01), US, pages 2672 - 2680, XP002564131, ISSN: 0022-2623, DOI: 10.1021/jm950702c |
Campiani Get al, Pyrrolobenzothiazepinones and Pyrrolobenzoxazepinones: Novel and Specific Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Antiviral Activity, Journal of Medicinal Chemistry 39(14):2672-2680, Jan. 1, 1996 (Jan. 1, 1996), XP002564131, American Chemical Society ISSN: 0022-2623, DOI: 10.1021/JM950702C [retrieved on Jun. 1, 1996]. |
Campiani, et al. Document No. 125:25616, retrieved from STN; entered in STN on Jun. 19, 1996. * |
Chen, et al. Document No. 153:554937, retrieved from STN; entered in STN Oct. 29, 2010. * |
Combs, et al. Document No. 159:577331, retrieved from STN; entered in STN on Oct. 4, 2013. * |
Conte-Camerino, D., Mambrini, M., DeLuca, A., Tricarico, D., Bryant, S.H., Tortorella, V., Bettoni, G. Enantiomers of clofibric acid analogs have opposite actions on rat skeletal muscle chloride channels, Pflugers Archiv., 1988, 413, 105-107. |
D. Gowing et al., Uncommon Plant Growth Regulators for the control of Nutgrass and Oxalis, Weeds, pp. 279-283, 1960. |
D. Khydyrov et al., Synthesis and herbicide activity of N-methylcarbamate derivatives of 2-hydroxyethyl 2,4-dichloroaryloxyalkanoates, Akademiya Nauk Azerbaidzhanskoi SSR, 43(1):38-41, 1987. |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 June 2018 (2018-06-18), RAM, BHAGAT ET AL: "Potential hypolipidemic agents part VI: synthesis and biological activity of some new 4-chloro/methyl-2-pyrazolylphenoxy alkanoates", XP002782149, retrieved from STN |
Database Registry [Online], Chemical Abstracts Service, Columbus, Ohio, US; Propanoic acid, 2-[2-(2-benzolhiazolyl)phenoxy]-(CA INDEX NAME), XP002789551, Mar. 13, 2007, retrieved from STN Database accession No. RN-926236-33-1. |
DATABASE REGISTRY 13 March 2007 (2007-03-13), "Propanoic acid, 2-¢2-(2-benzothiazolyl)phenoxy!- (CA INDEX NAME)", XP002789551, retrieved from STN |
Del Bello, et al. Document No. 153:580197, retrieved from STN; entered in STN on Oct. 8, 2010. * |
Diamanti, et al. Document No. 156:410758, retrieved from STN; entered in STN on Mar. 2, 2012. * |
E. Duintjer et al., Synthetic Plant Hormones, VI. Preparation of some alpha-Phenoxy and alpha-1-Naphtohoxy fatty Acids (Addition to Part IV), Short Communications, Part V. Aeta Chem. Scand., 8(119):1493-1494, 1954. |
E. J. Lien et al., Quantitative Structure-Activity Correlation of Optical Isomers: a Molecular Basis for Pfeiffer's Rule, Molecular Pharmacology, 12:598-604, Aug. 22, 1975. |
Fabio Del Bello et al, Fruitful Adrenergic [alpha] 2C-Agonism/[alpha] 2A-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence ( 1) , +, Journal of Medicinal Chemistry. 53(21):7825-7835, Nov. 11, 2010, XP055484778, ISSN: 0022-2623, DOI: 10.1021/jm100977d. |
FABIO DEL BELLO, LAURA MATTIOLI, FRANCESCA GHELFI, MARIO GIANNELLA, ALESSANDRO PIERGENTILI, WILMA QUAGLIA, CLAUDIA CARDINALETTI, M: "Fruitful Adrenergic α 2C -Agonism/α 2A -Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence(1) , †", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, no. 21, 11 November 2010 (2010-11-11), US, pages 7825 - 7835, XP055484778, ISSN: 0022-2623, DOI: 10.1021/jm100977d |
FCH Group, Chemical Catalog, 2167656-52-0 Registry. |
Feller, D.R., Kamanna, V.S., Newman, H.A.I., Romstedt, K.J., Witiak, D.T., Bettoni, G., Bryant, S.H., Conte-Camerino, D., Loiodice, F., Tortorella, V. Dissociation of hypolipidemic and antiplatelet actions from adverse myotonic effects of clofibric acid related enantiomers. J. Med. Chem., 1987, 30, 1265-1267. |
Finlayson S1, Beeson D, Palace J. Congenital myasthenic syndromes: an update. Pract Neurol. Apr. 2013; 13(2):80-91. |
Fletcher SN1, Kennedy DD, Ghosh IR, Misra VP, Kiff K, Coakley JH, Hinds CJ. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med. Apr. 2003; 31(4):1012-6. |
Francesco Gentili et al, [alpha] 2-Adrenoreceptors Profile Modulation. 2. 1 Bipehnyline Analogues as Tools for Selective Activation of the [alpha] 2C-Subtype, Journal of Medicicnal Chemistry, 47(25):6160-6173, Dec. 1, 2004, XP055484835, ISSN: 0022-2623, DOI: 10.1021/jm0408215. |
FRANCESCO GENTILI, FRANCESCA GHELFI, MARIO GIANNELLA, ALESSANDRO PIERGENTILI, MARIA PIGINI, WILMA QUAGLIA, CRISTIAN VESPRINI, PIER: "α 2 -Adrenoreceptors Profile Modulation. 2. 1 Biphenyline Analogues as Tools for Selective Activation of the α 2C -Subtype", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, no. 25, 1 December 2004 (2004-12-01), US, pages 6160 - 6173, XP055484835, ISSN: 0022-2623, DOI: 10.1021/jm0408215 |
Fulvio Gualtieri et al., Presynaptic Cholinergic Modulators as Potent Cognition Enhancers and Analgesic Drugs. 2. 2-Phenoxy-, 2-(Phenylthio)-, and 2-(Phenylamino)alkanoic Acid Esters, Journal of Medicinal Chemistry (1994), 37(11), 1712-19. |
G. Carbonara et al., Carboxylic acids and skeletal muscle chloride channel conductance: effects on the biological activity induced by the introduction of an aryloxyalkyl group alpha to the carboxylic function of 4-chloro-phenoxyacetic acid, II Farmaco, 56:749-754, 2001. |
G. Fracchiolla et al., Supporting Information, Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARa and PPARc agonist activity, 2008. |
G. Fracchiolla et al., Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors a/c dual agonists, Bioorganic & Medicinal Chemistry 20:2141-2151, 2012. |
G. Fracchiolla et al., Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARa and PPARc agonist activity, Bioorganic & Medicinal Chemistry 16:9498-9510, 2008. |
G. Fracchiolla et al., Synthesis, Biological Evaluation, and Molecular Modeling Investigation of Chiral Phenoxyacetic Acid Analogues with PPARa and PPARg Agonist Activity, ChemMedChem, 2:641-654, 2007. |
G. W. K. Cavill et al., The Chemistry of Plant Growth-regulators. Part II. Modification of the Side-chain of 2:4-Dichlorophenoxyacetic Acid, University of California-Los Angeles, pp. 1388-1391, 1954. |
G. Zeiger et al., Aryloxyalkanoic acids, their esters and cycling products as pesticide-active compounds, Scientific Journal of the "Karl Liebknecht" University of Pedagogic of Potsdam, 21(1):29-46, 1977. |
Garcia CC, Potian JG, Hognason K, Thyagarajan B, Sultatos LG, Souayah N, Routh VH, McArdle JJ. Acetylcholinesterase deficiency contributes to neuromuscular junction dysfunction in type 1 diabetic neuropathy. Am J Physiol Endocrinol Metab. Aug. 15, 2012;303(4):E551-61. |
Gilhus, N.E. New England Journal of Medicine, 2016, 375, 2570-2581. |
Gilhus, N.E., Owe, J.F., Hoff, J.M., Romi, F., Skeie, G.O., Aarli, J.A. Myasthenia Gravis: A Review of Available Treatment Approaches, Autoimmune Diseases, 2011, Article ID 84739). |
Gilmore KJ, Morat T, Doherty TJ4, Rice CL. Motor unit number estimation and neuromuscular fidelity in 3 stages of sarcopenia. 2017 55(5):676-684). |
Giniatullin RA, Khazipov RN, Oranska TI, Nikolsky EE, Voronin VA, Vyskocil F. The effect of non-quantal acetylcholine release on quantal miniature currents at mouse diaphragm. J Physiol. Jul. 1993;466:105-14. |
Giuseppe Fracchiolla et al., Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARα and PPARγ agonist activity, ChemMedChem (2007), 2(6), 641-654. |
H. E. Thompson et al., New Growth-Regulating Compounds. I. Summary of Growth-Inhibitory Activities of Some Organic Compounds as Determined by Three Tests, Botanical Gazette, pp. 476-507, 1946. |
Howard JF Jr1. Adverse drug effects on neuromuscular transmission. Semin Neurol. Mar. 1990;10(1):89-102. |
Hubbard, et al. Document No. 87:34423, retrieved from STN; entered in STN on May 12, 1984. * |
Hwee, D.T., Kennedy, A.R., Hartman, J.J., Ryans, J., Durham, N., Malik, F.I., Jasper, J.R. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 159-168). |
I. D. Jurberg et al., A gold(I)-Catalyzed Cyclization / Photochemical Rearrangement Sequence for the Synthesis of Functionalized Benzofurans from Aryloxy Propargyl Malonates Supporting Information, 2013. |
I. D. Jurberg et al., Synthesis of Functionalized Chromenes and Benzofurans from Aryloxy Proparagyl Malonates, Israel Journal of Chemistry, 53:915-922, 2013. |
International Search Report and Written Opinion dated Apr. 3, 2019 in counterpart lnternational Application No. PCT/JP2018/084989. |
J. A. Zwar et al., Inhibition of Transport of Indole-3-Acetic Acid in the Etiolated Hypocotyl of Phaseolus Vulgaris L., Inhibition of IAA Transport, Jun. 11, 1956. |
J. D. Williams et al., Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS), 23(5):1027-1043, 2015. |
J. Munch-Petersen et al., Acylations of Certain alpha-Alkoxy and alpha-Aryloxy Ketones and Esters, University of Claifornia Los Angeles, 71:770-773, Mar. 1949. |
J. Munch-Petersen, alpha-Aryloxyesters. II. Further Studies on Certain Self-Condesations, Acta Chemica Scandinavica, 7:14-20, 1953. |
J. Munch-Petersen, Aryloxyesters. The Reacitivity of the alpha-Hydrogen and the Carbonyl Carbon towards GBasic Reagents, Acta Chemica Scandinavica, 5:519-528, 1951. |
K. Burger et al., Decomposition of Phenoxyalkyl Carboxylic Acids, Soil Science Society of America Proceedings, 26(3):243-246, May-Jun. 1962. |
K. Gasanov et al., Proton NMR study of solavation of lead derivatives of aryloxy carboxylic acids, Azerbaidzhanskii Khimicheskii Zhurnal, 2:58-61, 1988. |
K. Gasanov et al., Synthesis and carbon-13 NMR study of some organosilicon derivatives of aryloxycarboxylic acids, Azerbaidzhanskii Khimicheskii Zhumal, 5:47-50, 1982. |
K. Gasanov et al., Synthesis and Research of Tri-n-Butylstannyl Ester of 2,4-Dichlorophenoxy-∝-Butyric Acid, Academic Council of the Institute of Petrochemical Processes of the Academy of Sciences of Azerbaijan SSR, Deposited Doc. 309:10, 1980. |
K. Hayashi et al., Small-molecule agonists and antagonists of F-box protein-substrate interactions in auxin perception and signaling, PNAS, 105(14): 5632-5637, Apr. 8, 2008. |
Kawamura Y, Kihara M, Nishimoto K, Taki M. Efficacy of a half dose of oral pyridostigmine in the treatment of chronic fatigue syndrome: three case reports. Pathophysiology. May 2003;9(3):189-194. |
Killian JM1, Wilfong AA, Burnett L, Appel SH, Boland D. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve. Jul. 1994;17(7):747-54. |
Kirkiacharian et al., Structure-activity relationships of some 3-substituted-4-hydroxycoumarins as HIV-1 protease inhibitors; EFARMA, ISSN: 0014-827X, 57(9):703-708, 2002. |
Kwiecinski H, Lehmann-Horn F, Rüdel R. Membrane currents in human intercostal muscle at varied extracellular potassium. Muscle Nerve. Jul.-Aug. 1984;7(6):465-9. |
Kwiecinski H1, Lehmann-Horn F, Rüdel R. Drug-induced myotonia in human intercostal muscle. Muscle Nerve. Jun. 1988;11(6):576-81. |
L. Haskelberg, The Halogenation of Aryloxyacetic Acids and Their Homologs, Daniel Sieff Research Institute, pp. 426-433, Dec. 16, 1946. |
L. J. Edgerton et al., The Effect of Some Growth Substances on Leaf Petiole Abscission and Preharvest Drop of Several Apple Varieties, Proceedings of the American Society for Horticultural Science, 62:159-166, 1953. |
Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011 10(10):931-41. |
Le Panse R1, Berrih-Aknin S. Autoimmune myasthenia gravis: autoantibody mechanisms and new developments on immune regulation. Curr Opin Neurol. Oct. 2013;26(5):569-76. |
Liantonio A, Accardi A, Carbonara G, Fracchiolla G, Loiodice F, Tortorella P, Traverso S, Guida P, Pierno S, De Luca A, Camerino DC, Pusch M. Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid. Mol Pharmacol. Aug. 2002;62(2):265-71. |
Liantonio, A. et al., Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1. Br. J. Phamacol., 2003, 129, 1255-1264. |
Liantonio, A. Pusch, M., Picollo, A., Guida, P., De Luca, A., Pierno, S., Fracchiolla, G., Loiodice, F., Tortorella, P., Conte-Camerino, D. Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride hannels blockers. J. Am. Soc. Nephrol., 2004, 15, 13-20. |
M. A. Mikhaleva et al., Use of the Amidomethylation Reaction for the Synthesis of 2-(Aryloxy)-3-Alanines, Novosibirsk Institute o f Organic Chemistry, Siberian Division, Academy o f Sciences, USSR Translated from Zhurnal Obshchei Khimii, 34(7):2153-2157, Jul. 1964. |
M. Alexander et al., Effect of Chemical Structure on Microbial Decomposition of Aromatic Herbicides, Agricultural and Food Chemistry, 9(1):44-47, Jan.-Feb. 1961. |
M. Alexander, Persistence and Biological Reactions of Pesticides in Soils, Soil Science Society of America Proceedings, 29(1):1-7, Jan.-Feb. 1965. |
M. Bolli et al., 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1 Receptor Agonists, J. Med. Chem., 53:4198-4211, 2010. |
M. Bolli et al., Supporting Information, 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1 Receptor Agonists, 2010. |
M. Julia, No. 158.—Plant growth factors. VIII.—On some aliphatic α-dichloro-phenoxy-diacids, pp. 396-399, Jun. 1955. |
M. Matell, On the Use of 2-Amino-1-phenyl-propane (Benzedrine) for Optical Resolution of Acids, Short Communications, Aeta Chem. Scand. 7(4):698-699, 1953. |
M. Matell, Stereochemical studies on plant growth regulators. VII, Optically active alpha-(2-methyl-4-chlorophenoxy)-propionic acid and alpha-(2,4-dichlorophenoxy)-n-butyric acid and their steric relations, Arkiv for Kemi, 6(4):365-373, 1953. |
M. Matell, Stereochemical Studies on Plant Growth Substances, Kungl. Lantbruks-Hogskolans Annaler, 20:206-240, 1953. |
M. Ochiai et al., Studies on Herbicides and Plant Growth Regulators. II. Synthesis and Some Reactions of 1-Aryloxyacylpyrazoles, Chem. Pharm. Bull, 14(6):628-641, 1966. |
M. Protiva et al., Potential Cerebral Stimulants: Esters of 2-Dimethyl-Aminoethanol With Some Lipophilic Carboxylic Acids, Collect Czech. Chem., 55:1278-1289, 1990. |
Maria Grazia Perrone et al., Baker's yeast-mediated reduction of ethyl 2-(4-chlorophenoxy)-3-oxoalkanoates intermediates for potential PPARα ligands, Tetrahedron: Asymmetry (2004), 15(22), 3501-3510. |
Maria Grazia Perrone et al., Diastereo- and enantioselective bioreduction of ethyl 2-(4-chlorophenoxy)-3-oxobutanoate clofibrate analogues by Kluyveromyces marxianus and other whole cell biocatalysts, Tetrahedron: Asymmetry (2004), 15(22), 3511-3517. |
Maria Grazia Perrone et al., Reaction of cesium 4-chlorophenate and chlorohydrins from threonines: synthesis of clofibrate analogs, Tetrahedron: Asymmetry (2005), 16(4), 783-792. |
Maria Grazia Perrone et al., Screening yeasts for the stereoselective reduction of oxoester clofibrate analogues, Tetrahedron: Asymmetry (2005), 16(8), 1473-1477. |
Maria Grazia Perrone et al., Stereoselective prostereogenic 3-oxo ester reduction mediated by a novel yeast alcohol dehydrogenase derived from Kluyveromyces marxianus CBS 6556, Advanced Synthesis & Catalysis (2007), 349(7), 1111-1118. |
Maria Grazia Perrone et al., Synthesis and biological evaluation of new clofibrate analogues as potential PPARα agonists, European Journal of Medicinal Chemistry (2005), 40(2), 143-154. |
Maslosz, et al. Document No. 116:194187, retreived from STN; entered in STN on May 16, 1992. * |
Maslosz, et al. Document No. 117:26382, retrieved from STN; entered in STN Jul. 26, 1992. * |
Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev. Oct. 13, 2014. |
Milone Ml, Wong LJ. Diagnosis of mitochondrial myopathies. Mol Genet Metab. Sep.-Oct. 2013;110(1-2):35-41. |
Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 111(1):120-8. |
Myasthenia Gravis Diagnosis and Treatment [online]. Retrieved from internet; URL https://www.webmd.com/brain/understanding-myasthenia-gravis-treatment#2-4. * |
Myasthenia gravis[online]. Retrieved from the internet; URL https://medlineplus.gov/myastheniagravis.html. * |
N. M. White (edited), Eurosensors XII, 1:511-514, Sep. 1998. |
N. Shams et al., Four-component reaction of alkyl isocyanide, acetylenic esters, phenols and pyrrole; synthesis of dialkyl 2-[(alkylimino)(1H-pyrrol-2-yl)methyl]-3-(aryloxy) succinate, Journal of Chemical Research, 39:270-273, May 2015. |
O. H. Rubio et al., A molecular receptor selective for zwitterionic alanine, Org. Biomol. Chem., 15:477-485, 2017. |
O. H. Rubio et al., A molecular receptor selective for zwitterionic alanine, Supplementary Material (ESI) for Organic & Biomolecular Chemistry, The Royal Society of Chemistry, 2016. |
Overgaard K, Nielsen OB. Activity-induced recovery of excitability in K(+)-depressed rat soleus muscle. Am J Physiol Regul Integr Comp Physiol. Jan. 2001; 280(1):R48-55. |
Pedersen, T.H., F. de Paoli, and O.B. Nielsen. 2005. Increased excitability of acidified skeletal muscle: role of chloride conductance. J. Gen. Physiol. 125:237-246. |
Pedersen, T.H., Riisager, A., Vincenzo de Paoli, F., Chen, T-Y, Nielsen, O.B. Role of physiological ClC-1 CI-ion channel regulation for the excitability and function of working skeletal muscle. J. Gen. Physiol. 2016, 147, 291-308. |
Plomp JJ, Morsch M, Phillips WD, Verschuuren JJ. Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models. Exp Neurol. 2015. 270:41-54. |
Pusch, M., Liantonio, A., Bertorello, L., Accardi, A., De Luca, A., Pierno, S., Tortorella, V., Conte-Camerino, D. Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives. Molecular Pharmacology, 2000, 58, 498-507. |
R. C. Brian, Action of Plant Growth Regulators III, Adsorption of Aromatic Acids to Oat Monolayers, Plant Physiology, 35(6):773-782, Nov. 1960. |
R. Nakashima et al., Effect of α-Substituted Carboxilyc Acids and Their Ethyl Esters on the Growth of Lettuces seedings, Japan Society of Agricultural Chemistry, 65(12):1777-1780, 1991. |
Ram, Bhagat et al, Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, US; Potential hypolipidemic agents part VI: synthesis and biological activity of some new 4-chloro/methyl-2-yrazolylphenoxy alkanoates, XP002782149, retrieved from STN Database accession No. 1992:255529. |
Richard Rips. Document No. 103:87769, retrieved from STN; entered in STN on Sep. 22, 1985. * |
Riisager A, Duehmke R, Nielsen OB, Huang CL, Pedersen TH. Determination of cable parameters in skeletal muscle fibres during repetitive firing of action potentials. J Physiol. Oct. 15, 2014; 592(Pt 20):4417-29. |
Roberts Ml, Willison HJ, Vincent A, Newsom-Davis J. Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol. Jul. 1995; 38(1):111-8. |
S. Mamedov et al., Synthesis of Complex Ethers of 3-Chlorethyl Ether α-(2,4-Dichlorophenoxy) Butyric Acid, Chemical Magazine of Azerbaijan, 4:79-82, 1977. |
S. N. Lutokhin, Parthenocarpy in Cucurbita Maxima L. Induced by Phytohormones With Glycerin, Reports of the Academy of Sciences of USSR, LVIII(7):1-3, 1947. |
Sandham, D.A. et al., Bioorganic & Medicinal Letters, 17, 4347-4350. |
Skov M, De Paoli FV, Lausten J, Nielsen OB, Pedersen TH. Extracellular magnesium and calcium reduce myotonia in isolated ClC-1 chloride channel-inhibited human muscle. Muscle Nerve. Jan. 2015.;51(1):65-71. |
Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth. 2009. 103(1):115-29. |
Stevic, Z.a, Peric, S.a , Pavlovic, S.b, Basta, I.a, Lavrnic, D.a. Myasthenic symptoms in a patient with Kennedy's disorder Acta Neurologica Belgica (Letter) vol. 114, Issue 1, Mar. 2014, pp. 71-73. |
Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. Dec. 2011;10(12):1098-107. |
Trojan DA1, Gendron D, Cashman NR. Electrophysiology and electrodiagnosis of the post-polio motor unit. Orthopedics. Dec. 1991;14(12):1353-61. |
Ukrorgsyntez Ltd., Chemical Catalog, 1855714-49-6 Registry. |
Ukrorgsyntez Ltd., Chemical Catalog, 1874151-65-1 Registry. |
V. D. Cihimil, Determination of Chlorophenoxylkankarbronic Acids and Chlorphenols in Water by the Method of Gas-Liquidchromatography in the Form of 2,2,2-Trichlorethyl and Ether and Pentaftorbenzyl Etherand Pentaf Etherether Journal of Analytical Chemistry, XXXI(4):711-714, 1984. |
V. Koula et al., Analysis of the analogues of 2,4-dichlorophenoxyacetic acid and related substances, Annals of the Czechoslovak Academy of Agricultural Sciences, XXVII(A-4):289-294, 1954. |
V. V. Dovlattan et al., 5-aryloxypyrimidines, Academy of the Agricultural Sciences of Armenia, 56(1-2):102-108, 2003. |
V. V. Feofilaktov et al., Synthesis of α-(2,4-Dichloro-Phenoxy)-n.-Butyric Acid, Magazine General Chemistry, XVII(2):253-256, 1947. |
V.P. Mamaev et al., Synthese of -aryloxy- -alanines, SSSR, News Bulletin of the Siberian Department of the USSR Academy of Science, 11:145-148, 1962. |
W. C. Shaw et al., The Selective Herbicidal Properties of Several Variously Substituted Phenoxyalkylcarboxylic Acids, Journal of the Weed Society of America, V(2):75-92, Apr. 1957. |
Wadman RI1, Vrancken AF, van den Berg LH, van der Pol WL. Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology. Nov. 13, 2012;79(20):2050-5. |
Wittbrodt, Drugs and myasthenia gravis. An update. Arch. Intern. Med., 157, 399-408, 1997. |
Wood SJ, Slater CR. Safety factor at the neuromuscular junction. Prog Neurobiol. Jul. 2001.; 64(4):393-429. |
Yamada, M.ab, Inaba, A.a, Shiojiri, T.a. X-linked spinal and bulbar muscular atrophy with myasthenic symptoms (Article) Journal of the Neurological Sciences. vol. 146, Issue 2, Mar. 10, 1997, pp. 183-185. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220306564A1 (en) * | 2019-06-19 | 2022-09-29 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
WO2024068862A1 (en) | 2022-09-30 | 2024-04-04 | Nmd Pharma A/S | Compositions and methods for treating myasthenia gravis |
Also Published As
Publication number | Publication date |
---|---|
US20190185437A1 (en) | 2019-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2986611C (en) | Compounds for use in treating neuromuscular disorders | |
EP3724173B1 (en) | Compounds for the treatment of neuromuscular disorders | |
US20140200215A1 (en) | Lysophosphatidic acid receptor antagonists | |
US10385028B2 (en) | Compounds for the treatment of neuromuscular disorders | |
US20190183863A1 (en) | Compounds For The Treatment Of Neuromuscular Disorders | |
US20110269744A1 (en) | Benzazepine Compound | |
US20220388938A1 (en) | Compounds for the treatment of neuromuscular disorders | |
JP7287607B6 (en) | Phenoxy acids for the treatment of neuromuscular disorders | |
KR102667838B1 (en) | Compounds for the treatment of neuromuscular disorders | |
US11147788B2 (en) | Compounds for the treatment of neuromuscular disorders | |
US11730714B2 (en) | Compounds for the treatment of neuromuscular disorders | |
US11591284B2 (en) | Compounds for the treatment of neuromuscular disorders | |
US20190183812A1 (en) | Compounds For The Treatment Of Neuromuscular Disorders | |
US20220274938A1 (en) | 5-[(1s)-1-(4-bromophenoxy)ethyl]-2h-tetrazole derivatives and related compounds as clc-1 ion channel inhibitors for treating neuromuscular disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: NMD PHARMA A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KNUTSEN, LARS J.S.;COOPER, MARTIN E.;BROWN, ANDREW W.;AND OTHERS;REEL/FRAME:048469/0081 Effective date: 20190125 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |